The Journal of Organic Chemistry

pubs.acs.org/joc

Article

¹ Synthetic Approaches to Phosphasugars (2-oxo-1,2-² oxaphosphacyclanes) Using the Anomeric Alkoxyl Radical ³ β -Fragmentation Reaction as the Key Step

⁴ Daniel Hernández-Guerra, Alan R. Kennedy, Elisa I. Leo'n, Ángeles Martín, Ine's Pe'rez-Martín, ⁵ María S. Rodríguez,* and Ernesto Suárez*



9 introduced via the Arbuzov reaction. After selective hydrolysis and subsequent 10 cyclization, the phosphonate or phosphinate intermediates can be converted into 2-11 deoxy-1-phosphahexopyranose and 2-deoxy-1-phosphapentopyranose sugars. The ARF 12 of carbohydrates with an electron-donor group (EDG) at C2 proceeds by a radical-polar 13 crossover mechanism, and the cyclization occurs by nucleophilic attack of a conveniently 14 positioned phosphonate or phosphinate group to the transient oxocarbenium ion. This



15 alternative methodology leads to 5-phosphasugars with a 4-deoxy-5-phosphapentopyranose framework. The structure and 16 conformation of the 2-oxo-1,2-oxaphosphinane and 2-oxo-1,2-oxaphospholane ring systems in different carbohydrate models have 17 been studied by NMR and X-ray crystallography.

18 INTRODUCTION

19 1-Phosphapyranosyl and 1-phosphafuranosyl carbohydrates 20 possessing a 2-oxo-1,2-oxaphosphacyclane skeleton have 21 attracted considerable attention from synthetic chemists due 22 to their unusual non-natural structures and great diversity of 23 biological activities.¹ Cyclic phosphonate and phosphinate 24 esters with a six-membered 2-oxo-1,2-oxaphosphinane ring 25 system, also known as phostones and phostines, respectively, 26 have been prepared almost exclusively by acid- or base-27 catalyzed Pudovik-Abramov addition of the phosphorus atom ²⁸ to the sugar carbonyl.² Originally reported by Thiem et al.³ on 29 a D-mannofuranose derivative, this methodology has been 30 extended to other sugars giving always C1-P expanded 1,2-31 oxaphosphinane rings with respect to the original sugar.⁴ 32 Generally, the reaction occurs with little stereoselectivity on 33 the adjacent phosphorus and carbon centers, and a mixture of 34 the four possible isomers is formed. Nevertheless, asymmetric 35 Abramov hydrophosphonylation enables optimization of the 36 synthesis of phostones for the formation of the manno-37 isomers.^{4f} The total synthesis of phostones using ring-closing 38 metathesis has also been reported.⁵

What has been less well documented, however, is the preparation of 1-phosphafuranosyl carbohydrates. Cyclic phosphonates and phosphinates with a five-membered 2-oxo-1,2-oxaphospholane ring have been synthesized by the analogous unselective Abramov addition to the aldehyde in four-carbon-atom acyclic sugar derivatives.⁶ The total synthesis of racemic cyclic phosphonate analogs of 2-deoxy-ribose and 2de deoxy-xylose has also been accomplished.⁷ Some of these 2oxo-1,2-oxaphosphacyclanes of a carbohydrates origin have $_{47}$ been shown to exhibit biological activities as anticancer⁸ and $_{48}$ enzyme inhibitors.⁹ 49

In previous papers, we have studied that the anomeric $_{50}$ alkoxyl radical (i.e., II, Scheme 1) β -fragmentation (ARF) of $_{51 s1}$ sugars initiated under oxidative¹⁰ or reductive¹¹ conditions. $_{52}$ We have shown that with the system (diacetoxyiodo)benzene $_{53}$ (DIB)/I₂, the reaction mechanism is strongly dependent on $_{54}$ the polarity of the C2 substituent.¹² With an electron- $_{55}$ withdrawing group (EWG), the C2 radical initially formed is $_{56}$ trapped by the iodine atoms in the medium to give an open- $_{57}$ chain iodide with one carbon less than the original $_{58}$ carbohydrate (i.e., III). Notwithstanding, if the C2 substituent $_{59}$ is an oxygen-containing electron-donor group (EDG), the $_{60}$ intermediate radical is rapidly oxidized to an oxocarbenium ion $_{61}$ by a radical-polar crossover mechanism, 13 which may $_{62}$ subsequently react inter- or intramolecularly with nucleophiles $_{63}$ (i.e., VI).¹⁴

This unique behavior of the C2 radical during the ARF $_{65}$ reaction motivated us to investigate the use of this dual $_{66}$

Received: January 9, 2020 Published: March 16, 2020



pubs.acs.org/joc





Scheme 2. Synthesis of Models for the Preparation of 1-Phosphasugars^a



^aReagents and conditions: (a) Ph₃P·HBr, tetrahydrofuran (THF), H₂O, 2–24 h; (b) PhI(OAc)₂/I₂, CH₂Cl₂, room temperature (rt), 1–2 h; (c) (EtO)₃P, Δ, 3–6 h; (d) (EtO)₂PPh, 160 °C, 6 h; (e) (i) Hg(OAc)₂, THF, H₂O, rt, 1 h, (ii) KI, H₂O, 0 °C, 0.5 h, (iii) NaBH₄, H₂O, 0 °C, 1.5 h. For brevity, β-D-Gal refers to the perbencylated moiety of galactose.

67 methodology for the preparation of two completely different 2-68 oxo-1,2-oxaphosphacyclane ring systems.

In the first method (path a), the synthesis starts with a 2-70 deoxy-sugar (I, $R^1 = H$) and the phosphorus is introduced in 71 the final steps of the synthesis by the Michaelis–Arbuzov 72 reaction of the iodide generated by the ARF reaction (III).¹⁵ 73 The obtained phosphinates or phosphonates after hydrolysis of 74 the formyl group (IV, $R^2 =$ Aryl, OAlkyl) can be conveniently 75 cyclized to 2-oxo-1,2-oxaphosphinanes (V, $R^2 =$ Aryl, OAlkyl). 76 The final result of this method is the formation of 1-77 phosphasugars by net substitution of the anomeric carbon by an atom of pentavalent phosphorus, maintaining the ring size 78 and the stereochemistry of the original 2-deoxy-sugar.¹⁶ 79

The second approach (path b) requires the placement of an $_{80}$ EDG at C2 (I, $R^1 = OAlkyl$), and phosphorus is now $_{81}$ introduced at earlier steps of the synthesis, before the ARF $_{82}$ reaction. As can be seen, the same four steps of the previous $_{83}$ methodology are now introduced in a different order: $_{84}$ Arbuzov-hydrolysis-ARF-cyclization. The strategically lo- $_{85}$ cated monophosphonate ester (VI, $R^2 = OAlkyl$) or $_{86}$ phosphinic acid (VI, $R^2 = Aryl$) is cyclized by a tandem $_{87}$ ARF-nucleophilic addition on the intermediate oxocarbenium $_{88}$

Scheme 3. Synthesis of Models for the Preparation of 5-Phosphasugars^a



^{*a*}Reagents and conditions: (a) I₂, PPh₃, imidazole, PhH, Δ , 0.5 h; (b) (EtO)₃P, Δ , 28 h; (c) H₂, Pd/C 10%, EtOAc, 2.5–20 h; (d) NaOH, EtOH, rt, 42–48 h; (e) (EtO)₂PPh, 160 °C, 28 h; (f) TBDPSiCl, imidazole, 4-dimethylaminopyridine (DMAP), dimethylformamide (DMF), rt, 2 h; (g) pyridinium chlorochromate (PCC), MS 3 Å, CH₂Cl₂, rt, 9 h; (h) (MeO)₂P(O)H, DBU, 0 °C, 0.5 h; (i) (i) MeO(CO)₂Cl, DMAP, MeCN, 0 °C, 1 h, (ii) Bu₃SnH, AIBN, PhCH₃, Δ , 2 h; (j) NaOMe, MeOH, rt, 2 h.

89 ion. In the new 2-oxo-1,2-oxaphosphinane (VII, $R^2 = Aryl$, 90 OAlkyl) formed, the ether bridge is now linked to C2 and the 91 ring has been expanded in relation to the original sugar. This 92 structure can actually be considered to be a 4-deoxy-5-93 phosphapyranose sugar.

94 RESULTS AND DISCUSSION

s2

Preparation of Carbohydrate Models. Intermediates primary alkyl iodides **3**, **9**, and **15** were prepared from the corresponding 2-deoxy-sugars **2**, **8**, and **14** via anomeric alkoxyl radical fragmentation with DIB and iodine in good to excellent yield (Scheme 2). The 2-deoxy-sugars **2** and **14** were to in turn synthesized using a modification of the procedure lot developed by Mioskowsky and Falck¹⁷ by catalytic hydration of glycals **1** and **13** employing triphenylphosphine hydrobromide and water as nucleophile. This reaction failed in the tot case of 2-deoxy-pent-1-enitol **7**, and an oxymercurationdemercuration protocol¹⁸ with the glycal 7 was utilized instead ¹⁰⁵ (Scheme 2). The required phosphonates **4**, **10**, and **16** and ¹⁰⁶ phosphinates **5**, **6**, **11**, and **12** were prepared by the Michaelis – ¹⁰⁷ Arbuzov reaction: by heating the corresponding primary ¹⁰⁸ iodides with triethyl phosphate and diethyl phenylphosphonite, ¹⁰⁹ respectively. ¹¹⁰

Although the high temperature required was feared to be a 111 problem with these sensitive substrates, the reaction proceeded 112 efficiently.¹⁹ The pairs of phosphorus-centered diastereomers 113 of phenylphosphinates **5**, **6** and **11**, **12** could be separated by 114 high-performance liquid chromatography (HPLC), although 115 the absolute stereochemistry was more conveniently determined at later stages after the cyclization step (vide infra). 117

The preparation of models **21**, **24**, **31**, and **32** for the ¹¹⁸ synthesis of 1,2-oxaphosphinanes using the second method- ¹¹⁹ ology (route b, Scheme 1) is described in Scheme 3. To access ^{120 s3} the 5-phosphonate **19** and 5-phosphinate **22**, benzyl 2,3-O- ¹²¹

Table 1. Synthesis of 1-Phosphasugars





122 isopropylidene- β -D-ribofuranoside (17) was converted into the 123 5-iodo derivative 18 in 85% yield by treatment with 124 triphenylphosphine in the presence of iodine and imidazole. 125 Iodide 18 was subsequently submitted to Michaelis-Arbuzov 126 conditions, as described above, to afford 5-phosphonate 19 and 127 5--phosphinate 22 derivatives, that were then debenzylated by catalytic hydrogenolysis in the presence of Pd/C 10% under 1 128 129 atm of H₂ to deprotect the anomeric alcohols to give 20 and 23, respectively. Selective hydrolysis of the phosphonate 130 diester 20 and the phosphinate ester 23 was performed using 131 132 sodium hydroxide in ethanol to furnish the required monoester 133 21 and phosphinic acid derivative 24, respectively.

Finally, the introduction of the 5-dimethoxyphosphoryl nas group in a mannofuranose skeleton was accomplished through

a methodology developed by Hanaya et al.,²⁰ which essentially ¹³⁶ consists of an Abramov addition to a 5-ulose carbohydrate ¹³⁷ (Scheme 3). The sequence was initiated by the selective ¹³⁸ protection of 1-O-benzoyl-O-isopropylidene- α -D-mannofura- ¹³⁹ nose (25) with ^tBuPh₂SiCl to give 26. The 5-ulose 27 was ¹⁴⁰ efficiently obtained by the oxidation of the secondary alcohol ¹⁴¹ with PCC, and the addition of dimethyl phosphite to the ¹⁴² carbonyl group in the presence of DBU afforded a mixture of ¹⁴³ α -hydroxyphosphonate esters 28*R* and 28*S*. Both isomers can ¹⁴⁴ be separated by chromatography, but since the next step is the ¹⁴⁵ deoxygenation of the tertiary 5-hydroxyl group, the determi- ¹⁴⁶ nation of 5-stereochemistry at 28 was deemed to be ¹⁴⁷ unnecessary. Nevertheless, the stereochemistry has been ¹⁴⁸

D

149 tentatively assigned in analogy with that observed in a similar 150 case.²⁰

The deoxygenation was carried out by the Dolan and MacMillan protocol;²¹ the 5-O-methyl oxalyl derivative prepared by methyl oxalyl chloride in the presence of DMAP the neduced with the *n*-Bu₃SnH/AIBN system to give a mixture of **29** and **30** (88%, 80:20). The C-5 stereochemistry key a also more easily accomplished in the next step after the the rycilization. Debenzoylation with NaOMe in MeOH afforded models **31** and **32** with the free anomeric alcohol prepared for the ARF reaction.

Synthesis of 1-Phosphasugars. Open-chain diethoxy-160 161 phosphoryl intermediate 4 cyclized by a base-catalyzed 162 intramolecular transesterification process furnished $S_{\rm P}$ and $R_{\rm P}$ diastereomeric mixtures of 1-phospha-1-oxo-D-lyxo-hexopyra-163 164 nose derivatives 36 and 37 (Table 1, entry 1). The sensitive δ -165 formate ester was hydrolyzed rapidly under the reaction 166 conditions. The $R_{\rm P}$ -isomer 37 in which the ethyl group is 167 disposed at the less sterically congested α -side of the ring is the 168 major component. Nuclear over-Hauser effect spectroscopy 169 (NOESY) experiments were used for the assignment of the 170 H2 α and H2 β protons and the relative configuration of the 171 phosphorus chiral center [see Figures S1 and S2 in the 172 Supporting Information (SI)]. The conformational situation of 173 the 1,2-oxophosphacyclane ring was evaluated on the basis of 174 ³J_{HH}, ³J_{PH}, and ³J_{PC} vicinal NMR coupling constants suggesting 175 a preferential $B_{2,5}$ conformation in both compounds.²² The 176 values of the ${}^{3}J$ constants calculated on minimized structures of 177 **36** and **37**, using the corresponding Karplus equations,²³ agree 178 well with the experimental data (see Tables S1 and S2 in the 179 SI).

The cyclization proceeded analogously with pure phenyl-180 181 phosphinates 5 and 6 to give 2-phenyl-1,2-oxaphosphinanes 38 182 and 39, respectively, in good overall yield (Table 1, entries 2 183 and 3). The ring conformations are similar to those previously 184 commented for compounds 36 and 37 and very close to a 185 theoretical $B_{2,5}$ boat (Cremer-Pople parameters: $\varphi = 290^{\circ}$, $\theta =$ $_{186}$ 94°, Q = 0.7 Å) confirmed by the large $^{3}J_{PCCH_{3}}$ (24 Hz) 187 coupling constant observed, consistent with an almost 188 antiperiplanar arrangement of the atoms (torsion angle \approx 189 170°) (Figures and Tables S3 and S4 in the SI). The P-190 stereochemistry has also been established with the aid of 191 NOESY experiments. The NOESY spectrum of 38 unequiv-192 ocally related the phenylphosphinate protons to β -face 193 hydrogens (H2 β and the endo methyl group of the 194 isopropylidene), while in the spectrum of **39**, the phenyl 195 protons are related to α -face hydrogens (H2 α and H5). In this 196 context, the substantial deshielding of the endo methyl group 197 of the isopropylidene (ca. 0.26 ppm) is also significant, with 198 the consequent shielding of the 2H α (-0.25 ppm) and 5H $_{199}$ (-0.58 ppm) protons observed on going from the ¹H NMR 200 spectrum of 38-39 caused by the anisotropic shielding effect 201 of the P-Ph group. Under these conditions, the cyclization 202 proceeded stereospecifically; only one isomer was formed in 203 each case, as detected by ³¹P NMR spectroscopy of the crude reaction mixture. As described in the literature, the phosphorus 204 205 nucleophilic substitution mechanism is produced through an 206 intermediary with trigonal bipyramidal geometry, the final 207 result being a P-stereochemical inversion.²⁴ Consequently, the 208 configuration of open-chain precursors 5 and 6 can now be 209 determined as S_p and R_p , respectively.

This methodology can readily be extended to the synthesis 210 of five-membered 1,2-oxaphospholanes ring compounds. 211 Starting from a hexose sugar in furanose form [e.g., 2-deoxy- 212 5,6-O-isopropylidene-3-O-methyl-D-*arabino*-hexofuranose (8), 213 Scheme 2], the alkoxyl radical fragmentation led, across γ - 214 hydroxy-phosphonates (e.g., 33) or -phosphinates (e.g., 34 and 215 35), finally to the required 1,2-oxaphospholanes (e.g., 40–43). 216

In this particular model, the cyclization step was performed 217 using PPTS in anhydrous CHCl₃ after hydrolysis of the formyl 218 ester. This two-step method provides better yields than the 219 direct cyclization used previously for the six-membered rings. It 220 has been reported in the literature that the intramolecular 221 transesterification is highly favored in the case of five- 222 membered 1,2-oxaphospholanes.²⁵ This may be the reason 223 why small amounts of the corresponding cyclized compounds 224 can be detected during the hydrolysis of the formyl group in 225 the preparation of γ -hydroxy-precursors 33–35 (Table 1, 226 entries 4-6), or even in the Arbuzov reactions of iodide 9. 227 Indeed, a mixture of cyclized 42 and 43 can be obtained 228 directly when heating 9 with PhP(OEt)₂ at 120 °C for a long 229 period of time (68 h), although in moderate yield (37%, 6:4, 230 three steps). The P-stereochemistries were assigned by analysis 231 of their NOESY spectra (Figures S5-S8 in the SI) and in the 232 case of 2-phenyl-1,2-oxaphospholanes 42 and 43 confirmed by 233 the chemical shift displacement of H2 α (-0.32 ppm), H2 β 234 (0.14 ppm), and 3β -methoxyl group (0.1 ppm) observed on 235 going from the ¹H NMR spectrum of 42-43 motivated by the 236 aromatic ring current effect. According to the ${}^{3}J_{HH}$, ${}^{3}J_{PH}$, and 237 ${}^{3}J_{PC}$ coupling constants, the 1,2-oxaphospholane rings in ${}_{238}$ compounds 40–43 adopt preferentially very similar ${}^{3}T_{2}$ 239 conformation patterns. The experimental ${}^{3}J$ values are 240 consistent with those calculated on a minimized ${}^{3}T_{2}$ structure. 241 This is also in accordance with a pseudorotational analysis of 242 the ${}^{3}J_{\rm HH}$ ring constants. The most populated conformers 243 appear at phase angles of $P = 0-42^{\circ} ({}^{3}T_{2} - {}^{3}E - {}^{3}T_{4})$ of the 244 northern region of the pseudorotational itinerary (see Tables 245 S5-S8 in the SI for details).²⁶ 2.46

For the sake of completeness, this methodology was also 247 extended to a disaccharide model derived from perbenzylated 248 D-lactose [β -D-Galp-(1 \rightarrow 4)-D-Glcp]. The diethyl phospho- 249 nate 16 was effectively cyclized under similar reaction 250 conditions to give a 1,2-oxaphosphinane derivative as a 251 mixture of P-diastereomers 44 and 45 (62%, 1:2) (Table 1, 252 entry 7). The reaction can be expected to come under some 253 steric control and to lead to the major diastereomer 45 having 254 the ethyl group positioned on the less hindered α -side of the 255 ring. NOE interactions observed between this ethyl group and 256 the H2 α and H3 α protons are also in agreement with the $R_{\rm P}$ 257 stereochemistry assigned to this isomer (Figures S9 and S10 in 258 the SI). In this case, the 1,2-oxaphosphinane ring adopts 259 preferentially a ${}^{4}C_{1}$ chair conformation in both isomers.²⁷ This 260 is evident from the ${}^{3}J_{\rm HH}$ vicinal coupling values between the 261 axial ring protons (H2 β , H3, H4, and H5) and further 262 supported by the relatively small ${}^{3}J_{PCCH}\beta$ (ca. 2 Hz) observed, ${}_{263}$ which is consistent with a $P-C_2-C_3-H$ dihedral angle of 264 approximately 60° (Table S9 and S10 in the SI).^{5b} This is the 265 first synthesis of a β -D-Galp-(1 \rightarrow 4)-1-phospha-D-Arap 266 structure via direct introduction of the phosphorus at the 267 reducing unit on a disaccharide framework.² 268

Synthesis of 5-Phosphasugars. The second approach 269 was first tested with compound **21**, which possesses a tethered 270 5-phosphonate monoester functionality on a D-ribofuranose 271

Table 2. Synthesis of 5-Phosphasugars^{abc}



"Reagents and conditions per mmol of substrate: DIB (2.0 mmol), I_2 (1.1 mmol), $CHCl_3$, rt. ^{*b*}DIB (2.2 mmol), I_2 (1.1 mmol), CH_2Cl_2 , rt, *hv*. ^{*c*}(i) NaOH/MeOH (2 M, 5.3 mL), 40–43 °C, 30 h; (ii) DIB (2.1–2.2 mmol), I_2 (1.0–1.1 mmol), CH_2Cl_2 , rt, *hv*. ^{*d*}Two-step overall yield. n.d. = not detected.

 $_{272}$ skeleton. The reaction with PhI(OAc)₂ and iodine triggers the 273 alkoxyl radical fragmentation and the intramolecular cycliza-274 tion via a nucleophilic radical-polar crossover mechanism. In 275 consequence, a 2-ethoxy-1,2-oxaphosphinane 2-oxide ring 276 system was formed and isolated as a chromatographically separable mixture of P-diastereomers 46 and 47 (Table 2, 277 entry 1). The 6-exo cyclization is highly stereoselective; only 278 one isomer at C5 is formed leaving the isopropilidene in cis 279 disposition. P-Stereochemistries were assigned by NOESY 280 analyses, and the rings adopt predominantly very similar E_3 281 282 conformations. The calculated vicinal coupling constants in these E_3 minimized structures agreed reasonably well with the 2.83 experimental values (Figures and Tables S11 and S12 in the 284 285 SI). The ¹H NMR spectrum of 46 shows a ${}^{4}J_{w}$ coupling (0.7 286 Hz, calcd 1.2 Hz)²⁹ between H2 α and H4 hydrogens, which also supports the previously mentioned conformation. 287

t2

²⁸⁸ Curiously, in the ¹H NMR spectra of both isomers, the ²⁸⁹ formyl hydrogen signal appears splitting as a doublet of ²⁹⁰ doublets with two long-range couplings: ${}^{4}J_{w}$ with the H3 (ca. 1 ²⁹¹ Hz) and ${}^{5}J_{PH}$ with the atom of phosphorus (ca. 2.8 Hz), as ²⁹² determined by selective spin decoupling and ${}^{1}H{}^{31}P{}$ NMR ²⁹³ spectroscopy, respectively.

The cyclized 2-phenyl-1,2-oxaphosphinanes **48** and **49** were prepared analogously from the free phosphinic acid **24** (Table 296 2, entry 2). The stereochemical assignment of these examples 297 rests on spectroscopic evidences and on a single-crystal X-ray 298 crystallographic analysis of **48** (Figure S17 in the SI). The 299 solution conformation of the 1,2-oxaphosphinane ring, 300 elucidated from the experimental homo- and heteronuclear ³J coupling constants of the ring protons, was practically identical 301 to the slightly distorted $B_{3,0}$ boat conformation (Cremer-Pople 302 parameters: $\varphi = 188.9^{\circ}$, $\theta = 79.5^{\circ}$, Q = 0.636 Å) observed in 303 the crystalline structure of **48** (Figure and Table S13 in the SI). 304 The ${}^{4}J_{w}$ coupling (0.9 Hz, calcd 1.2 Hz)²⁹ between H2 α and 305 H4 hydrogens provides additional support for this conforma- 306 tion. Interestingly, the ring of the $R_{\rm P}$ isomer **49** seems to adopt 307 in solution a conformation closer to a ${}^{4}C_{1}$ chair than to the $B_{3,0}$ 308 boat (Figure and Table S14 in the SI). The most significant 309 difference was observed in the heteronuclear ${}^{3}J_{\rm POCH_{5}}$ coupling 310 constant [**48** (19.0 Hz, calcd 21.1 Hz, TA = -161.5° , $B_{3,0}$); **49** 311 (0.7 Hz, calcd 1.5 Hz, TA = -89.6° , ${}^{4}C_{1}$)] in full agreement 312 with the Karplus equation and the geometry of the rings.³⁰

An example with the phosphorous on a secondary carbon of 314 the sugar side chain has also been accomplished. The 5- 315 dimethoxyphosphoryl-L-gulofuranose derivative (31) was 316 partially hydrolyzed to the monoester and immediately 317 subjected to the ARF reaction (Table 2, entry 3). The P- 318 configuration of the two 1,2-oxaphosphinane derivatives 319 obtained 50 and 51 was determined on the basis of NOE 320 interactions of the P-OMe with protons in close spatial 321 proximity to the β - and α -side of the ring, respectively (Figures 322) S15 and S16 in the SI). The ${}^{3}J_{H2\alpha,H3}$ coupling constant and the 323 NOE interaction of the H2 with the endo methyl group of the 324 isopropylidene established the stereochemistry at C2 and, 325 consequently, confirmed that of compounds 28-32. Both 326 epimeric compounds appear to exist in solution predominantly 327 in a ${}^{3}E$ conformation (Tables S15 and S16 in the SI). 328

However, the cyclization completely failed with the minor 329 330 isomeric 5-dimethoxyphosphoryl-D-mannofuranose derivative 331 (32) (Table 2, entry 4). The reaction is slower, and the 332 expected 5-phosphasugar 52 could not be detected in the 333 complex mixture of products obtained. Instead, a compound 334 eventually identified as the cyclized olefin 53 was obtained by 335 chromatography in a low yield. A hypothesis that can 336 rationalize this result is based on unfavorable steric interactions 337 between the large side chain and the crowded α -side of the 338 molecule that may hinder the cyclization step. The formation 339 of 53 may be explained by cyclization after desilylation and 340 subsequent elimination of the alcohol. The 3-methylene-1,2-341 oxaphosphinane structure of 53 was characterized by 342 spectroscopic means. Most significantly, ${}^{3}J_{PH6cis} = 23.6$ Hz ³⁴³ and ³ $J_{PH6trans}$ = 43.8 Hz coupling constants of the methylene ³⁴⁴ protons are observed in the ¹H NMR spectrum.³¹

Assignment of P-Stereochemistry. Phosphorous stereo-345 346 chemistry in cyclic phosphonates or phosphinates was 347 determined by studying one-dimensional (1D) and two-348 dimensional (2D) NOE experiments on minimized structures 349 with the established conformation for the five- or six-350 membered rings. In some cases, other ¹H and ³¹P NMR supporting data have also been taken into account. In general, 351 352 it has been observed that in hexopyranoses possessing a 2-353 methoxy-1,2-oxaphosphinane 2-oxide ring system, the signal of 354 the ³¹P{¹H} NMR for the axial α -P–OMe is 2–4 ppm upfield 355 from the corresponding equatorial β -P–OMe.^{45,c,f,9b} This 356 trend has also been detected in our 2-deoxy compounds, 357 although the observed difference is smaller (ca. 1 ppm) 358 [compare ³¹P-chemical shift displacements of compounds **36**– 359 37 (1 ppm), 44-45 (1 ppm), and 47-46 (1.6 ppm)]. In some 360 previous cases, this decrease has been attributed to conforma-361 tional changes in the chair ring, and this may be the reason for ³⁶² the small difference observed in our compounds.^{4c} Five- or six-363 membered cyclic phosphinates show a greater difference in the ³¹P NMR chemical shifts displacement between both P-364 365 isomers [i.e., 38-39 (3.3 ppm), 42-43 (4.0 ppm), and 49-48 366 (3.2 ppm)]. This trend, which the small number of examples 367 does not allow us to generalize, however coincides with that 368 observed for another pair of this type of compounds described $_{369}$ in the literature.^{4h} The $^2J_{PH2}$ coupling constant has also been 370 used for the determination of the configuration at phosphorus 371 in the glucopyranose series. This constant is considerably 372 smaller in the α -P-OMe (2-5 Hz) than in the β -P-OMe 373 compounds (6–10 Hz).^{4f} As one might expect this correlation 374 of ${}^{2}J_{PH2}$ with phosphorus, stereochemistry does not seem to be 375 applicable to our 2-deoxy compounds, in which the ${}^{2}J_{PH2\alpha}$ and $_{376}$ $^{2}J_{PH2\beta}$ are in general very similar and considerably higher (ca. 377 16-20 Hz).

378 CONCLUSIONS

379 In summary, we have successfully applied the anomeric ARF 380 reaction for the synthesis of 1-phosphahexopyranose, 1-381 phosphahexofuranose, and 5-phosphapentopyranose sugars. 382 The process initiated by the 1-O-yl radical is strongly 383 influenced by the polarity of the C2 substituent. In the 384 presence of an EWG at C2, rapid β -fragmentation affords a 385 stabilized C2 radical, which is trapped by the iodine atoms 386 present in the medium. The acyclic iodide can be readily 387 transformed into 1-phosphasugars using a three-step sequence: 388 Arbuzov reaction, selective hydrolysis, and intramolecular 389 cyclization. Cyclic phosphonates and phosphinates with 2408

oxo-1,2-oxaphosphinane and 2-oxo-1,2-oxaphospholane ring 390 systems can be obtained using this methodology. The 1- 391 phosphasugar ring has the same number of atoms and 392 stereochemistry as the original carbohydrate. This sequence 393 has also been applied to D-lactose for the synthesis of β -D-Galp- 394 $(1 \rightarrow 4)$ -1-phospha-D-Arap with a disaccharide structure. 395 Nevertheless, if the C2 substituent is an EDG, the C2 radical 396 intermediate undergoes one-electron oxidation causing a 397 crossover from the radical to an oxocarbenium ion that can 398 be trapped intramolecularly by tethered P-nucleophiles 399 strategically located in the carbohydrate skeleton. This 400 methodology using the same sequence of reactions, although 401 in a different order, provides access to ring-expanded 402 phosphinates and phosphonates with a hitherto unknown 5- 403 phosphapentopyranose skeleton. The five- and six-membered 404 cyclic phosphinates and phosphonates prepared herein present 405 a wide variety of solution conformations that have been 406 studied using ³J homo- and heteronuclear coupling constants. 407

EXPERIMENTAL SECTION

General Methods. Melting points were determined with a hot- 409 stage apparatus. Optical rotations were measured at the sodium line at 410 ambient temperature in CHCl₃ solutions. IR spectra were measured as 411 thin films on CHCl₃ solutions. NMR spectra were determined at 500 412 MHz for ¹H, 125.7 MHz for ${}^{13}C{}^{1}H{}^{3}$, and 162 or 202.5 MHz for 413 $^{31}\mathrm{P}\{^{1}\mathrm{H}\}$ in CDCl_3 as stated. The chemical shifts are given in parts per $_{414}$ million (ppm) relative to TMS at δ 0.00 ppm or to residual CDCl₃ at 415 δ 7.26 ppm for proton spectra, relative to CDCl₃ at δ 77.00 ppm for 416 carbon spectra, and relative to external phosphoric acid at δ 0.00 ppm 417 for phosphorus spectra. ¹³C DEPT-90, -135 and 2D correlation 418 spectroscopy (COSY), heteronuclear single-quantum coherence 419 (HSQC), NOESY, and heteronuclear multiple bond correlation 420 (HMBC) experiments were performed routinely for all new 421 compounds. When necessary, J_{PH} coupling constants have been 422 determined using ${}^{1}H{}^{31}P{}$ NMR decoupled spectra. The DAISY 423 program as implemented in the TopSpin 4.0.6 software package was 424 used for the simulation of ¹H NMR spectra. Low- and high-resolution 425 mass spectra were recorded using electrospray ionization (ESI⁺) and 426 time-of-flight (TOF) analyzer. Merck silica gel 60 PF (0.063-0.2 427 mm) was used for column chromatography. Circular layers of 1 and 2 428 mm of Merck silica gel 60 PF₂₅₄ were used on a Chromatotron for 429 centrifugally assisted chromatography. HPLC separations were 430 undertaken using a semipreparative (10 mm × 250 mm) Ascentis 431 Si normal-phase column. Commercially available reagents and 432 solvents were of analytical grade or were purified by standard 433 procedures prior to use. The spray reagents for TLC analysis were 434 used with 0.5% vanillin in H2SO4-EtOH (4:1), with Hanessian's 435 stain,³² or alternatively with ninhydrin and further heating until 436 development of color.

6-O-tert-Butyldiphenylsilyl-2-deoxy-3,4-O-isopropylidene-D-lyxo- 438 hexopyranose (2).³³ A solution of glycal 1^{34} (228.0 mg, 0.537 mmol) 439 in THF (11.7 mL) containing water (233 μ L, 12.9 mmol) and Ph₃P· 440 HBr (29.5 mg, 0.086 mmol) was stirred at room temperature for 24 h. 441 The reaction mixture was then poured into a saturated solution of 442 NaHCO₃ and extracted with CH₂Cl₂. The combined organic extracts 443 were washed with a saturated solution of NaHCO₃, dried over 444 Na₂SO₄, and concentrated under reduced pressure. The residue was 445 purified by silica gel column chromatography (hexanes-EtOAc, 446 70:30) to give 2 (237.1 mg, 0.536 mmol, 100%, anomeric mixture, α / 447 β , 3.7:1) as a colorless oil: IR (CHCl₃) 3592, 2932, 1427, 1112 cm⁻¹; 448 ¹H NMR (500 MHz, CDCl₃, major isomer) $\delta_{\rm H}$ 1.08 (9H, s), 1.33 449 (3H, s), 1.42 (3H, s), 1.70 (1H, ddd, J = 15.0, 6.8, 3.8 Hz, H2a), 2.23 450 (1H, ddd, J = 15.1, 5.0, 4.2 Hz, H2b), 3.83 (1H, dd, J = 10.1, 6.6 Hz, 451 H6a), 3.90 (1H, dd, J = 10.1, 6.3 Hz, H6b), 3.99 (1H, ddd, J = 6.6, 452 6.6, 1.9 Hz, H5), 4.24 (1H, dd, J = 7.3, 1.9 Hz, H4), 4.51 (1H, ddd, J 453 = 7.3, 4.2, 4.2 Hz, H3), 5.33 (1H, dd, J = 6.9, 5.0 Hz, H1), 7.36-7.43 454 (6H, m), 7.69–7.74 (4H, m); ¹³C{¹H} NMR (125.7 MHz, CDCl₃ 455

456 major isomer) $\delta_{\rm C}$ 19.3 (C), 25.2 (CH₃), 26.6 (CH₃), 26.8 (3 × CH₃), 457 31.4 (CH₂, C2), 63.0 (CH₂, C6), 69.7 (CH, C5), 70.3 (CH, C3), 72.3 458 (CH, C4), 90.5 (CH, C1), 108.8 (C), 127.55 (2 × CH), 127.60 (2 × 459 CH), 129.6 (2 × CH), 133.6 (C), 133.7 (C), 135.6 (2 × CH), 135.7 460 (2 × CH); MS (ESI⁺-TOF) *m/z* (%) 465 [(M + Na)⁺, 100]; HRMS 461 (ESI⁺-TOF) *m/z*: [M + Na]⁺ calcd for C₂₅H₃₄NaO₅Si 465.2073; 462 found 465.2072. Anal. calcd for C₂₅H₃₄O₅Si: C, 67.84; H, 7.74. 463 Found: C, 67.85; H, 8.07.

1-O-tert-Butyldiphenylsilyl-5-deoxy-2-O-formyl-3,4-O-isopropyli-464 465 dene-5-iodo-D-arabinitol (3). A solution of alcohol 2 (101.5 mg, 466 0.229 mmol) in CH₂Cl₂ (5.8 mL) containing PhI(OAc)₂ (81.2 mg, 467 0.252 mmol) and I₂ (64 mg, 0.252 mmol) under nitrogen was stirred 468 at room temperature for 1 h. The reaction mixture was then poured 469 into 10% aqueous Na2S2O3, extracted with CH2Cl2, dried over 470 Na₂SO₄, and concentrated. The residue was purified by Chromato-471 tron chromatography (hexanes-EtOAc, 80:20) to give compound 3 472 (130.1 mg, 0.229 mmol, 100%) as a yellowish oil: $[\alpha]_{\rm D}$ -1.4 (c, 0.98, 473 CHCl₃); IR (CHCl₃) 2934, 1726, 1428, 1181, 1113 cm⁻¹; ¹H NMR 474 (500 MHz, CDCl₃) $\delta_{\rm H}$ 1.10 (9H, s), 1.40 (3H, s), 1.52 (3H, s), 3.13 475 (1H, dd, J = 10.2, 5.4 Hz, H2a), 3.23 (1H, dd, J = 9.8, 8.0 Hz, H2b), 476 3.80 (1H, dd, J = 10.6, 6.1 Hz, H6a), 3.85 (1H, dd, J = 10.6, 6.1 Hz, 477 H6b), 4.43-4.48 (2H, m, H3, H4), 5.29-5.33 (1H, m, H5), 7.41-478 7.50 (6H, m), 7.69–7.73 (4H, m), 8.08 (1H, s, CHO); ${}^{13}C{}^{1}H$ 479 NMR (125.7 MHz, CDCl₃) $\delta_{\rm C}$ 2.4 (CH₂, C2), 19.0 (C), 25.5 (CH₃), 480 26.7 (3 × CH₃), 27.2 (CH₃), 62.5 (CH₂ C6), 70.7 (CH, C5), 75.3 481 (CH, C4), 77.4 (CH, C3), 109.2 (C), 127.76 (2 × CH), 127.78 (2 × 482 CH), 129.9 (2 × CH), 132.57 (C), 132.64 (C), 135.4 (2 × CH), 483 135.5 (2 × CH), 160.0 (CH, CHO); MS (ESI⁺-TOF) m/z (%) 591 484 $[(M + Na)^+, 100]$; HRMS (ESI⁺-TOF) m/z: $[M + Na]^+$ calcd for 485 C25H33INaO5Si 591.1040; found 591.1037. Anal. calcd for 486 C25H33IO5Si: C, 52.82; H, 5.85. Found: C, 52.96; H, 6.18.

1-O-tert-Butyldiphenylsilyl-5-deoxy-5-diethoxyphosphoryl-2-O-487 488 formyl-3,4-O-isopropylidene-D-arabinitol (4). A solution of 3 (114 489 mg, 0.2 mmol) in (EtO)₃P (1.82 mL, 10.6 mmol) was stirred at reflux 490 temperature for 3.5 h. The reaction mixture was concentrated under 491 high vacuum, and the residue was purified by Chromatotron 492 chromatography (hexanes-EtOAc, 50:50) to give compound 4 493 (81.7 mg, 0.141 mmol, 71%) as a colorless oil: $[\alpha]_D$ -13.1 (c, 0.49, 494 CHCl₃); IR (CHCl₃) 2993, 1724, 1383, 1253, 1183, 1029 cm⁻¹; ¹H 495 NMR (500 MHz, CDCl₃) $\delta_{\rm H}$ 1.05 (9H, s), 1.325 (3H, t, J = 7.1 Hz), 496 1.327 (3H, t, J = 7.1 Hz), 1.36 (3H, s), 1.48 (3H, s), 1.97 (1H, ddd, ⁴⁹⁷ ${}^{2}J_{PH}$ = 19.6 Hz, J = 15.1, 5.7 Hz, H2a), 2.11 (1H, ddd, ${}^{2}J_{PH}$ = 18.9 Hz, 498 J = 14.8, 8.2 Hz, H2b), 3.77 (1H, dd, J = 10.7, 5.7 Hz, H6a), 3.81 499 (1H, dd, J = 10.7, 6.6 Hz, H6b), 4.08–4.16 (4H, m), 4.37 (1H, dd, J 500 = 6.3, 3.5 Hz, H4), 4.58 (1H, dddd, ${}^{3}J_{PH}$ = 8.4 Hz, J = 8.4, 6.0, 6.0 Hz, 501 H3), 5.26 (1H, ddd, J = 5.8, 5.8, 3.8 Hz, H5), 7.37-7.45 (6H, m), 502 7.64-7.68 (4H, m), 8.07 (1H, s, CHO); ¹³C{¹H} NMR (125.7 MHz, 503 CDCl₃) $\delta_{\rm C}$ 16.3 (CH₃, d, ${}^{3}J_{\rm PC}$ = 6.4 Hz), 16.4 (CH₃, d, ${}^{3}J_{\rm PC}$ = 5.3 Hz), 504 19.1 (C), 25.6 (CH₃), 26.7 (3 × CH₃), 26.8 (CH₃), 27.1 (CH₂, d, $_{505}$ $^{1}J_{PC}$ = 143.1 Hz, C2), 61.7 (CH₂, d, $^{2}J_{PC}$ = 6.4 Hz), 62.1 (CH₂, d, $^{2}J_{PC}$ 506 = 6.4 Hz), 62.8 (CH₂, C6), 71.6 (CH, C5), 71.7 (CH, d, ${}^{2}J_{PC} = 3.2$ 507 Hz, C3), 75.4 (CH, \vec{d} , ${}^{3}J_{PC}$ = 10.6 Hz, C4), 108.9 (C), 127.73 (2 × ⁵⁰⁸ CH), 127.74 (2 × CH), 129.80 (2 × CH), 132.89 (C), 132.91 (C), ⁵⁰⁹ 135.5 (2 × CH), 135.6 (2 × CH), 160.2 (CH, CHO); ³¹P{¹H} NMR 510 (162 MHz, CDCl₃) $\delta_{\rm P}$ 27.5 (P); MS (ESI⁺-TOF) m/z (%) 601 [(M 511 + Na)⁺, 100]; HRMS (ESI⁺-TOF) m/z: [M + Na]⁺ calcd for 512 C₂₉H₄₃NaO₈PSi 601.2363; found 601.2363. Anal. calcd for 513 C₂₉H₄₃O₈PSi: C, 60.19; H, 7.49. Found: C, 60.47; H, 7.46.

⁵¹⁴ (*S*_{*p*})-6-O-tert-Butyldiphenylsilyl-1,2-dideoxy-1-ethoxy-3,4-O-iso-⁵¹⁵ propylidene-1-phospha-1-oxo-*D*-lyxo-hexopyranose (**36**) and (*R*_{*p*})-⁵¹⁶ 6-O-tert-Butyldiphenylsilyl-1,2-dideoxy-1-ethoxy-3,4-O-isopropyli-⁵¹⁷ dene-1-phospha-1-oxo-*D*-lyxo-hexopyranose (**37**). A solution of 4 ⁵¹⁸ (44.4 mg, 0.077 mmol) in NaOEt/EtOH 0.01 M (0.67 mL, 0.0067 ⁵¹⁹ mmol) was stirred at room temperature for 102 h. The reaction ⁵²⁰ mixture was concentrated under reduced pressure, and the residue ⁵²¹ was purified by Chromatotron chromatography (hexanes–EtOAc, ⁵²² 50:50) to give an inseparable mixture of isomers **36** and **37** (34.9 mg, ⁵²³ 0.069 mmol, 90%, **36**:**37**, 1:3) as a colorless oil. The mixture was then ⁵²⁴ separated by HPLC (hexanes–EtOAc, 40:60; Φ = 3 mL/min) to give ⁵²⁵ compound **36**: [*α*]_D –12.7 (*c*, 0.52, CHCl₃); IR (CHCl₃) 2931, 1251,

1228, 1113, 1020 cm⁻¹; ¹H NMR (500 MHz, CDCl₃, simulated 526 coupling constants using DAISY) $\delta_{\rm H}$ 1.06 (9H, s), 1.33 (3H, t, J = 6.9 527 Hz), 1.36 (3H, s), 1.46 (3H, s), 2.17 (1H, ddd, ${}^{2}J_{PH} = 16.3$ Hz, J = 52815.9, 4.7 Hz, H2 α), 2.31 (1H, ddd, ${}^{2}J_{PH}$ = 17.6 Hz, J = 15.9, 4.9 Hz, 529 H2 β), 3.90 (1H, dd, J = 9.8, 5.9 Hz, H6a), 3.97 (1H, ddd, ${}^{4}J_{PH} = 0.7$ 530 Hz, J = 9.8, 8.0 Hz, H6b), 4.12–4.22 (2H, m), 4.44 (1H, ddd, ${}^{4}J_{PH} = 531$ 0.9 Hz, J = 6.7, 1.8 Hz, H4), 4.47 (1H, dddd, ${}^{3}J_{PH} = 4.7$ Hz, J = 8.0, 532 5.9, 1.8 Hz, H5), 4.73 (1H, dddd, ${}^{3}J_{PH} = 26.4$ Hz, J = 6.7, 4.9, 4.7 Hz, 533 H3), 7.37–7.46 (6H, m), 7.67–7.72 (4H, m); ${}^{13}C{}^{1}H$ NMR (125.7 534 MHz, CDCl₃) $\delta_{\rm C}$ 16.5 (CH₃, d, ³J_{PC} = 5.3 Hz), 19.2 (C), 24.9 (CH₃), 535 25.5 (CH₂, d, ${}^{1}J_{PC}$ = 126.1 Hz, C2), 26.5 (CH₃), 26.7 (3 × CH₃), 536 62.4 (CH₂, d, ${}^{3}J_{PC} = 10.6$ Hz, C6), 62.6 (CH₂, d, ${}^{2}J_{PC} = 5.3$ Hz), 71.5 537 (CH, d, ${}^{2}J_{PC}$ = 6.4 Hz, C3), 72.2 (CH, d, ${}^{3}J_{PC}$ = 5.3 Hz, C4), 75.4 538 (CH, d, ${}^{2}J_{PC}$ = 3.2 Hz, C5), 109.0 (C), 127.65 (2 × CH), 127.74 (2 × 539 CH), 129.7 (CH), 129.8 (CH), 133.0 (C), 133.1 (C), 135.56 (2 × 540 CH), 135.63 (2 × CH); ${}^{31}P{}^{1}H{}$ NMR (162 MHz, CDCl₃) δ_{P} 25.0 541 (P); MS (ESI⁺-TOF) m/z (%) 527 [(M + Na)⁺, 100]; HRMS (ESI⁺- 542 TOF) m/z: $[M + Na]^+$ calcd for $C_{26}H_{37}NaO_6PSi$ 527.1995; found 543 527.1995. Anal. calcd for C₂₆H₃₇O₆PSi: C, 61.88; H, 7.39. Found: C, 544 61.97; H, 7.55. Compound 37: [α]_D +7.7 (c, 0.48, CHCl₃); IR 545 (CHCl₃) 2932, 1272, 1227, 1113, 1031 cm⁻¹; ¹H NMR (500 MHz, 546 CDCl₃, simulated coupling constants using DAISY) $\delta_{\rm H}$ 1.07 (9H, s), 547 1.31 (3H, t, J = 6.9 Hz), 1.33 (3H, s), 1.50 (3H, s), 2.11 (1H, ddd, 548 ${}^{2}J_{\rm PH}$ = 16.4 Hz, J = 15.8, 4.6 Hz, H2 α), 2.33 (1H, ddd, ${}^{2}J_{\rm PH}$ = 18.9 Hz, 549 J = 15.8, 5.8 Hz, H2 β), 3.93 (1H, dd, J = 10.5, 7.0 Hz, H6a), 3.96 550 $(1H, ddd, {}^{4}J_{PH} = 2.0 \text{ Hz}, J = 10.5, 5.8 \text{ Hz}, H6b), 4.06-4.17 (2H, m), 551$ 4.19 (1H, dddd, ${}^{3}J_{PH} = 4.7$ Hz, J = 7.0, 5.8, 1.9 Hz, H5), 4.25 (1H, 552 ddd, ${}^{4}J_{PH}$ = 1.0 Hz, J = 6.1, 1.9 Hz, H4), 4.62 (1H, dddd, ${}^{3}J_{PH}$ = 23.2 553 Hz, J = 6.1, 5.8, 4.6 Hz, H3), 7.38–7.47 (6H, m), 7.68–7.71 (4H, m); 554 ¹³C{¹H} NMR (125.7 MHz, CDCl₃) $\delta_{\rm C}$ 16.4 (CH₃, d, ³ $J_{\rm PC}$ = 6.4 Hz), 555 19.2 (C), 25.4 (CH₃), 25.5 (CH₂, d, ${}^{1}J_{PC}$ = 128.2 Hz, C2), 26.8 (3 × 556 CH₃), 26.9 (CH₃), 61.0 (CH₂, d, ${}^{2}J_{PC}$ = 6.4 Hz), 63.0 (CH₂, d, ${}^{3}J_{PC}$ = 557 9.5 Hz, C6), 72.0 (CH, d, ${}^{2}J_{PC}$ = 6.4 Hz, C3), 72.5 (CH, d, ${}^{3}J_{PC}$ = 5.3 558 Hz, C4), 76.8 (CH, d, ${}^{2}J_{PC}$ = 5.5 Hz, C5), 109.6 (C), 127.7 (2 × 559 CH), 127.8 (2 × CH), 129.8 (2 × CH), 133.0 (C), 133.1 (C), 135.6 560 $(4 \times CH)$; ³¹P{¹H} NMR (162 MHz, CDCl₃) $\delta_{\rm P}$ 24.0 (P); MS (ESI⁺ 561 TOF) m/z (%) 527 [(M + Na)⁺, 100]; HRMS (ESI⁺-TOF) m/z: [M 562 + Na]⁺ calcd for C₂₆H₃₇NaO₆PSi 527.1995; found 527.2007. Anal. 563 calcd for C26H37O6PSi: C, 61.88; H, 7.39. Found: C, 61.86; H, 7.49. 564

(S_P)-1-O-tert-Butyldiphenylsilyl-5-deoxy-5-ethoxyphenylphos- 565 phoryl-2-O-formyl-3,4-O-isopropylidene-D-arabinitol (5) and (R_p) - 566 1-O-tert-Butyldiphenylsilyl-5-deoxy-5-ethoxyphenylphosphoryl-2- 567 O-formyl-3,4-O-isopropylidene-D-arabinitol (6). A solution of 3 (71 568 mg, 0.125 mmol) in PhP(OEt)₂ (140 μ L, 0.73 mmol) was stirred at 569 160 °C under nitrogen for 6 h. The reaction mixture was concentrated 570 under high vacuum, and the residue was purified by Chromatotron 571 chromatography (hexanes-EtOAc, 70:30) to give starting material 3 572 (7.4 mg, 0.013 mmol, 10%) and a mixture of compounds 5 and 6 573 (66.3 mg, 0.109 mmol, 87%, 5/6, 1:1.1) as a colorless oil. The mixture 574 was separated by HPLC (hexanes-EtOAc, 50:50; $\Phi = 3 \text{ mL/min}$). 575 Compound 5: $[\alpha]_{\rm D}$ -25.5 (c, 0.2, CHCl₃); IR (CHCl₃) 1722, 1185, 576 1113 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) $\delta_{\rm H}$ 1.02 (9H, s), 1.31 (3H, 577 t, J = 7.3 Hz), 1.32 (3H, s), 1.42 (3H, s), 2.03 (1H, ddd, ${}^{2}J_{PH} = 13.6$ 578 Hz, J = 15.1, 5.7 Hz, H2a), 2.30 (1H, ddd, ${}^{2}J_{PH} = 15.1$ Hz, J = 15.1, 579 8.2 Hz, H2b), 3.66 (1H, dd, J = 10.7, 5.0 Hz, H6a), 3.74 (1H, dd, J = 580 10.7, 6.9 Hz, H6b), 3.94 (1H, ddddd, ${}^{2}J_{PH}$ = 7.2 Hz, J = 10.1, 7.2, 7.2, 581 7.2 Hz), 4.09–4.19 (1H, m), 4.26 (1H, dd, J = 6.0, 3.8 Hz, H4), 4.60 582 $(1H, dddd, {}^{3}J_{PH} = 8.2 Hz, J = 8.2, 5.7, 5.7 Hz, H3), 5.11 (1H, m, H5), 583$ 7.35–7.44 (6H, m), 7.46–7.51 (2H, m), 7.54–7.58 (1H, m), 7.61–584 7.64 (4H, m), 7.78–7.85 (2H, m), 8.04 (1H, s, CHO); $^{13}\mathrm{C}\{^{1}\mathrm{H}\}$ 585 NMR (125.7 MHz, CDCl₃, the C-ipso was not observed) $\delta_{\rm C}$ 16.5 586 $(CH_3, d, {}^{3}J_{PC} = 6.4 Hz), 19.1 (C), 25.6 (CH_3), 26.7 (3 \times CH_3), 26.8 587$ (CH₃), 31.3 (CH₂, d, ${}^{1}J_{PC}$ = 99.6 Hz, C2), 61.0 (CH₂, d, ${}^{2}J_{PC}$ = 5.3 588 Hz), 62.8 (CH₂, C6), 71.2 (CH, d, ${}^{2}J_{PC}$ = 3.2 Hz, C3), 71.7 (CH, 589 C5), 75.5 (CH, d, ${}^{3}J_{PC}$ = 9.5 Hz, C4), 108.9 (C), 127.72 (2 × CH), 590 127.74 (2 × CH), 128.7 (2 × CH, d, ${}^{3}J_{PC}$ = 12.7 Hz), 129.80 (CH), 591 128.82 (CH), 131.6 (2 × CH, d, ${}^{2}J_{PC}$ = 10.6 Hz), 132.5 (CH, d, ${}^{4}J_{PC}$ 592 = 2.1 Hz), 132.9 (2 × C), 135.5 (2 × CH), 135.6 (2 × CH), 160.4 593 (CH, CHO); ${}^{31}P{}^{1}H$ NMR (162 MHz, CDCl₃) δ_{P} 40.1 (P); MS 594 $(\text{ESI}^+\text{-}\text{TOF}) m/z$ (%) 633 $[(M + \text{Na})^+, 100]$; HRMS $(\text{ESI}^+\text{-}\text{TOF}) m/595$

596 z: [M + Na]⁺ calcd for C₃₃H₄₃NaO₇PSi 633.2413; found 633.2404. 597 Anal. calcd for C33H43O7SiP: C, 64.90; H, 7.10. Found: C, 64.76; H, 598 7.45. Compound 6: $[\alpha]_D$ -2.7 (c, 0.15, CHCl₃); IR (CHCl₃) 1729, 599 1374, 1249 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) $\delta_{\rm H}$ 1.06 (9H, s), 1.19 600 (3H, s), 1.25 (3H, s), 1.27 (3H, t, J = 6.9 Hz), 2.15-2.31 (2H, m, 601 H2a, H2b) 3.76 (1H, dd, J = 10.7, 5.0 Hz, H6a), 3.82 (1H, dd, J = 602 10.7, 6.9 Hz, H6b), 3.83-3.88 (1H, m), 4.03-4.11 (1H, m), 4.36 603 (1H, dd, J = 5.8, 3.6 Hz, H4), 4.63 (1H, dddd, ${}^{3}J_{PH} = 6.8$ Hz, J = 6.8, 604 6.8, 6.8 Hz, H3), 5.40 (1H, ddd, J = 6.9, 5.7, 4.1 Hz, H5), 7.38-7.46 605 (6H, m), 7.48-7.51 (2H, m), 7.55-7.58 (1H, m), 7.65-7.69 (4H, 606 m), 7.80-7.84 (2H, m), 8.07 (1H, s, CHO); ¹³C{¹H} NMR (125.7 607 MHz, CDCl₃, the C-ipso was not observed) $\delta_{\rm C}$ 16.4 (CH₃, d, ³J_{PC} = 608 7.4 Hz), 19.1 (C), 25.5 (CH₃), 26.4 (CH₃), 26.7 (3 × CH₃), 30.8 609 (CH₂, d, ${}^{1}J_{PC}$ = 100.7 Hz, C2), 60.8 (CH₂, d, ${}^{2}J_{PC}$ = 6.4 Hz), 62.9 610 (CH₂, C6), 71.4 (CH, C3), 71.6 (CH, C5), 75.4 (CH, d, ${}^{3}J_{PC} = 8.5$ 611 Hz, C4), 108.7 (C), 127.75 (2 × CH), 127.78 (2 × CH), 128.5 (2 × 612 CH, d, ${}^{3}J_{PC}$ = 12.7 Hz), 129.8 (2 × CH), 131.9 (2 × CH, d, ${}^{2}J_{PC}$ = 613 10.6 Hz), 132.4 (CH, d, ${}^{4}J_{PC}$ = 2.1 Hz), 132.9 (2 × C), 135.5 (2 × 614 CH), 135.6 (2 × CH), 160.5 (CH, CHO); ³¹P{¹H} NMR (162 MHz, 615 CDCl₃) $\delta_{\rm P}$ 41.1 (P); MS (ESI⁺-TOF) m/z (%) 633 [(M + Na)⁺, 616 100]; HRMS (ESI⁺-TOF) m/z: [M + Na]⁺ calcd for C₃₃H₄₃NaO₇PSi 617 633.2413; found 633.2400. Anal. calcd for C₃₃H₄₃O₇PSi: C, 64.90; H, 618 7.10. Found: C, 65.11; H, 7.32.

(R_P)-6-O-tert-Butyldiphenylsilyl-1,2-dideoxy-3,4-O-isopropyli-619 620 dene-1-phenyl-1-phospha-1-oxo-p-lyxo-hexopyranose (38). A sol-621 ution of 5 (8.5 mg, 0.014 mmol) in NaOEt/EtOH 0.01 M (0.12 mL, 622 1.2×10^{-3} mmol) was stirred at room temperature under nitrogen for 623 24 h. The reaction mixture was concentrated under reduced pressure, 624 and the residue was purified by Chromatotron chromatography 625 (hexanes-EtOAc, 40:60) to give compound 38 (5.2 mg, 0.01 mmol, 626 70%) as a crystalline solid: mp 134.4-135.6 °C (from n-hexane-627 EtOAc); [α]_D +11.9 (*c*, 0.27, CHCl₃); IR (CHCl₃) 2996, 1428, 1243, 628 1229, 1113 cm⁻¹; ¹H NMR (500 MHz, CDCl₃, simulated coupling 629 constants using DAISY) $\delta_{\rm H}$ 1.07 (9H, s), 1.37 (3H, s), 1.39 (3H, s), 630 2.36 (1H, ddd, ${}^{2}J_{PH}$ = 17.8 Hz, J = 16.3, 4.5 Hz, H2 α), 2.59 (1H, ddd, $_{631}$ $^{2}J_{PH} = 7.9$ Hz, J = 16.3, 4.5 Hz, H2 β), 3.96 (1H, dd, J = 9.8, 6.0 Hz, 632 H6a), 4.05 (1H, dd, J = 9.8, 7.6 Hz, H6b), 4.52 (1H, ddd, ${}^{3}J_{PH}$ = 0.8 633 Hz, J = 6.9, 1.9 Hz, H4), 4.72 (1H, dddd, ${}^{3}J_{PH}$ = 6.3 Hz, J = 7.6, 6.0, 634 1.9 Hz, H5), 4.81 (1H, dddd, ${}^{3}J_{PH} = 24.6$ Hz, J = 6.9, 4.5, 4.5 Hz, 635 H3), 7.34-7.47 (8H, m), 7.53-7.56 (1H, m), 7.67-7.70 (2H, m), 636 7.72-7.75 (2H, m), 7.90-7.95 (2H, m); ¹³C{¹H} NMR (125.7 MHz, $_{637}$ CDCl₃) δ_{C} 19.2 (C), 24.6 (CH₃), 26.2 (CH₃), 26.7 (3 × CH₃), 28.1 638 (CH₂, d, ${}^{1}J_{PC}$ = 85.8 Hz, C2), 62.6 (CH₂, d, ${}^{3}J_{PC}$ = 9.5 Hz, C6), 70.8 639 (CH, d, ${}^{2}J_{PC}$ = 6.4 Hz, C3), 72.1 (CH, d, ${}^{3}J_{PC}$ = 4.2 Hz, C4), 73.7 640 (CH, d, ${}^{2}J_{PC}$ = 5.3 Hz, C5), 108.8 (C), 127.6 (2 × CH), 127.7 (2 × 641 CH), 128.3 (2 × CH, d, ${}^{3}J_{PC}$ = 13.8 Hz), 129.7 (CH), 129.73 (CH), 642 130.7 (C, d, ${}^{1}J_{PC}$ = 142.0 Hz), 131.6 (2 × CH, d, ${}^{2}J_{PC}$ = 10.6 Hz), 643 132.5 (CH, d, ${}^{4}J_{PC}$ = 3.2 Hz), 133.0 (C), 133.2 (C), 135.6 (2 × CH), 644 135.7 (2 × CH); ${}^{31}P{}^{1}H$ NMR (162 MHz, CDCl₃) δ_{P} 37.2 (P); MS 645 (ESI⁺-TOF) m/z (%) 559 [(M + Na)⁺, 100]; HRMS (ESI⁺-TOF) m/z646 z: [M + Na]⁺ calcd for C₃₀H₃₇NaO₅PSi 559.2046; found 559.2057. 647 Anal. calcd for C₃₀H₃₇O₅PSi: C, 67.14; H, 6.95. Found: C, 67.32; H, 648 6.92

(S_P)-6-O-tert-Butyldiphenylsilyl-1,2-dideoxy-3,4-O-isopropyli-649 650 dene-1-phenyl-1-phospha-1-oxo-p-lyxo-hexopyranose (39). A sol-651 ution of 6 (4.8 mg, 0.0079 mmol) in NaOEt/EtOH 0.01 M (0.07 mL, 652 0.7×10^{-3} mmol) was stirred at room temperature under nitrogen for 653 24 h. The reaction mixture was concentrated under reduced pressure, 654 and the residue was purified by Chromatoron chromatography 655 (hexanes-EtOAc, 40:60) to give 39 (3.2 mg, 6.0×10^3 mmol, 75%) 656 as a crystalline solid: mp 171.8-173.2 °C (from n-hexane-EtOAc); $657 \ [\alpha]_{\rm D}$ +10.8 (c, 0.12, CHCl₃); IR (CHCl₃) 2997, 1229, 1113 cm⁻¹; ¹H 658 NMR (500 MHz, CDCl₃, simulated coupling constants using DAISY) 659 $\delta_{\rm H}$ 1.08 (9H, s), 1.35 (3H, s), 1.63 (3H, s), 2.11 (1H, ddd, ²J_{PH} = 6.6 660 Hz, J = 15.9, 4.0 Hz, H2 α), 2.62 (1H, ddd, ${}^{2}J_{PH} = 14.8$ Hz, J = 15.9, 661 4.1 Hz, H2β), 3.99 (1H, ddd, ${}^{4}J_{PH}$ = 2.3 Hz, J = 10.7, 5.5 Hz, H6a), 662 4.07 (1H, dd, J = 10.7, 6.8 Hz, H6b), 4.19 (1H, dddd, ${}^{3}J_{PH} = 3.3$ Hz, J663 = 6.8, 5.5, 1.5 Hz, H5), 4.35 (1H, ddd, ${}^{3}J_{PH}$ = 0.9 Hz, J = 7.2, 1.5 Hz, 664 H4), 4.78 (1H, dddd, ${}^{3}J_{PH}$ = 24.2 Hz, J = 7.2, 4.0, 4.1 Hz, H3), 7.37-665 7.41 (4H, m), 7.43-7.47 (4H, m), 7.53-7.57 (1H, m), 7.68-7.71 (4H, m), 7.76–7.80 (2H, m); ${}^{13}C{}^{1}H$ NMR (125.7 MHz, CDCl₃, 666 the C-*ipso* was not observed) $\delta_{\rm C}$ 19.2 (C), 24.8 (CH₃), 26.2 (CH₃), 667 26.8 (3 × CH₃), 27.5 (CH₂, d, ${}^{1}J_{\rm PC}$ = 85.8 Hz, C2), 63.6 (CH₂, d, ${}^{3}J_{\rm PC}$ 668 = 9.5 Hz, C6), 71.4 (CH, d, ${}^{2}J_{\rm PC}$ = 7.4 Hz, C3), 72.4 (CH, d, ${}^{3}J_{\rm PC}$ 669 6.4 Hz, C4), 77.7 (CH, d, ${}^{2}J_{\rm PC}$ = 6.4 Hz, C5), 110.0 (C), 127.7 (2 × 670 CH), 127.8 (2 × CH), 128.79 (2 × CH, d, ${}^{3}J_{\rm PC}$ = 13.8 Hz), 129.82 (2 671 × CH), 130.2 (2 × CH, d, ${}^{2}J_{\rm PC}$ = 9.5 Hz), 132.2 (CH, d, ${}^{4}J_{\rm PC}$ = 2.1 672 Hz), 132.9 (C), 133.0 (C), 135.6 (4 × CH); ${}^{31}P{}^{1}H$ NMR (162 673 MHz, CDCl₃) $\delta_{\rm P}$ 33.9 (P); MS (ESI⁺-TOF) m/z (%) 559 [(M + 674 Na)⁺, 100]; HRMS (ESI⁺-TOF) m/z: [M + Na]⁺ calcd for 675 C₃₀H₃₇NaO₅PSi 559.2046; found 559.2043. Anal. calcd for 676 C₃₀H₃₇O₅PSi: C, 67.14; H, 6.95. Found: C, 67.03; H, 6.96.

2-Deoxy-5,6-O-isopropylidene-3-O-methyl-D-arabino-hexofura- 678 nose (8). To 1,4-anhydro-2-deoxy-3-O-methyl-5,6-O-isopropylidene- 679 D-arabino-hex-1-enitol 7³⁵ (4 g, 20 mmol) in THF (56 mL) and water 680 (40 mL), Hg(OAc)₂ (7 g, 22 mmol) was added at room temperature. 681 The reaction mixture was stirred at this temperature for 1 h, and 682 afterward, the solution was kept at 0 °C for 15 min. To this reaction 683 mixture, an aqueous solution of KI (15.9 g, 96 mmol in 18 mL of 684 water) was added and the mixture was stirred for another 30 min. To 685 the resulting reaction mixture at 0 °C, an aqueous solution of NaBH4 686 (831 mg, 22 mmol in 40 mL of water) was added dropwise and 687 stirred for 1.5 h at this temperature. The insoluble part was removed 688 by filtration through a bed of Celite and washed with EtOAc. The 689 filtrate was separated, and the organic layer was extracted with EtOAc, 690 dried over Na₂SO₄, and concentrated under reduced pressure to give 691 a residue (5 g), which was purified by column chromatography 692 (hexanes-EtOAc, 60:40) to obtain 8 (1.63 g, 7.48 mmol, 37%) as a 693 crystalline mixture of anomeric isomers (6:4); IR (CHCl₃) 3597, 694 3398, 2938, 1228, 1069 cm⁻¹; ¹H NMR (500 MHz, CDCl₃, minor 695 isomer) δ 1.37 (3H, s), 1.43 (3H, s), 2.00 (1H, ddd, J = 14.2, 5.7, 3.5 696 Hz, H2a), 2.26 (1H, ddd, J = 14.3, 5.6, 1.5 Hz, H2b), 3.33 (3H, s), 697 3.94 (1H, dd, J = 8.8, 6.1 Hz, H6a), 4.02 (1H, m, H3), 4.05 (1H, dd, J 698 = 8.6, 6.4 Hz, H6b), 4.19 (1H, dd, J = 6.6, 4.1 Hz, H4), 4.32 (1H, 699) ddd, J = 6.3, 6.3, 6.3 Hz, H5), 5.64 (1H, ddd, J = 5.6, 3.0, 3.0 Hz, 700 H1); ${}^{13}C{}^{1}H$ NMR (125.7 MHz, CDCl₃, minor isomer) δ 25.3 701 (CH₃), 26.6 (CH₃), 39.7 (CH₂, C2), 57.2 (CH₃), 66.6 (CH₂, C6), 702 73.3 (CH, C5), 80.6 (CH, C3), 80.9 (CH, C4), 98.0 (CH, C1) 108.7 703 (C); ¹H NMR (500 MHz, CDCl₃, major isomer) δ 1.37 (3H, s), 1.42 704 (3H, s), 1.97 (1H, ddd, I = 13.9, 5.0, 4.1 Hz, H2a), 2.25 (1H, br d, I = 705)13.9 Hz, H2b), 3.45 (3H, s), 3.71 (1H, d, J = 11.3 Hz, OH), 3.85 706 (1H, dd, J = 7.7, 3.6 Hz, H4), 3.96 (1H, m, H3), 4.02 (1H, m, H6a), 707 4.13 (1H, dd, J = 8.7, 6.1 Hz, H6b), 4.37 (1H, ddd, J = 7.9, 5.8, 5.8 708 Hz, H5), 5.36 (1H, dd, J = 11.3, 5.0 Hz, H1); ¹³C{¹H} NMR (125.7 709 MHz, CDCl₃, major isomer) δ 25.4 (CH₃), 26.8 (CH₃), 38.6 (CH₂, 710 C2), 57.8 (CH₃), 67.2 (CH₂, C6), 73.8 (CH, C5), 80.1 (CH, C3), 711 83.8 (CH, C4), 99.0 (CH, C1), 108.9 (C); MS (ESI⁺-TOF) m/z (%) 712 241 [(M + Na)⁺, 100]; HRMS (ESI⁺-TOF) m/z [M + Na]⁺ calcd for 713 C10H18NaO5 241.1052; found 241.1051. Anal. calcd for C10H18O5: C, 714 55.03; H, 8.31. Found: C, 54.93; H, 8.24. 715

1-Deoxy-3-O-formyl-1-iodo-4,5-O-isopropylidene-2-O-methyl-D-716 arabinitol (9). To a solution of 8 (52 mg, 0.24 mmol) in dry CH₂Cl₂ 717 (3.3 mL) were added PhI(OAc)₂ (93.4 mg, 0.29 mmol) and I₂ (61 718 mg, 0.24 mmol). The reaction mixture was stirred at room 719 temperature for 1.25 h, poured into an aqueous solution of 720 $Na_2S_2O_3$ (10%), and extracted with CH_2Cl_2 . The organic extracts 721 were dried over Na2SO4 and concentrated under reduced pressure. 722 The residue was purified by Chromatotron chromatography 723 (hexanes-EtOAc, 8:2) to give 9 (70 mg, 0.20 mmol, 85%) as a 724 colorless oil: [a]_D +11.7 (c, 0.97, CHCl₃); IR (CHCl₃) 1733, 1372, 725 1226, 1164, 1077 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 1.36 (3H, s), 726 1.43 (3H, s), 3.07 (1H, dd, J = 10.4, 8.2 Hz, H6a), 3.29 (1H, dd, J = 727 10.4, 5.7 Hz, H6b), 3.52 (3H, s), 3.72 (1H, ddd, J = 8.0, 5.6, 2.5 Hz, 728 H3), 3.85 (1H, dd, J = 8.8, 5.7 Hz, H2a), 4.02 (1H, dd, J = 8.8, 6.0 729 Hz, H2b), 4.27 (1H, ddd, J = 7.6, 6.0, 6.0 Hz, H5), 5.35 (1H, dd, J = 7307.3, 2.5 Hz, H4), 8.14 (1H, s, CHO); ¹³C{¹H} NMR (125.7 MHz, 731 CDCl₃) δ 1.6 (CH₂, C2), 25.4 (CH₃), 26.7 (CH₃), 59.3 (CH₃), 66.3 732 (CH₂, C6), 72.9 (CH, C4), 74.1 (CH, C5), 79.8 (CH, C3), 109.6 733 (C), 160.1 (CH, CHO); MS (ESI⁺-TOF) m/z (%) 367 [(M + Na)⁺, 734 100]; HRMS (ESI⁺-TOF) m/z [M + Na]⁺ calcd for C₁₀H₁₇INaO₅ 735

1-Deoxy-1-diethoxyphosphoryl-3-O-formyl-4,5-O-isopropyli-738 739 dene-2-O-methyl-D-arabinitol (10). A solution of 9 (311 mg, 0.90 740 mmol) in (EtO)₃P (8.2 mL, 48 mmol) was stirred at reflux 741 temperature for 3 h. The mixture was concentrated under high 742 vacuum, and the residue was purified by Chromatotron chromatog-743 raphy (hexanes-EtOAc, $3:7 \rightarrow 2:8$) to give compound 10 (248 mg, 744 0.7 mmol, 78%). Small quantities of alcohol 33 (14 mg, 0.043 mmol, 745 5%) and cyclized compounds 40 (13 mg, 0.046 mmol, 5%) and 41 746 (15 mg, 0.054 mmol, 6%) were also obtained (vide infra). Compound 747 10: colorless oil, $[\alpha]_{D}$ +1.6 (c, 0.87, CHCl₃); IR (CHCl₃) 2995, 1733, 748 1375, 1236, 1167, 1027 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 1.306 749 (3H, t, J = 6.9 Hz), 1.308 (3H, t, J = 6.9 Hz), 1.33 (3H, s), 1.38 (3H, 750 s), 1.91 (1H, ddd, ${}^{2}J_{PH}$ = 18.6 Hz, J = 15.4, 6.6 Hz, H2a), 2.02 (1H, 751 ddd, ${}^{2}J_{\rm PH}$ = 19.2 Hz, J = 16.1, 6.3 Hz, H2b), 3.46 (3H, s), 3.83 (1H, 752 dd, J = 8.7, 6.1 Hz, H6a), 3.92 (1H, dddd, ${}^{3}J_{PH} = 9.5$ Hz, J = 6.6, 6.6, 753 2.2 Hz, H3), 3.99 (1H, dd, J = 8.8, 6.3 Hz, H6b), 4.08 (4H, m), 4.26 754 (1H, ddd, J = 6.2, 6.2, 6.2 Hz, H5), 5.12 (1H, dd, J = 6.5, 2.0 Hz, H4), 755 8.13 (1H, s, CHO); ¹³C{¹H} NMR (125.7 MHz, CDCl₃) δ 16.30 756 (CH₃, d, ${}^{3}J_{PC}$ = 6.4 Hz), 16.32 (CH₃, d, ${}^{3}J_{PC}$ = 6.4 Hz), 25.4 (CH₃), 757 26.5 (CH₃), 27.6 (CH₂, d, ${}^{1}J_{PC}$ = 140.9 Hz, C2), 58.7 (CH₃), 61.7 758 (CH₂, d, ${}^{2}J_{PC} = 6.4$ Hz), 61.9 (CH₂, d, ${}^{2}J_{PC} = 6.4$ Hz), 66.3 (CH₂, 759 C6), 74.0 (CH, C5), 74.8 (CH, C4), 74.9 (CH, d, ${}^{2}J_{PC} = 9.5$ Hz, C3), 760 109.3 (C), 160.3 (CH, CHO); ³¹P{¹H} NMR (202.5 MHz, CDCl₃) δ 761 27.5 (P); MS (ESI⁺-TOF) m/z (%) 377 [(M + Na)⁺, 100]; HRMS 762 (ESI⁺-TOF) m/z [M + Na]⁺ calcd for C₁₄H₂₇NaO₈P 377.1341; found 763 377.1344. Anal. calcd for C₁₄H₂₇O₈P: C, 47.44; H, 7.68. Found: C, 764 47.23: H. 7.40.

1-Deoxy-1-diethoxyphosphoryl-4,5-O-isopropylidene-2-O-meth-765 766 yl-D-arabinitol (33). A solution of 10 (48 mg, 0.135 mmol) in 767 NaOEt/EtOH 0.011 M (1.1 mL, 0.012 mmol) was stirred at room 768 temperature under nitrogen for 1.25 h. The mixture was concentrated 769 under reduced pressure, and the residue was purified by 770 Chromatotron chromatography (hexanes-EtOAc, 2:98) to give alcohol 33 (34 mg, 0.104 mmol, 77%). Small quantities of cyclized 771 772 compounds 40 (2.8 mg, 0.01 mmol, 7%) and 41 (1.5 mg, 0.0054 773 mmol, 4%) were also obtained (vide infra). Compound 33: colorless 774 oil, $[\alpha]_{\rm D}$ -21.3 (c, 0.92, CHCl₃); IR (CHCl₃) 3389, 2986, 1373, 775 1231, 1160, 1072, 1032 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 1.33 776 (6H, t, J = 7.2 Hz), 1.34 (3H, s), 1.39 (3H, s), 2.14 (1H, ddd, ${}^{2}J_{HP} =$ 777 19.8 Hz, J = 15.5, 5.3 Hz, H2a), 2.23 (1H, ddd, ${}^{2}J_{HP} = 18.3$ Hz, J =778 15.4, 7.6 Hz, H2b), 2.91 (1H, br d, J = 8.0 Hz, OH), 3.44 (3H, s), 779 3.56 (1H, ddd, J = 7.8, 7.8, 1.6 Hz, H4), 3.83 (1H, dddd, ${}^{3}J_{\text{HP}} = 12.0$ 780 Hz, J = 7.5, 5.3, 1.6 Hz, H3), 4.09 (7H, m); ¹H NMR (500 MHz, 781 C_6H_6 δ 1.03 (3H, t, J = 6.9 Hz), 1.06 (3H, t, J = 6.9 Hz), 1.31 (3H, 782 s), 1.44 (3H, s), 2.12 (1H, ddd, ${}^{2}J_{HP}$ = 19.9 Hz, J = 15.1, 5.0 Hz, 783 H2a), 2.33 (1H, ddd, ${}^{2}J_{\rm HP}$ = 17.8 Hz, J = 15.3, 7.9 Hz, H2b), 2.42 784 (1H, m, OH), 3.26 (3H, s), 3.81 (1H, br dd, J = 7.0, 7.0 Hz, H4), 785 3.90 (4H, m), 3.98 (1H, m, H3), 4.10 (1H, dd, J = 8.2, 6.0 Hz, H6a), 786 4.23 (2H, m, H5 and H6b); ${}^{13}C{}^{1}H$ NMR (125.7 MHz, CDCl₃) δ 787 16.3 (2 × CH₃, d, ${}^{3}J_{PC}$ = 6.4 Hz), 25.4 (CH₃), 26.81 (CH₃), 27.2 788 (CH₂, d, ${}^{1}J_{PC}$ = 137.8 Hz, C2), 58.1 (CH₃), 61.7 (CH₂, d, ${}^{2}J_{PC}$ = 7.4 789 Hz), 61.8 (CH₂, d, ${}^{2}J_{PC}$ = 6.4 Hz), 67.3 (CH₂, C6), 74.2 (CH, d, ${}^{2}J_{PC}$ 790 = 6.4 Hz, C4), 75.2 (CH, C3), 75.4 (CH, C5), 109.1 (C); ${}^{13}C{}^{1}H{}$ 791 NMR (125.7 MHz, C₆D₆) δ 16.4 (2 × CH₃, d, ${}^{3}J_{PC}$ = 6.4 Hz), 25.7 792 (CH₃), 27.2 (CH₃), 27.6 (CH₂, d, J = 137.8 Hz, C2), 57.8 (CH₃), 793 61.5 (CH₂, d, ${}^{2}J_{PC}$ = 6.4 Hz), 61.6 (CH₂, d, ${}^{2}J_{PC}$ = 6.4 Hz), 68.0 794 (CH₂, C6), 74.7 (CH, d, ${}^{2}J_{PC}$ = 5.3 Hz, C4), 76.0 (CH, C5), 76.1 795 (CH, C3), 109.3 (C); ${}^{31}P{}^{1}H{}$ NMR (162 MHz, CDCl₃) δ 29.16 796 (1P, s); ${}^{31}P{}^{1}H$ NMR (162 MHz, C₆D₆) δ 42.91 (1P, s); MS (ESI⁺-797 TOF) m/z (%) 349 [(M + Na)⁺, 100]; HRMS (ESI⁺-TOF) m/z [M + Na]⁺ calcd for C₁₃H₂₇NaO₇P 349.1392; found 349.1395. Anal. 798 799 calcd for C₁₃H₂₇O₇P: C, 47.85; H, 8.34. Found: C, 47.98; H, 7.96. (S_P)-1,2-Dideoxy-1-ethoxy-5,6-O-isopropylidene-3-O-methyl-1-800 $_{801}$ oxo-1-phospha-D-arabino-hexofuranose (40) and (R_p)-1,2-Di-802 deoxy-1-ethoxy-5,6-O-isopropylidene-3-O-methyl-1-oxo-1-phos-803 pha-D-arabino-hexofuranose (41). A solution of 33 (29 mg, 0.089 804 mmol) and pyridinium p-toluenesulfonate (PPTS) (45 mg, 0.18 805 mmol) in dry CHCl₃ (0.8 mL), containing molecular sieves (4 Å

powder, 30 mg), was stirred at reflux temperature under nitrogen for 806 86.5 h. The mixture was poured into brine and extracted with CHCl₃, 807 and the residue was purified by Chromatotron chromatography 808 (CHCl₃-EtOAc, 30:70) to give the cyclized compounds 40 (1.8 mg, 809 0.0064 mmol, 7%, 9% brsm) and 41 (10.4 mg, 0.037 mmol, 41%, 52% 810 brsm) while the starting material 33 (6 mg, 0.018 mmol, 20%) was 811 recovered. Compound 40: colorless oil, $[\alpha]_D = -26.8$ (c, 0.96, 812 CHCl₃); IR (CHCl₃) 2935, 1373, 1250, 1221, 1077, 1044, 1013 ⁸¹³ cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 1.33 (3H, t, *J* = 7.1 Hz), 1.36 ⁸¹⁴ (3H, s), 1.42 (3H, s), 1.95 $(1H, ddd, {}^{2}J_{PH} = 15.9 Hz$, J = 15.9, 5.3 Hz, 815 H2 α), 2.24 (1H, ddd, ²J_{PH} = 11.8 Hz, J = 15.7, 1.2 Hz, H2 β), 3.38 816 (3H, s), 4.08 (4H, m), 4.18 (2H, m), 4.46 (1H, ddd, J = 7.3, 6.3, 5.0 817 Hz); ¹H NMR (500 MHz, C₆D₆, simulated coupling constants using 818 DAISY) δ 1.02 (3H, t, J = 7.0 Hz), 1.22 (3H, s), 1.32 (1H, ddd, ²J_{PH} 819 = 15.9 Hz, J = 15.7, 5.7 Hz, H2 α), 1.36 (3H, s), 1.80 (1H, ddd, ${}^{2}J_{\text{PH}} = 820$ 11.7 Hz, J = 15.7, 1.2 Hz, H2 β), 2.83 (3H, s), 3.45 (1H, dddd, ${}^{3}J_{\text{PH}} = 821$ 28.7 Hz, J = 5.7, 3.3, 1.2 Hz, H3), 3.83 (1H, dd, J = 7.3, 3.3 Hz, H4), 822 3.92 (1H, dd, J = 9.0, 6.5 Hz, H6a), 3.97 (2H, m), 4.07 (1H, dd, J = 823 9.0, 5.1 Hz, H6b), 4.42 (1H, ddd, J = 7.3, 6.5, 5.1 Hz, H5); ${}^{13}C{}^{1}H{}$ 824 NMR (125.7 MHz, CDCl₃) δ 16.4 (CH₃, d, ³J_{PC} = 5.3 Hz), 25.3 825 (CH_3) , 26.3 $(CH_2, d, {}^{1}J_{PC} = 124.0 \text{ Hz}, C2)$, 26.9 (CH_3) , 57.2 (CH_3) , 826 62.4 (CH₂, d, ${}^{2}J_{PC}$ = 6.4 Hz), 66.6 (CH₂, C6), 73.1 (CH, d, ${}^{3}J_{PC}$ = 827 11.7 Hz, C5), 77.6 (CH, C3), 81.6 (CH, d, ${}^{2}J_{PC}$ = 7.4 Hz, C4), 109.4 828 (C); ${}^{13}C{}^{1}H$ NMR (125.7 MHz, C_6D_6) δ 16.5 (CH₃, d, ${}^{3}J_{PC} = 5.3$ 829 Hz), 25.3 (CH₃), 26.2 (CH₂, d, ${}^{1}J_{PC} = 122.9$ Hz, C2), 27.0 (CH₃), 830 56.6 (CH₃), 61.9 (CH₂, d, ${}^{2}J_{PC} = 6.4$ Hz), 66.9 (CH₂, C6), 73.6 (CH, 831 d, ${}^{3}J_{PC} = 11.7$ Hz, C5), 77.9 (CH, C3), 81.7 (CH, d, ${}^{2}J_{PC} = 7.4$ Hz, 832 C4), 109.2 (C); ${}^{31}P{}^{1}H{}$ NMR (162 MHz, CDCl₃) δ 45.02 (1P, s); 833 ³¹P{¹H} NMR (162 MHz, C₆D₆) δ 57.0 (1P, s); MS (ESI⁺-TOF) *m*/₈₃₄ z (%) 303 [(M + Na)⁺, 100]; HRMS (ESI⁺-TOF) m/z [M + Na]⁺ 835 calcd for C11H21NaO6P 303.0973; found 303.0970. Anal. calcd for 836 C11H21O6P: C, 47.14; H, 7.55. Found: C, 47.16; H, 7.24. Compound 837 41: colorless oil, $[\alpha]_D = -49.5$ (c, 0.98, CHCl₃); IR (CHCl₃) 2934, 838 1375, 1252, 1160, 1077, 1046, 1013 cm⁻¹; ¹H NMR (500 MHz, 839 $C_6 D_6$, simulated coupling constants using DAISY) δ 1.01 (3H, t, J = 840 7.1 Hz), 1.23 (3H, s), 1.36 (3H, s), 1.53 (1H, ddd, ${}^{2}J_{PH} = 16.7$ Hz, J = 84116.0, 5.3 Hz, H2 α), 1.67 (1H, ddd, ${}^{2}J_{\rm PH}$ = 10.6 Hz, J = 16.0, 0.9 Hz, 842 $H2\beta$), 2.79 (3H, s), 3.40 (1H, dddd, ${}^{3}J_{PH} = 30.7$ Hz, J = 5.3, 4.1, 0.9 843 Hz, H3), 3.93 (1H, dd, J = 8.8, 6.9 Hz, H6a), 3.97 (2H, m, CH₂-P), 844 3.97 (1H, dd, J = 7.0, 4.1 Hz, H4), 4.04 (1H, dd, J = 8.8, 5.3 Hz, 845 H6b), 4.32 (1H, ddd, J = 7.0, 6.9, 5.3 Hz, H5); ¹³C{¹H} NMR (125.7 846 MHz, C₆D₆) δ 16.5 (CH₃, d, ³J_{PC} = 5.3 Hz), 25.4 (CH₃), 26.1 (CH₂, 847 d, ${}^{1}J_{PC}$ = 121.9 Hz, C2), 27.0 (CH₃), 56.6 (CH₃), 62.5 (CH₂, d, ${}^{2}J_{PC}$ 848 = 6.4 Hz), 66.9 (CH₂, C6), 73.6 (CH, d, ${}^{3}J_{PC}$ = 10.6 Hz, C5), 78.3 849 (CH, C3), 82.1 (CH, d, ${}^{2}J_{PC}$ = 8.5 Hz, C4), 109.3 (C); ${}^{31}P{}^{1}H$ NMR 850 (162 MHz, CDCl₃) δ 45.4 (1P, s); ³¹P{¹H} NMR (162 MHz, C₆D₆) 851 δ 57.3 (1P, s); MS (ESI⁺-TOF) m/z (%) 303 [(M + Na)⁺, 100]; 852 HRMS (ESI⁺-TOF) m/z [M + Na]⁺ calcd for C₁₁H₂₁NaO₆P 853 303.0973; found 303.0981. Anal. calcd for C11H21O6P: C, 47.14; H, 854 7.55. Found: C, 47.20; H, 7.38.

(S_p)-1-Deoxy-1-ethoxyphenylphosphoryl-3-O-formyl-4,5-O-iso-856 prop/lidene-2-O-methyl-D-arabinitol (11) and (R_p)-1-Deoxy-1- 857 ethoxyphenylphosphoryl-3-O-formyl-4,5-O-isopropylidene-2-O- 858 methyl-D-arabinitol (12). A solution of 9 (61 mg, 0.177 mmol) in 859 $PhP(OEt)_2$ (360 μ L, 1.87 mmol) was stirred at 150 °C for 6 h under 860 nitrogen. The mixture was concentrated under high vacuum, and the 861 residue was purified by Chromatotron chromatography (toluene- 862 EtOAc, 30:70) to give a mixture of P-isomers (49.6 mg, 0.128 mmol, 863 1:1, 72%), which was separated by HPLC: Nucleosil 100-5 chiral-3, 864 250 mm × 4 mm, n-hexane-EtOAc, 40:60, 0.65 mL/min, 12 at 25 865 min (22 mg, 0.057 mmol, 32%), 11 at 31 min (23.5 mg, 0.061 mmol, 866 34%). Compound 12: colorless oil, $[\alpha]_{D} = +24.9$ (c, 0.94, CHCl₃); IR 867 (CHCl₃) 3017, 1730, 1228, 1170, 1123, 1075, 1036 cm⁻¹; ¹H NMR 868 $(500 \text{ MHz}, \text{CDCl}_3) \delta 1.28 (3\text{H}, \text{t}, J = 6.9 \text{ Hz}), 1.35 (3\text{H}, \text{s}), 1.41 (3\text{H}, 869)$ s), 2.15 (2H, dd, ${}^{2}J_{PH}$ = 14.8 Hz, J = 6.6 Hz, H2), 3.29 (3H, s), 3.80 870 (1H, m), 3.85 (1H, dd, J = 8.7, 6.1 Hz, H6a), 4.01 (1H, dd, J = 8.7, 871 6.1 Hz, H6b), 4.06 (2H, m), 4.27 (1H, ddd, J = 6.5, 6.5, 6.5 Hz, H5), 872 5.19 (1H, dd, J = 6.6, 2.2 Hz, H4), 7.50 (2H, m), 7.56 (1H, m), 7.78 873 (2H, m), 8.17 (1H, s, CHO); ${}^{13}C{}^{1}H$ NMR (125.7 MHz, CDCl₃) δ 874 16.4 (CH₃, d, ${}^{3}J_{PC}$ = 7.4 Hz), 25.4 (CH₃), 26.54 (CH₃), 31.7 (CH₂, d, 875

 $_{876}$ $^{1}J_{PC}$ = 100.7 Hz, C2), 58.7 (CH₃), 60.9 (CH₂, d, $^{2}J_{PC}$ = 6.4 Hz), 66.3 877 (CH₂, C6), 74.0 (CH, C5), 74.5 (CH, C3), 75.5 (CH, d, ${}^{3}J_{PC} = 8.5$ 878 Hz, C4), 109.4 (C), 128.7 (2 × CH, ${}^{3}J_{PC}$ = 12.7 Hz, C-meta), 131.5 879 (2 × CH, d, ${}^{2}J_{PC}$ = 9.5 Hz, C-ortho), 132.4 (CH, d, ${}^{4}J_{PC}$ = 3.2 Hz, C-880 para), 160.5 (CH, CHO), (the C-ipso is not observed); ¹H NMR 881 (500 MHz, C_6D_6) δ 0.96 (3H, t, J = 7.1 Hz), 1.24 (3H, s), 1.37 (3H, 882 s), 2.08 (1H, ddd, ${}^{2}J_{PH}$ = 12.0 Hz, J = 15.4, 6.9 Hz, H2a), 2.21 (1H, 883 ddd, ${}^{2}J_{\rm PH}$ = 16.7 Hz, J = 15.1, 6.0 Hz, H2b), 3.10 (3H, s), 3.52 (1H, 884 m), 3.79 (1H, dd, J = 8.7, 6.1 Hz, H6a), 3.84 (1H, m), 3.90 (1H, dd, J 885 = 8.5, 6.0 Hz, H6b), 4.14 (1H, m, H3), 4.16 (1H, ddd, J = 6.3, 6.3, 6.3) 886 Hz, H5), 5.37 (1H, dd, J = 6.5, 3.0 Hz, H4), 7.07 (3H, m), 7.68 (1H, 887 s, CHO), 7.79 (2H, m); ${}^{13}C{}^{1}H$ NMR (125.7 MHz, C₆D₆) δ = 16.3 888 (CH₃, d, ${}^{3}J_{PC}$ = 6.4 Hz), 25.6 (CH₃), 26.7 (CH₃), 31.9 (CH₂, d, ${}^{1}J_{PC}$ $889 = 102.8 \text{ Hz}, \text{ C2}), 58.2 (CH_3), 60.6 (CH_2, d_2)^2 J_{PC} = 6.4 \text{ Hz}), 66.4$ 890 (CH₂, C6), 74.7 (CH, C3 or C5), 75.1 (CH, C5 or C3), 75.7 (CH, d, ${}^{3}J_{PC} = 8.5 \text{ Hz}, \text{ C4}$, 109.3 (C), 128.6 (2 × CH, d, ${}^{3}J_{PC} = 11.7 \text{ Hz}, \text{ C-}$ 892 meta), 131.9 (2 × CH, d, ${}^{2}J_{PC}$ = 9.5 Hz, C-ortho), 132.0 (CH, d, ${}^{4}J_{PC}$ 893 = 2.1 Hz, C-para), 132.7 (C, d, ${}^{1}J_{PC}$ = 124.0 Hz, C-ipso), 160.5 (CH, 894 CHO); ${}^{31}P{}^{1}H{}$ NMR (162 MHz, CDCl₃) δ 40.9 (1P, s); ${}^{31}P{}^{1}H{}$ 895 NMR (162 MHz, C_6D_6) δ 52.5 (1P, s); MS (ESI⁺-TOF) m/z (%) 896 409 [(M + Na)⁺, 100]; HRMS (ESI⁺-TOF) m/z [M + Na]⁺ calcd for 897 C₁₈H₂₇NaO₇P 409.1392; found 409.1392. Anal. calcd for C₁₈H₂₇O₇P: 898 C, 55.95; H, 7.04. Found: C, 55.71; H, 7.15. Compound 11: colorless 899 oil, $[\alpha]_{\rm D} = -9.8$ (c, 0.89, CHCl₃); IR (CHCl₃) 3024, 1729, 1439, 900 1373, 1228, 1203, 1172, 1035 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 901 1.30 (3H, t, J = 6.9 Hz), 1.33 (3H, s), 1.34 (3H, s), 2.04 (1H, ddd, 902 ${}^{2}J_{PH}$ = 12.2 Hz, J = 15.4, 5.5 Hz, H2a), 2.25 (1H, ddd, ${}^{2}J_{PH}$ = 15.9 Hz, 903 J = 15.9, 6.9 Hz, H2b), 3.47 (3H, s), 3.80 (1H, dd, J = 8.5, 6.3 Hz, 904 H6a), 3.87 (1H, m), 3.99 (1H, dd, J = 8.8, 6.3 Hz, H6b), 4.01 (1H, 905 m, H3), 4.09 (1H, m), 4.26 (1H, ddd, J = 6.3, 6.3, 6.3 Hz, H5), 5.00 906 (1H, dd, J = 6.5, 1.7 Hz, H4), 7.50 (2H, m), 7.57 (1H, m), 7.79 (2H, 907 m), 8.05 (1H, s, CHO); ¹³C{¹H} NMR (125.7 MHz, CDCl₃) δ 16.4 908 (CH₃, d, ${}^{3}J_{PC}$ = 7.4 Hz), 25.4 (CH₃), 26.5 (CH₃), 32.0 (CH₂, d, ${}^{1}J_{PC}$ = 909 100.7 Hz, C2), 58.7 (CH₃), 61.0 (CH₂, d, ${}^{2}J_{PC}$ = 6.4 Hz), 66.2 (CH₂, 910 C6), 74.0 (CH, C5), 74.2 (CH, C3), 75.5 (CH, d, ${}^{3}J_{PC}$ = 8.5 Hz, C4), 911 109.3 (C), 128.8 (2 × CH, d, ${}^{3}J_{PC}$ = 12.7 Hz, C-meta), 131.5 (2 × 912 CH, d, ${}^{2}J_{\rm PC}$ = 10.6 Hz, C-ortho), 132.6 (CH, d, ${}^{4}J_{\rm PC}$ = 3.2 Hz, C-913 para), 160.4 (CH, CHO) (the C-ipso is not observed); ¹H NMR (500 914 MHz, C_6D_6) δ 0.97 (3H, t, J = 7.3 Hz), 1.22 (3H, s), 1.29 (3H, s), 915 2.06 (1H, ddd, ${}^{2}J_{PH}$ = 11.7 Hz, J = 15.8, 5.7 Hz, H2a), 2.26 (1H, ddd, $_{916}$ $^{2}J_{PH}$ = 16.1 Hz, J = 16.1, 6.3 Hz, H2b), 3.29 (3H, s), 3.57 (1H, m), 917 3.76 (1H, dd, J = 8.5, 6.6 Hz, H6a), 3.84 (1H, dd, J = 8.2, 6.6 Hz, 918 H6b), 3.90 (1H, m), 4.05 (1H, m, H3), 4.15 (1H, ddd, J = 6.2, 6.2, 919 6.2 Hz, H5), 5.16 (1H, dd, J = 6.0, 2.5 Hz, H4), 7.07 (3H, m), 7.57 920 (1H, s, CHO), 7.78 (2H, m); ¹H NMR (500 MHz, C_6D_6 , 60 °C, 921 simulated coupling constants using DAISY) δ 1.01 (3H, t, J = 6.9 Hz), 922 1.23 (3H, s), 1.29 (3H, s), 2.10 (1H, ddd, ${}^{2}J_{PH} = 11.5$ Hz, J = 15.3, 6.0 923 Hz, H2a), 2.25 (1H, ddd, ²*J*_{PH} = 17.2 Hz, *J* = 15.3, 6.3 Hz, H2b), 3.30 924 (3H, s), 3.65 (1H, m), 3.79 (1H, dd, J = 8.6, 6.3 Hz, H6a), 3.83 (1H, 925 dd, J = 8.6, 6.3 Hz, H6b), 3.92 (1H, m), 4.03 (1H, dddd, ${}^{3}J_{PH} = 11.1$ 926 Hz, J = 6.3, 6.0, 3.1 Hz, H3), 4.17 (1H, ddd, J = 6.3, 6.3, 6.2 Hz, H5), 927 5.15 (1H, dd, J = 6.3, 3.1 Hz, H4), 7.10 (3H, m), 7.64 (1H, s, CHO),928 7.78 (2H, m); ${}^{13}C{}^{1}H$ NMR (125.7 MHz, C₆D₆) δ 16.4 (CH₃, d, $_{929}$ $^{3}J_{PC} = 6.4 \text{ Hz}$), 25.6 (CH₃), 26.6 (CH₃), 32.1 (CH₂, d, $^{1}J_{PC} = 98.5 \text{ Hz}$, 930 C2), 58.1 (CH₃), 60.6 (CH₂, d, ${}^{2}J_{PC}$ = 7.4 Hz), 66.4 (CH₂, C6), 74.7 931 (CH, C5), 74.8 (CH, C3), 75.7 (CH, d, ${}^{3}J_{PC}$ = 8.5 Hz, C4), 109.3 932 (C), 128.8 (2 × CH, d, ${}^{3}J_{PC}$ = 12.7 Hz, C-meta), 131.9 (2 × CH, d, $_{933}$ $^{2}J_{PC} = 9.5$ Hz, C-ortho), 132.2 (CH, br. s., C-para), 160.5 (CH, 934 CHO), (the C-ipso is not observed); ³¹P{¹H} NMR (162 MHz, 935 CDCl₃) δ 40.5 (1P, s); ³¹P{¹H} NMR (162 MHz, C₆D₆) δ 52.3 (1P, 936 s); MS (ESI⁺-TOF) m/z (%) 409 [(M + Na)⁺, 100]; HRMS (ESI⁺-937 TOF) m/z [M + Na]⁺ calcd for C₁₈H₂₇NaO₇P 409.1392; found 938 409.1399. Anal. calcd for C₁₈H₂₇O₇P: C, 55.95; H, 7.04. Found: C, 939 55.83; H, 7.15.

940 (S_p) -1-Deoxy-1-ethoxyphenylphosphoryl-4,5-O-isopropylidene-941 2-O-methyl-*p*-arabinitol (**34**). A solution of **11** (7.5 mg, 0.019 mmol) 942 in NaOEt/EtOH 0.011 M (160 μ L, 1.65 × 10⁻³ mmol) was stirred at 943 room temperature under nitrogen for 1.25 h. The organic extracts 944 were concentrated under reduced pressure, and the residue was

purified by purified by Chromatotron chromatography (CHCl₃- 945 EtOAc, 30:70) to give alcohol 34 (3.2 mg, 0.009 mmol, 46%), and a 946 small amount of the cyclized compound 42 (0.5 mg, 0.0016 mmol, 947 8%) is also obtained (vide infra). Compound 34: colorless oil, ¹H 948 NMR (500 MHz, $CDCl_3$) δ 1.30 (3H, t, J = 7.1 Hz), 1.34 (3H, s), 949 1.38 (3H, s), 2.33-2-38 (2H, m, H2), 3.29 (3H, s), 3.42 (1H, d, J = 950 6.9 Hz, OH), 3.56 (1H, ddd, J = 7.6, 7.6, 1.6 Hz, H4), 3.82-3.87 951 (1H, m), 3.87-3.93 (1H, m, H3), 3.96-4.01 (1H, m, H6a), 4.05- 952 4.14 (3H, m, H5, H6b, P-O-CH2), 7.45-7.53 (2H, m), 7.54-7.60 953 (1H, m), 7.77–7.85 (2H, m); ${}^{13}C{}^{1}H{}$ NMR (125.7 MHz, CDCl₃) δ 954 16.4 (CH₃, d, ${}^{3}J_{PC}$ = 6.4 Hz), 25.5 (CH₃), 26.9 (CH₃), 31.7 (CH₂, d, J 955 = 98.5 Hz, C2), 57.9 (CH₃), 60.9 (CH₂, d, ${}^{2}J_{PC}$ = 6.4 Hz), 67.5 (CH₂, 956 C6), 74.7 (CH, d, J = 4.2 Hz, C4), 75.3 (CH), 75.4 (CH), 109.1 (C), 957 128.7 (2 × CH, d, ${}^{3}J_{PC}$ = 12.7 Hz, C-meta), 131.6 (2 × CH, d, ${}^{2}J_{PC}$ = 958 9.5 Hz, C-ortho), 132.5 (CH, d, ${}^{4}J_{PC}$ = 4.2 Hz, C-para), (the C-ipso is 959 not observed); ¹H NMR (500 MHz, C_6D_6) δ 0.96 (3H, t, J = 7.1 Hz), 960 1.31 (3H, s), 1.44 (3H, s), 2.22 (1H, ddd, ${}^{2}J_{PH}$ = 17.0 Hz, J = 15.4, 4.4 961 Hz, H2a), 2.32 (1H, ddd, ${}^{2}J_{PH}$ = 11.3 Hz, J = 15.4, 8.2 Hz, H2b), 3.08 962 (3H, s), 3.48-3.57 (1H, m), 3.75 (1H, br dd, J = 6.9, 6.9 Hz, H4), 963 3.82-3.88 (1H, m), 3.90 (1H, br d, J = 6.9 Hz, OH), 4.04 (1H, dddd, 964 ${}^{3}J_{\rm PH} = 12.6$ Hz, J = 7.9, 4.4, 1.6 Hz, H3), 4.08 (1H, dd, J = 8.2, 6.0 Hz, 965 H6a), 4.19 (1H, dd, J = 8.5, 5.0 Hz, H6b), 4.24 (1H, ddd, J = 8.4, 5.8, 966 5.8 Hz, H5), 6.98–7.09 (3H, m), 7.70–7.77 (2H, m); ¹³C{¹H} NMR 967 $(125.7 \text{ MHz}, C_6D_6) \delta 16.3 (CH_3, d, {}^{3}J_{PC} = 5.3 \text{ Hz}), 25.6 (CH_3), 27.2 968$ (CH_3) , 31.8 $(CH_2, d, {}^{1}J_{PC} = 95.4 \text{ Hz}, C2)$, 57.4 (CH_3) , 60.5 $(CH_2, d, 969)$ ${}^{2}J_{PC}$ = 5.3 Hz), 68.0 (CH₂, C6), 75.3 (CH, d, ${}^{3}J_{PC}$ = 4.2 Hz, C4), 75.9 ₉₇₀ (CH), 76.0 (CH), 109.1 (C), 128.5 (2 × CH, d, ${}^{3}J_{PC}$ = 12.7 Hz, C- 971 meta), 131.9 (2 × CH, d, ${}^{2}J_{PC}$ = 9.5 Hz, C-ortho), 132.0 (CH, d, ${}^{4}J_{PC}$ 972 = 2.1 Hz, C-para), (the C-ipso is not observed); ${}^{31}P{}^{1}H$ NMR (162 973 MHz, CDCl₃) δ 42.6 (1P, s); ³¹P{¹H} NMR (202.5 MHz, C₆D₆) δ 974 54.9 (1P, s); MS (ESI⁺-TOF) m/z (%) 381 [(M + Na)⁺, 100]; 975 HRMS (ESI⁺-TOF) m/z [M + Na]⁺ calcd for C₁₇H₂₇NaO₆P 976 381.1443; found 381.1443. 977

 (R_n) -1-Deoxy-1-ethoxyphenylphosphoryl-4,5-O-isopropylidene- 978 2-O-methyl-D-arabinitol (35). A solution of 12 (6.8 mg, 0.018 mmol) 979 in NaOEt/EtOH 0.011 M (150 μ L, 1.65 \times 10⁻³ mmol) was stirred at 980 room temperature under nitrogen for 1.25 h. The organic extracts 981 were concentrated under reduced pressure, and the residue was 982 purified by Chromatotron chromatography (hexanes-EtOAc, 5:95) 983 to give alcohol 35 (3.3 mg, 0.0092 mmol, 52%), and a small amount 984 of the cyclized compound 43 (0.5 mg, 0.0016 mmol, 9%) is also 985 obtained (vide infra). Compound 35: colorless oil, ¹H NMR (500 986 MHz, CDCl₃) δ 1.29 (3H, t, J = 7.1 Hz), 1.33 (3H, s), 1.35 (3H, s), 987 2.26 (1H, ddd, ${}^{2}J_{PH}$ = 12.5 Hz, J = 15.4, 5.5 Hz, H2a), 2.44 (1H, ddd, 988 ${}^{2}J_{\rm PH}$ = 17.5 Hz, J = 15.3, 7.6 Hz, H2b), 2.99 (1H, br d, J = 7.9 Hz, 989 OH), 3.32 (3H, s), 3.58 (1H, br dd, J = 7.9, 7.9 Hz, H4), 3.84 (2H, 990 m, H3, P-O-CH₂), 4.00 (1H, m, H6), 4.08 (3H, m, H6, P-O-CH₂, 991 C5), 7.51 (2H, m), 7.57 (1H, m), 7.80 (2H, m); $^{13}C{^{1}H}$ NMR 992 (125.7 MHz, CDCl₃) δ 16.4 (CH₃, d, ³J_{PC} = 6.4 Hz), 25.5 (CH₃), 993 26.9 (CH₃), 31.4 (CH₂, d, ${}^{1}J_{PC}$ = 99.6 Hz, C2), 58.1 (CH₃), 60.8 994 $(CH_2, d, {}^2J_{PC} = 6.4 Hz), 67.4 (CH_2, C6), 74.6 (CH, d, {}^3J_{PC} = 5.3 Hz, 995$ C4), 75.0 (CH, C3), 75.5 (CH, C5), 109.2 (C), 128.7 (2 × CH, d, 996 ${}^{3}J_{\rm PC}$ = 12.7 Hz, C-meta), 131.5 (2 × CH, d, ${}^{2}J_{\rm PC}$ = 10.6 Hz, C-ortho), 997 132.4 (CH, d, ${}^{4}J_{PC}$ = 3.2 Hz, C-para) (the C-ipso is not observed); ¹H 998 NMR (500 MHz, C_6D_6) δ 0.93 (3H, t, J = 7.1 Hz), 1.28 (3H, s), 1.40 999 (3H, s), 2.11 (1H, ddd, ${}^{2}J_{PH}$ = 12.3 Hz, J = 15.1, 5.0 Hz, H2a), 2.48 1000 (1H, ddd, ${}^{2}J_{PH} = 17.8$ Hz, J = 15.1, 8.0 Hz, H2b), 3.12 (3H, s), 3.40 1001 (1H, br d, J = 7.3 Hz, OH), 3.56 (1H, ddq, ${}^{2}J_{PH} = 8.2$ Hz, J = 10.1, 1002 6.9, 6.9, 6.9 Hz), 3.79 (1H, br dd, J = 7.1, 7.1 Hz, H4), 3.85 (1H, ddq, 1003 ${}^{2}J_{\rm PH}$ = 7.9 Hz, J = 10.1, 6.9, 6.9, 6.9 Hz), 3.94 (1H, dddd, ${}^{3}J_{\rm PH}$ = 10.8 1004 Hz, J = 7.9, 4.9, 1.9 Hz, H3), 4.04 (1H, dd, J = 8.0, 5.5 Hz, H6a), 4.16 1005 (1H, ddd, J = 8.2, 5.4, 5.4 Hz, H5), 4.19 (1H, dd, J = 7.9, 4.7 Hz, 1006)H6b), 7.08 (3H, m), 7.76 (2H, m); $^{13}\mathrm{C}\{^{1}\mathrm{H}\}$ NMR (125.7 MHz, 1007 C_6D_6) $\delta = 16.4$ (CH₃, d, ${}^{3}J_{PC} = 6.4$ Hz), 25.7 (CH₃), 27.2 (CH₃), 1008 31.6 (CH₂, d, ${}^{1}J_{PC}$ = 99.6 Hz, C2), 57.7 (CH₃), 60.6 (CH₂, d, ${}^{2}J_{PC}$ = 1009 6.4 Hz), 68.0 (CH₂, C6), 75.1 (CH, d, ${}^{3}J_{PC} = 4.2$ Hz, C4), 75.8 (CH), 1010 76.0 (CH), 109.3 (C), 128.7 (2 × CH, d, ${}^{3}J_{PC} = 12.7$ Hz, C-meta), 1011 131.8 (2 × CH, d, ${}^{2}J_{PC}$ = 9.5 Hz, C-ortho), 132.1 (CH, d, ${}^{4}J_{PC}$ = 2.1 1012 Hz, C-para) (the C-ipso is not observed); ³¹P{¹H} NMR (162 MHz, 1013

1014 CDCl₃) δ 42.0 (1P, s); ³¹P{¹H} NMR (162 MHz, C₆D₆) δ 54.1 (1P, 1015 s); MS (ESI⁺-TOF) m/z (%) 381 [(M + Na)⁺, 100]; HRMS (ESI⁺-1016 TOF) m/z [M + Na]⁺ calcd for C₁₇H₂₇NaO₆P 381.1443; found 1017 381.1439.

(R_P)-1,2-Dideoxy-1-phenyl-5,6-O-isopropylidene-3-O-methyl-1-1018 1019 oxo-1-phospha-D-arabino-hexofuranose (42). To a solution of 34 1020 (12.5 mg, 0.035 mmol) in dry $CHCl_3$ (0.4 mL) were added molecular 1021 sieves (4 Å powder, 10 mg) and PPTS (20 mg, 0.08 mmol) under 1022 nitrogen. The mixture was stirred at reflux temperature for 90 h and 1023 then filtered, poured into brine, and exhaustively extracted with 1024 CHCl₃. The organic extract was concentrated under reduced pressure, 1025 and the residue was purified by Chromatotron chromatography 1026 (hexanes-EtOAc, 5:95) to give the cyclized compounds 42 (10 mg, 1027 0.032 mmol, 92%). Compound 42: colorless oil, $[\alpha]_{\rm D} = -44.3$ (c, 1028 0.98, CHCl₃); IR (CHCl₃) 2933, 1372, 1228, 1157, 1121, 1072, 1043, 1029 1008 cm⁻¹; ¹H NMR (500 MHz, CDCl₃, simulated coupling 1030 constants using DAISY) δ 1.38 (3H, s), 1.43 (3H, s), 2.33 (1H, 1031 ddd, ${}^{2}J_{PH}$ = 19.3 Hz, J = 16.4, 5.1 Hz, H2 α), 2.46 (1H, ddd, ${}^{2}J_{PH}$ = 1.9 1032 Hz, J = 16.4, 0.9 Hz, H2 β), 3.38 (3H, s), 4.10 (1H, dd, J = 8.9, 4.3 Hz, 1033 H6a), 4.13 (1H, dd, J = 8.9, 6.1 Hz, H6b), 4.25 (1H, dddd, ${}^{3}J_{PH} =$ 1034 27.3 Hz, J = 5.1, 2.8, 0.9 Hz, H3), 4.50 (1H, dd, J = 8.0, 2.8 Hz, H4), 1035 4.52 (1H, ddd, J = 8.0, 6.1, 4.3 Hz, H5), 7.45-7.50 (2H, m), 7.54-1036 7.59 (1H, m), 7.88-7.95 (2H, m); ¹³C{¹H} NMR (125.7 MHz, 1037 CDCl₃) δ 25.4 (CH₃), 26.9 (CH₃), 32.7 (CH₂, d, ¹J_{PC} = 81.6 Hz, 1038 C2), 57.0 (CH₃), 67.1 (CH₂, C6), 72.8 (CH, d, J_{PC} = 11.7 Hz), 79.5 1039 (CH, C3), 84.4 (CH, d, J_{PC} = 3.2 Hz), 109.6 (C), 128.4 (2 × CH, d, $_{1040}$ $^{3}J_{PC}$ = 14.8 Hz, C-meta), 129.8 (CH, d, $^{1}J_{PC}$ = 134.6 Hz, C-ipso), 1041 132.4 (2 × CH, d, ${}^{2}J_{PC}$ = 11.7 Hz, C-ortho), 132.8 (CH, d, ${}^{4}J_{PC}$ = 3.2 1042 Hz, C-para); ¹H NMR (500 MHz, C₆D₆) δ 1.23 (3H, s), 1.32 (3H, 1043 s), 1.87 (1H, ddd, ${}^{2}J_{PH} = 2.5$ Hz, J = 16.1, 0.0 Hz, H2 β), 1.93 (1H, 1044 ddd, ${}^{2}J_{\rm PH}$ = 16.1 Hz, J = 16.1, 4.7 Hz, H2 α), 2.78 (3H, s), 3.58 (1H, 1045 dddd, ${}^{3}J_{PH}$ = 25.5 Hz, J = 3.5, 3.5, 0.0, H3), 3.89 (1H, dd, J = 9.0, 6.1 1046 Hz, H6a), 3.98 (1H, dd, J = 8.8, 5.0 Hz, H6b), 4.27 (1H, dd, J = 8.2, 1047 2.8 Hz, H4), 4.41 (1H, ddd, J = 7.9, 5.7, 5.7 Hz, H5), 7.09 (4H, m), 1048 8.15 (2H, m); $^{13}C{^{1}H}$ NMR (125.7 MHz, C_6D_6) δ 25.5 (CH₃), 27.0 1049 (CH₃), 32.8 (CH₂, d, ${}^{1}J_{PC}$ = 80.5 Hz, C2), 56.5 (CH₃), 67.4 (CH₂, 1050 C6), 73.3 (CH, d, ${}^{3}J_{PC}$ = 12.7 Hz, C5), 79.9 (CH, C3), 84.5 (CH, d, $_{1051}$ $^{2}J_{PC}$ = 4.2 Hz, C4), 109.4 (C), 128.5 (2 × CH, d, $^{3}J_{PC}$ = 12.7 Hz, C-1052 meta), 132.4 (CH, d, ${}^{4}J_{PC}$ = 3.2 Hz, C-para), 132.9 (2 × CH, d, ${}^{2}J_{PC}$ = 1053 11.7 Hz, C-ortho), (the C-ipso is not observed); ³¹P{¹H} NMR (162 1054 MHz, CDCl₃) δ 57.7 (1P, s); ³¹P{¹H} NMR (162 MHz, C₆D₆) δ 68.1 1055 (1P, s); MS (ESI⁺-TOF) m/z (%) 335 [(M + Na)⁺, 100]; HRMS 1056 (ESI⁺-TOF) m/z [M + Na]⁺ calcd for C₁₅H₂₁NaO₅P 335.1024; found 1057 335.1018. Anal. calcd for C15H21O5P: C, 57.69; H, 6.78. Found: C, 1058 57.79; H, 6.95.

(S_P)-1,2-Dideoxy-1-phenyl-5,6-O-isopropylidene-3-O-methyl-1-1059 1060 oxo-1-phospha-D-arabino-hexofuranose (43). To a solution of 35 1061 (13.7 mg, 0.038 mmol) in dry CHCl₃ (0.4 mL) were added molecular 1062 sieves (4 Å powder, 10 mg) and PPTS (22 mg, 0.088 mmol) under 1063 nitrogen. The mixture was stirred at reflux temperature for 94 h and 1064 then filtered, poured into brine, and exhaustively extracted with 1065 CHCl₃. The organic extract was concentrated under reduced pressure, 1066 and the residue was purified by Chromatotron chromatography 1067 (hexanes-EtOAc, 5:95) to give the cyclized compounds 43 (8.2 mg, 1068 0.026 mmol, 69%). Compound 43: colorless oil, $[\alpha]_{\rm D} = -33.8$ (c, 1069 0.48, CHCl₃); IR (CHCl₃) 2929, 1373, 1230, 1122, 1074, 1012 cm⁻¹; $_{1070}$ ¹H NMR (500 MHz, CDCl₃) δ 1.39 (3H, s), 1.45 (3H, s), 2.01 (1H, 1071 ddd, ${}^{2}J_{\rm PH}$ = 6.9 Hz, J = 15.5, 4.7 Hz, H2 α), 2.60 (1H, ddd, ${}^{2}J_{\rm PH}$ = 9.7 $1072 \text{ Hz}, J = 15.4, 1.3 \text{ Hz}, \text{H}2\beta$, 3.48 (3H, s), 4.18 (2H, m), 4.23 (1H, m),1073 4.27 (1H, m), 4.64 (1H, ddd, J = 7.4, 5.4, 5.4 Hz), 7.50 (2H, m), 7.57 1074 (1H, m), 7.76 (2H, m); ${}^{13}C{}^{1}H$ NMR (125.7 MHz, CDCl₃) δ 25.3 1075 (CH₃), 26.9 (CH₃), 31.8 (CH₂, d, ${}^{1}J_{PC}$ = 83.7 Hz, C2), 57.5 (CH₃), 1076 66.8 (CH₂, C6), 73.4 (CH, d, J_{PC} = 6.4 Hz), 77.5 (CH), 86.1 (CH, d, 1077 J = 3.2 Hz), 109.4 (C), 128.8 (2 × CH, d, ${}^{3}J_{PC}$ = 13.8 Hz, C-meta), 1078 131.3 (2 × CH, d, ${}^{2}J_{PC}$ = 10.6 Hz, C-ortho), 132.7 (CH, d, ${}^{4}J_{PC}$ = 2.1 1079 Hz, C-para), (the C-ipso is not observed); ¹H NMR (500 MHz, C₆D₆, 1080 simulated coupling constants using DAISY) δ 1.23 (1H, ddd, ${}^{2}J_{\rm PH}$ = 1081 6.5 Hz, J = 15.6, 4.9 Hz, H2 α), 1.26 (3H, s), 1.42 (3H, s), 2.09 (1H, 1082 ddd, ${}^{2}J_{PH} = 9.5$ Hz, J = 15.6, 1.4 Hz, H2 β), 2.99 (3H, s), 3.60 (1H, 1083 dddd, ${}^{3}J_{PH} = 26.0 \text{ Hz}, J = 4.9, 3.6, 1.4 \text{ Hz}, \text{H3}), 3.97 (1H, dd, J = 9.0, J)$

6.4 Hz, H6a), 4.03 (1H, ddd, ${}^{3}J_{PH}$ = 2.8 Hz, *J* = 7.1, 3.6 Hz, H4), 4.18 1084 (1H, dd, *J* = 9.0, 5.2 Hz, H6b), 4.57 (1H, ddd, *J* = 7.1, 6.4, 5.2 Hz, 1085 H5), 7.05 (3H, m), 7.70 (2H, m); ${}^{13}C{}^{1H}$ NMR (125.7 MHz, 1086 $C_{6}D_{6}$) δ 25.2 (CH₃), 27.1 (CH₃), 31.1 (CH₂, d, ${}^{1}J_{PC}$ = 89.0 Hz, C2), 1087 56.8 (CH₃), 67.0 (CH₂, C6), 73.9 (CH, d, *J*_{PC} = 6.4 Hz, C5), 77.8 1088 (CH, C3), 86.2 (CH, d, *J* = 3.2 Hz, C4), 109.2 (C), 128.7 (2 × CH, 1089 d, ${}^{3}J_{PC}$ = 13.8 Hz, C-meta), 131.7 (2 × CH, d, ${}^{2}J_{PC}$ = 9.5 Hz, C-ortho), 1090 132.2 (CH, d, ${}^{4}J_{PC}$ = 2.1 Hz, C-para), (the C-ipso is not observed); 1091 ${}^{31}P{}^{1H}$ NMR (162 MHz, CDCl₃) δ 53.7 (1P, s); ${}^{31}P{}^{1H}$ NMR (1093 + Na)⁺, 100]; HRMS (ESI⁺-TOF) m/z [M + Na]⁺ calcd for 1094 $C_{15}H_{21}NaO_{5}P$ 335.1024; found 335.1026.

 (R_p) -1,2-Dideoxy-1-phenyl-5,6-O-isopropylidene-3-O-methyl-1- 1096 oxo-1-phospha-D-arabino-hexofuranose (**42**) and (S_p) -1,2-Di- 1097 deoxy-1-phenyl-5,6-O-isopropylidene-3-O-methyl-1-oxo-1-phos- 1098 pha-D-arabino-hexofuranose (**43**). A solution of iodine **9** (67 mg, 1099 0.195 mmol) in PhP(OEt)₂ (225 μ L, 1.17 mmol) was stirred at 120 1100 °C for 68 h under nitrogen. The mixture was concentrated under high 1101 vacuum, and the residue was purified by Chromatotron chromatog- 1102 raphy (toluene–EtOAc, 20:80) to give a mixture of the cyclized 1103 compounds **42** and **43** (22.4 mg, 0.072 mmol, 60:40, 37%). 1104

3,6-Di-O-benzyl-2-deoxy-4-O-(2,3,4,6-tetra-O-benzyl- β -D-galactopyranosyl)-D-arabino-hexopyranose (14).³⁶ A solution of lactal 1106 13³⁷ (401 mg, 0.473 mmol) in THF (10.3 mL) containing water (206 1107 μ L, 11.4 mmol) and Ph₃P-HBr (43.8 mg, 0.127 mmol) was stirred at 1108 reflux temperature for 2 h. The reaction mixture was then poured into 1109 a saturated solution of NaHCO₃ and extracted with CH₂Cl₂. The 1110 combined organic extracts were washed with a saturated solution of 1111 NaHCO₃, dried over Na₂SO₄, and concentrated under reduced 1112 pressure. The residue was purified by silica gel column chromatog-1113 raphy (hexanes–EtOAc, 70:30) to give the anomeric mixture 14 (329 1114 mg, 0.379 mmol, 80%) as a colorless oil.

2.5-Di-O-benzvl-1-deoxv-4-O-formvl-1-iodo-3-O-(2.3.4.6-tetra- 1116 O-benzyl- β -D-galactopyranosyl)-D-arabinitol (15). A solution of the 1117 alcohol 14 (329 mg, 0.38 mmol) in CH2Cl2 (9.5 mL) containing 1118 PhI(OAc)₂ (134.5 mg, 0.418 mmol) and I₂ (106 mg, 0.417 mmol) 1119 under nitrogen was irradiated with a 80 W tungsten-filament lamp at 1120 room temperature for 2 h. The reaction mixture was then poured into 1121 10% aqueous Na₂S₂O₃, extracted with CH₂Cl₂, dried over Na₂SO₄, 1122 and concentrated. The residue was purified by Chromatotron 1123 chromatography (hexanes-EtOAc, 70:30) to give compound 15 1124 (283 mg, 0.285 mmol, 75%) as a colorless oil: $[\alpha]_D$ –11.3 (*c*, 0.62, 1125 CHCl₃); IR (CHCl₃) 2870, 1725, 1098, 1070 cm⁻¹; ¹H NMR (500 1126 MHz, CDCl₃) $\delta_{\rm H}$ 3.34 (1H, dd, J = 10.0, 5.2 Hz, H2a), 3.39 (1H, dd, 1127 J = 9.8, 3.1 Hz, H3'), 3.43 (1H, ddd, J = 8.0, 5.2, 0.9 Hz, H5'), 3.62 1128 (1H, dd, J = 9.8, 8.0 Hz, H2b), 3.64 (1H, dd, J = 11.2, 2.5 Hz, H6a), 1129 3.65 (1H, dd, J = 8.1, 8.1 Hz, H6'a), 3.71 (1H, dd, J = 9.1, 5.4 Hz, 1130 H6'b), 3.78 (1H, dd, J = 9.8, 7.8 Hz, H2'), 3.83 (1H, dd, J = 11.2, 4.6 1131 Hz, H6b), 3.85 (1H, ddd, J = 7.8, 5.2, 2.3 Hz, H3), 3.90 (1H, dd, J = 1132 2.9, 0.9 Hz, H4'), 4.25 (1H, d, J = 12.0 Hz), 4.28 (1H, dd, J = 7.8, 2.2 1133 Hz, H4), 4.32 (1H, d, J = 12.0 Hz), 4.36 (1H, d, J = 7.8 Hz, H1'), 1134 4.41 (1H, d, J = 11.7 Hz), 4.44 (1H, d, J = 11.4 Hz), 4.45 (1H, d, J = 1135 11.7 Hz), 4.57 (1H, d, J = 11.7 Hz), 4.65 (1H, d, J = 11.4 Hz), 4.69 1136 $(2H, s), 4.76 (1H, d, J = 11.2 Hz), 4.80 (1H, d, J = 11.4 Hz), 4.90 _{1137}$ (1H, d, J = 11.7 Hz), 5.22 (1H, dddd, J = 7.5, 4.2, 2.3, 0.5 Hz, H5), 1138 7.28 (30H, m), 7.84 (1H, d, J = 0.8 Hz, CHO); ¹³C{¹H} NMR 1139 (125.7 MHz, CDCl₃) δ_C 4.5 (CH₂, C2), 67.6 (CH₂, C6), 68.4 (CH₂, 1140 C6'), 72.1 (CH, C5), 72.5 (CH₂), 72.7 (2 × CH₂), 73.2 (CH, C5'), 1141 73.5 (CH₂), 73.6 (CH, C4'), 74.6 (CH₂), 75.2 (CH₂), 75.5 (CH, 1142 C4), 78.9 (CH, C3), 79.2 (CH, C2'), 82.5 (CH, C3'), 103.3 (CH, 1143 C1'), 127.4 (4 × CH), 127.51 (CH), 127.53 (CH), 127.6 (2 × CH), 1144 127.7 (CH), 127.8 (CH), 127.87 (2 × CH), 127.89 (4 × CH), 1145 128.14 (2 × CH), 128.16 (2 × CH), 128.25 (4 × CH), 128.29 (2 × 1146 CH), 128.3 (2 × CH), 128.4 (2 × CH), 137.5 (C), 137.9 (2 × C), 1147 138.4 (C), 138.6 (C), 138.7 (C), 160.0 (CH, CHO); MS (ESI+- 1148 TOF) m/z (%) 1015 [(M + Na)⁺, 100]; HRMS (ESI⁺-TOF) m/z: 1149 $[M + Na]^+$ calcd for $C_{54}H_{57}INaO_{10}$ 1015.2894; found 1015.2890. 1150 Anal. calcd for C54H57IO10: C, 65.32; H, 5.79. Found: C, 65.42; H, 1151 6.10. 1152

2,5-Di-O-benzyl-1-deoxy-1-diethoxyphosphoryl-4-O-formyl-3-O-1153 1154 (2,3,4,6-tetra-O-benzyl- β -D-qalactopyranosyl)-D-arabinitol (16). A 1155 solution of **15** (139 mg, 0.14 mmol) in (EtO)₃P (1.27 mL, 7.4 mmol) 1156 was stirred at reflux temperature under nitrogen for 6 h. The reaction 1157 mixture was concentrated under high vacuum, and the residue was 1158 purified by Chromatotron chromatography (hexanes-EtOAc, 50:50) 1159 to give compound 16 (115.5 mg, 0.115 mmol, 82%) as a colorless oil: 1160 $[\alpha]_{\rm D}$ -12.9 (c, 0.89, CHCl₃); IR (CHCl₃) 2870, 1724, 1099, 1072 1161 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) $\delta_{\rm H}$ 1.18 (3H, t, J = 7.3 Hz), 1.20 1162 (3H, t, J = 7.3 Hz), 2.14 (1H, ddd, ${}^{2}J_{PH} = 18.6$ Hz, J = 15.5, 6.6 Hz, 1163 H2a), 2.52 (1H, ddd, ${}^{2}J_{PH} = 18.3$ Hz, J = 15.8, 5.4 Hz, H2b), 3.41 1164 (1H, dd, J = 9.8, 2.8 Hz, H3'), 3.41–3.44 (1H, m, H5'), 3.57 (1H, dd, 1165 J = 8.8, 5.0 Hz, H6'a), 3.64 (1H, dd, J = 8.2, 8.2 Hz, H6'b), 3.66 (1H, 1166 dd, J = 11.0, 2.5 Hz, H6a), 3.77 (1H, dd, J = 9.5, 7.6 Hz, H2'), 3.84 1167 (1H, dd, J = 11.0, 4.7 Hz, H6b), 3.90 (1H, dd, J = 2.8, 0.6 Hz, H4'), 1168 3.99 (4H, m), 4.09 (1H, dddd, ${}^{3}J_{PH} = 12.0$ Hz, J = 6.6, 5.4, 2.5 Hz, 1169 H3), 4.16 (1H, dd, J = 7.3, 2.5 Hz, H4), 4.24 (1H, d, J = 12.0 Hz), 1170 4.31 (1H, d, J = 11.7 Hz), 4.41 (1H, d, J = 11.7 Hz), 4.43 (1H, d, J = 1171 6.9 Hz, H1'), 4.45 (1H, d, J = 11.7 Hz), 4.46 (1H, d, J = 11.4 Hz), 1172 4.56 (1H, d, J = 11.1 Hz), 4.65 (1H, d, J = 11.4 Hz), 4.71 (2H, s), 1173 4.78 (1H, d, J = 11.0 Hz), 4.82 (1H, d, J = 11.0 Hz), 4.92 (1H, d, J = 1174 11.7 Hz), 5.26 (1H, ddd, J = 7.3, 4.7, 2.5 Hz, H5), 7.28 (30H, m), 1175 7.84 (1H, d, J = 0.8 Hz, CHO); ${}^{13}C{}^{1}H{}$ NMR (125.7 MHz, CDCl₃) 1176 $\delta_{\rm C}$ 16.26 (CH₃, d, ${}^{3}J_{\rm PC}$ = 6.4 Hz), 16.28 (CH₃, d, ${}^{3}J_{\rm PC}$ = 6.4 Hz), 26.9 1177 (CH₂, d, ${}^{1}J_{PC}$ = 138.8 Hz, C2), 61.3 (CH₂, d, J_{PC} = 6.4 Hz), 61.5 1178 (CH₂, d, J_{PC} = 6.4 Hz), 68.0 (CH₂, C6), 68.1 (CH₂, C6'), 71.87 1179 (CH₂), 71.94 (CH, C5), 72.70 (CH₂), 72.72 (CH₂), 73.1 (CH, C5'), 1180 73.3 (CH, C3), 73.4 (CH₂), 73.6 (CH, C4'), 74.6 (CH₂), 75.2 1181 (CH₂), 76.9 (CH, d, ${}^{3}J_{PC}$ = 10.6 Hz, C4), 79.2 (CH, C2'), 82.4 (CH, 1182 C3'), 103.2 (CH, C1'), 127.39 (CH), 127.41 (3 \times CH), 127.48 1183 (CH), 127.51 (2 × CH), 127.53 (2 × CH), 127.7 (3 × CH), 127.8 (2 1184 × CH), 127.9 (2 × CH), 128.1 (2 × CH), 128.15 (6 × CH), 128.20 1185 (2 × CH), 128.3 (2 × CH), 128.4 (2 × CH), 137.85 (2 × C), 137.91 1186 (C), 138.3 (C), 138.6 (C), 138.7 (C), 160.1 (CH, CHO); ³¹P{¹H} 1187 NMR (162 MHz, CDCl₃) $\delta_{\rm P}$ 30.2 (P); MS (ESI⁺-TOF) m/z (%) 1188 1025 [(M + Na)⁺, 100]; HRMS (ESI⁺-TOF) m/z: [M + Na]⁺ calcd 1189 for C58H67NaO13P 1025.4217; found 1025.4203. Anal. calcd for 1190 C₅₈H₆₇O₁₃P: C, 69.45; H, 6.73. Found: C, 69.33; H, 6.74.

(S_P)-3,6-Di-O-benzyl-1,2-dideoxy-1-ethoxy-1-phospha-1-oxo-3-1191 1192 O-(2,3,4,6-tetra-O-benzyl- β -D-galactopyranosyl)-D-arabino-hexo-1193 pyranose (44) and (R_p)-3,6-Di-O-benzyl-1,2-dideoxy-1-ethoxy-1-1194 phospha-1-oxo-3-O-(2,3,4,6-tetra-O-benzyl- β -D-galactopyranosyl)-1195 D-arabino-hexopyranose (45). A solution of 16 (107 mg, 0.107 1196 mmol) in NaOEt/EtOH 0.01 M (0.94 mL, 9.4×10^{-3} mmol) was 1197 stirred at room temperature for 27 h. The reaction mixture was 1198 concentrated under reduced pressure, and the residue was purified by 1199 Chromatotron chromatography (hexanes-EtOAc, 50:50) to give 1200 compound 44 (20.2 mg, 0.022 mmol, 20%) and compound 45 (41.5 1201 mg, 0.045 mmol, 42%) as colorless oils. Compound 44: $[\alpha]_{\rm D}$ +6.6 (c, 1202 0.62, CHCl₃); IR (CHCl₃) 2868, 1249, 1230, 1094, 1028 cm⁻¹; ¹H 1203 NMR (500 MHz, CDCl₃, simulated coupling constants of ring I using 1204 DAISY) $\delta_{\rm H}$ 1.31 (3H, t, J = 6.9 Hz), 1.98 (1H, ddd, $^2J_{\rm PH}$ = 17.5 Hz, J $1205 = 14.4, 9.8 \text{ Hz}, \text{H}2\beta$, 2.42 (1H, ddd, $^{2}J_{\text{PH}} = 18.2 \text{ Hz}, J = 14.4, 5.1 \text{ Hz}, J = 14.4, 5.1 \text{ Hz}$ 1206 H2 α), 3.39 (1H, br dd, J = 6.0, 6.0 Hz, H5'), 3.41 (1H, dd, J = 9.5, 1207 2.8 Hz, H3'), 3.44 (1H, dd, J = 9.1, 5.4 Hz, H6'a), 3.54 (1H, dd, J = 1208 9.1, 7.9 Hz, H6'b), 3.64 (1H, dd, J = 11.0, 3.3 Hz, H6a), 3.78 (1H, 1209 dd, J = 9.5, 7.6 Hz, H2'), 3.88 (1H, br d, J = 2.5 Hz, H4'), 3.97 (1H, 1210 ddd, ${}^{4}J_{PH}$ = 3.7 Hz, J = 11.0, 2.6 Hz, H6b), 4.04 (1H, dd, J = 7.7, 7.2 1211 Hz, H4), 4.06 (1H, dddd, ${}^{3}J_{PH} = 2.1$ Hz, J = 9.8, 7.7, 5.1 Hz, H3), 1212 4.14 (2H, m), 4.31 (1H, d, J = 11.7 Hz), 4.33 (1H, dddd, ${}^{3}J_{PH} = 3.4$ 1213 Hz, J = 7.2, 3.3, 2.6 Hz, H5), 4.39 (1H, d, J = 12.0 Hz), 4.40 (1H, d, J 1214 = 12.0 Hz), 4.43 (1H, d, J = 7.6 Hz, H1'), 4.51 (1H, d, J = 12.0 Hz), 1215 4.55 (1H, d, J = 11.4 Hz), 4.56 (1H, d, J = 11.7 Hz), 4.72 (2H, s), 1216 4.75 (1H, d, J = 11.4 Hz), 4.78 (2H, s), 4.96 (1H, d, J = 11.4 Hz), 1217 7.28 (30H, m); ¹³C{¹H} NMR (125.7 MHz, CDCl₃) $\delta_{\rm C}$ 16.4 (CH₃, 1218 d, ${}^{3}J_{PC}$ = 5.5 Hz), 27.3 (CH₂, d, ${}^{1}J_{PC}$ = 122.9 Hz, C2), 62.5 (CH₂, d, $_{1219} {}^{2}J_{PC} = 6.4 \text{ Hz}$, 68.3 (CH₂, d, ${}^{3}J_{PC} = 8.5 \text{ Hz}$, C6), 68.5 (CH₂, C6'), 1220 72.81 (CH₂), 72.83 (CH₂), 73.0 (CH₂), 73.4 (CH, C5'), 73.5 (CH₂), 1221 73.65 (CH, C4'), 74.67 (CH₂), 75.4 (CH₂), 76.0 (CH, C3), 76.1 1222 (CH, d, J_{PC} = 3.2 Hz, C4), 77.2 (CH, d, ${}^{2}J_{PC}$ = 4.2 Hz, C5), 79.5

(CH, C2'), 82.4 (CH, C3'), 103.0 (CH, C1'), 127.4 (CH), 127.45 (3 1223 × CH), 127.53 (CH), 127.57 (CH), 127.60 (CH), 127.64 (2 × CH), 1224 127.7 (CH), 127.8 (4 × CH), 127.9 (2 × CH), 128.08 (2 × CH), 1225 128.13 (2 × CH), 128.18 (2 × CH), 128.25 (2 × CH), 128.3 (2 × 1226 CH), 128.4 (4 × CH), 137.99 (C), 138.06 (C), 138.3 (C), 138.4 (C), 1227 138.5 (C), 138.8 (C); ${}^{31}P{}^{1}H$ NMR (162 MHz, CDCl₃) δ_{P} 24.3 1228 (P); MS (ESI⁺-TOF) m/z (%) 951 [(M + Na)⁺, 100]; HRMS (ESI⁺- 1229 TOF) m/z: $[M + Na]^+$ calcd for $C_{55}H_{61}NaO_{11}P$ 951.3849; found 1230 951.3843. Anal. calcd for C55H61O11P: C, 71.10; H, 6.62. Found: C, 1231 71.17; H, 6.90. Compound 45: $[\alpha]_{D}$ +22.7 (c, 1.19, CHCl₃); IR 1232 (CHCl₃) 2868, 1275, 1230, 1094, 1028 cm⁻¹; ¹H NMR (500 MHz, 1233 CDCl₃, simulated coupling constants of ring I using DAISY) $\delta_{\rm H}$ 1.32 1234 $(3H, t, J = 7.3 \text{ Hz}), 2.00 (1H, ddd, {}^{2}J_{PH} = 18.0 \text{ Hz}, J = 14.9, 10.4 \text{ Hz}, 1235$ H2 β), 2.37 (1H, ddd, ${}^{2}J_{\rm PH}$ = 18.1 Hz, J = 14.9, 4.6 Hz, H2 α), 3.39 1236 (1H, ddd, J = 6.3, 6.3 Hz, H5'), 3.42 (1H, dd, J = 8.5, 5.4 Hz, H6'a), 1237 3.44 (1H, dd, J = 9.8, 2.8 Hz, H3'), 3.54 (1H, dd, J = 8.5, 7.6 Hz, 1238 H6'b), 3.68 (1H, dd, J = 10.9, 2.2 Hz, H6a), 3.77 (1H, dd, J = 9.8, 7.6 1239 Hz, H2'), 3.83 (1H, dddd, ${}^{3}J_{PH} = 2.3$ Hz, J = 10.4, 8.6, 4.6 Hz, H3), 1240 3.89 (1H, ddd, ${}^{4}J_{PH}$ = 3.2 Hz, J = 10.9, 3.2 Hz, H6b), 3.91 (1H, br d, J 1241 = 2.5 Hz, H4'), 3.99 (1H, dd, J = 8.9, 8.6 Hz, H4), 3.99 (1H, dddd, 1242 ${}^{3}J_{PH} = 2.7$ Hz, J = 8.9, 3.2, 2.2 Hz, H5), 4.13 (2H, m), 4.30 (1H, d, $J = {}_{1243}$ 12.0 Hz), 4.38 (1H, d, J = 11.8 Hz), 4.42 (1H, d, J = 12.0 Hz), 4.47 1244 (1H, d, J = 7.6 Hz, H1'), 4.52 (1H, d, J = 12.3 Hz), 4.56 (1H, d, J = 1245)11.4 Hz), 4.57 (1H, d, J = 11.4 Hz), 4.68 (1H, d, J = 12.0 Hz), 4.72 1246 (1H, d, J = 12.0 Hz), 4.74 (1H, d, J = 11.4 Hz), 4.77 (1H, d, J = 11.4 1247 Hz), 4.83 (1H, d, J = 11.0 Hz), 4.95 (1H, d, J = 11.4 Hz), 7.28 (30H, 1248 m); ${}^{13}C{}^{1}H$ NMR (125.7 MHz, CDCl₃) δ_{C} 16.4 (CH₃, d, ${}^{3}J_{PC}$ = 5.5 1249 Hz), 27.7 (CH₂, d, ${}^{1}J_{PC}$ = 122.6 Hz, C2), 61.4 (CH₂, d, ${}^{2}J_{PC}$ = 6.5 1250 Hz), 68.3 (CH₂, C6'), 68.6 (CH₂, d, ${}^{3}J_{PC}$ = 8.2 Hz, C6), 72.6 (CH₂), 1251 72.7 (CH₂), 73.2 (CH₂), 73.3 (CH, C5'), 73.45 (CH₂), 73.50 (CH, 1252 C4'), 74.7 (CH₂), 75.2 (CH₂), 76.1 (CH, C3), 76.6 (CH, br s, C5), 1253 77.5 (CH, d, ${}^{3}J_{PC} = 5.5$ Hz, C4), 79.7 (CH, C2'), 82.6 (CH, C3'), 1254 102.8 (CH, C1'), 127.36 (CH), 127.41 (CH), 127.45 (2 × CH), 1255 127.46 (CH), 127.5 (CH), 127.6 (3 × CH), 127.7 (CH), 127.76 (4 1256 × CH), 127.80 (2 × CH), 127.9 (2 × CH), 128.1 (2 × CH), 128.15 1257 $(2 \times CH)$, 128.2 $(2 \times CH)$, 128.3 $(2 \times CH)$, 128.34 $(2 \times CH)$, 128.4 1258 (2 × CH), 138.0 (C), 138.1 (C), 138.3 (2 × C), 138.6 (C), 138.8 1259 (C); ${}^{31}P{}^{1}H$ NMR (162 MHz, CDCl₃) δ_P 23.3 (P); MS (ESI⁺-TOF) 1260 m/z (%) 951 [(M + Na)⁺, 100]; HRMS (ESI⁺-TOF) m/z: [M + Na]⁺ 1261 calcd for C55H61NaO11P 951.3849; found 951.3849. Anal. calcd for 1262 C₅₅H₆₁O₁₁P: C, 71.10; H, 6.62. Found: C, 70.88; H, 6.88. 1263

Benzyl 5-Deoxy-5-iodo-2,3-O-isopropylidene- β -D-ribofuranoside 1264 (18). A solution of 17³⁸ (100 mg, 0.35 mmol) in benzene (3.18 mL) 1265 containing iodine (180 mg, 0.71 mmol), Ph₃P (186 mg, 0.71 mmol), 1266 and imidazole (76 mg, 1.11 mmol) was stirred at 80 °C under 1267 nitrogen for 25 min. The mixture was concentrated under reduced 1268 pressure, and the residue was purified by Chromatotron chromatog- 1269 raphy (hexanes-EtOAc, 90:10) to give 18 (115.2 mg, 0.295 mmol, 1270 85%) as a crystalline solid: mp 37.6-38.6 °C (from n-hexane- 1271 EtOAc); [α]_D -86.3 (c 1.12, CHCl₃); IR (CHCl₃) 2941, 1377, 1091, 1272 1014 cm⁻¹; 1H NMR (500 MHz, CDCl₃) $\delta_{\rm H}$ 1.34 (3H, s), 1.50 (3H, 1273 s), 3.23 (1H, dd, J = 9.8, 9.8 Hz, H5a), 3.34 (1H, dd, J = 10.1, 6.3 Hz, 1274 H5b), 4.50 (1H, dd, J = 9.8, 6.3 Hz, H4), 4.51 (1H, d, J = 11.7 Hz), 1275 4.74 (1H, d, J = 6.0 Hz, H2), 4.78 (1H, d, J = 11.7 Hz), 4.79 (1H, d, J 1276 = 6.0 Hz, H3), 5.27 (1H, s, H1), 7.35 (5H, m); ¹³C{¹H} NMR (125.7 1277 MHz, CDCl₃) $\delta_{\rm C}$ 6.8 (CH₂, C5), 24.9 (CH₃), 26.3 (CH₃), 69.6 1278 (CH₂), 83.0 (CH, C3), 85.5 (CH, C2), 87.6 (CH, C4), 107.6 (CH, 1279 C1), 112.6 (C), 127.9 (CH), 128.0 (2 × CH), 128.5 (2 × CH), 136.8 1280 (C); MS (ESI⁺-TOF) m/z (%) 413 [(M + Na)⁺, 100]; HRMS (ESI⁺- 1281 TOF) m/z: $[M + Na]^+$ calcd for $C_{15}H_{19}INaO_4$ 413.0215; found 1282 413.0220. Anal. calcd for C15H19IO4: C, 46.17; H, 4.91. Found: C, 1283 46.41: H. 4.78. 1284

Benzyl 5-Deoxy-5-diethoxyphosphoryl-2,3-O-isopropylidene- β - 1285 D-ribofuranoside (**19**). A solution of **18** (1 g, 2.56 mmol) in triethyl 1286 phosphite (23 mL) was heated at reflux temperature under nitrogen 1287 for 28 h. The mixture was concentrated under high vacuum, and the 1288 residue was purified by column chromatography (hexanes–EtOAc, 1289 50:50 \rightarrow 40:60) to give starting material **18** (271 mg, 0.69 mmol, 1290 27%) and **19** (718 mg, 1.8 mmol, 70%, 96% brsm). Compound **19**: 1291 colorless oil, [α]_D -67.8 (c 0.91, CHCl₃); IR (CHCl₃) 2994, 1378, 1292 1293 1241, 1026 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) $\delta_{\rm H}$ 1.28 (3H, s), 1.30 1294 (3H, t, *J* = 6.9 Hz), 1.31 (3H, t, *J* = 6.9 Hz), 1.44 (3H, s), 2.12 (1H, 1295 ddd, ²*J*_{PH} = 18.0 Hz, *J* = 15.1, 8.5 Hz, H5a), 2.21 (1H, ddd, ²*J*_{PH} = 1296 19.6 Hz, *J* = 15.5, 6.3 Hz, H5b), 4.11 (4H, m), 4.46 (1H, d, *J* = 11.7 1297 Hz), 4.54 (1H, ddd, ³*J*_{PH} = 7.9 Hz, *J* = 7.9, 6.3 Hz, H4), 4.69 (1H, d, *J* 1298 = 6.0 Hz, H2), 4.74 (1H, d, *J* = 11.7 Hz), 4.78 (1H, d, *J* = 6.0 Hz, 1299 H3), 5.13 (1H, d, ⁵*J*_{PH} = 1.6 Hz, H1), 7.30 (5H, m); ¹³C{¹H} NMR 1300 (125.7 MHz, CDCl₃) $\delta_{\rm C}$ 16.3 (2 × CH₃, d, ³*J*_{PC} = 5.3 Hz), 24.8 1301 (CH₃), 26.3 (CH₃), 32.3 (CH₂, d, ¹*J*_{PC} = 137.8 Hz, CS), 61.74 (CH₂) 1302 d, ²*J*_{PC} = 6.4 Hz), 61.71 (CH₂, d, ²*J*_{PC} = 6.4 Hz), 69.1 (CH₂), 81.9 1303 (CH, C4), 84.4 (CH, d, ³*J*_{PC} = 8.5 Hz, C3), 85.4 (CH, C2), 107.7 1304 (CH, C1), 112.3 (C), 127.7 (CH), 127.9 (2 × CH), 128.4 (2 × CH), 1305 137.1 (C); ³¹P{¹H} NMR (162 MHz, CDCl₃) $\delta_{\rm P}$ 26.5 (P); MS (ESI⁺-1306 TOF) *m/z* (%) 423 [(M + Na)⁺, 100]; HRMS (ESI⁺-TOF) *m/z*: [M 1307 + Na]⁺ calcd for C₁₉H₂₉NaO₇P 423.1549; found 423.1559. Anal. 1308 calcd for C₁₉H₂₉O₇P: C, 56.99; H, 7.30. Found: C, 56.61; H, 7.67.

5-Deoxy-5-diethoxyphosphoryl-2,3-O-isopropylidene-D-ribofura-1309 1310 nose (20). A solution of 19 (628 mg, 1.57 mmol) in EtOAc (18 mL) 1311 containing Pd/C 10% (605 mg) was stirred at room temperature 1312 under 1 atm of hydrogen (balloon) for 2.5 h. The mixture was then 1313 filtered over Celite and concentrated under reduced pressure. The 1314 residue was purified by Chromatotron chromatography (hexanes-1315 EtOAc, 10:90) to give 20 as an amorphous solid (451 mg, 1.45 mmol, 1316 92%, dr, 90:10): IR (CHCl₃) 2994, 1376, 1230, 1056, 1028 cm⁻¹; ¹H 1317 NMR (500 MHz, CDCl₃, major isomer) $\delta_{\rm H}$ 1.28 (3H, s), 1.29 (3H, t, 1318 J = 7.3 Hz), 1.31 (3H, t, J = 7.3 Hz), 1.43 (3H, s), 2.14 (1H, ddd, ${}^{2}J_{PH}$ 1319 = 19.2 Hz, J = 15.1, 6.3 Hz, H5a), 2.28 (1H, ddd, ${}^{2}J_{PH} = 18.6$ Hz, J =1320 15.4, 8.8 Hz, H5b), 4.11 (4H, m), 4.43 (1H, m, H4), 4.63 (1H, d, J = 1321 5.7 Hz, H2), 4.69 (1H, d, J = 6.0 Hz, H3), 5.42 (1H, s, H1); ${}^{13}C{}^{1}H{}$ 1322 NMR (125.7 MHz, CDCl₃, major isomer) $\delta_{\rm C}$ 16.31 (CH₃, d, ³J_{PC} = 1323 6.4 Hz), 16.32 (CH₃, d, ${}^{3}J_{PC}$ = 6.4 Hz), 24.9 (CH₃), 26.4 (CH₃), 32.6 1324 (CH₂, d, ${}^{1}J_{PC}$ = 139.9 Hz, C5), 61.7 (CH₂, d, ${}^{2}J_{PC}$ = 6.4 Hz), 62.4 1325 (CH₂, d, ${}^{2}J_{PC}$ = 6.4 Hz), 81.2 (CH, d, ${}^{2}J_{PC}$ = 4.2 Hz, C4), 85.0 (CH, 1326 d, ${}^{3}J_{PC}$ = 14.8 Hz, C3), 86.2 (CH, C2), 103.4 (CH, C1), 112.4 (C); ³¹P{¹H} NMR (162 MHz, CDCl₃, major isomer) $\delta_{\rm P}$ 27.7 (P); MS 1327 1328 (ESI⁺-TOF) m/z (%) 333 [(M + Na)⁺, 100]; HRMS (ESI⁺-TOF) m/z1329 z: [M + Na]⁺ calcd for C₁₂H₂₃NaO₇P 333.1079; found 333.1079. 1330 Anal. calcd for C12H23O7P: C, 46.45; H, 7.47. Found: C, 46.08; H, 1331 7.80

5-Deoxy-5-ethoxyphosphoryl-2,3-O-isopropylidene-D-ribofura-1332 1333 nose (21). A solution of 20 (370 mg, 1.19 mmol) in EtOH (29.8 mL) 1334 was treated with aqueous 2 M NaOH (5.37 mL) and stirred at room 1335 temperature for 48 h. The mixture was neutralized with acid ion-1336 exchange resin Amberlite IR120, filtered, and concentrated under 1337 reduced pressure. The residue was purified by silica gel column 1338 chromatography (CHCl₃-MeOH, 60:40) to give 21 (258 mg, 0.91 1339 mmol, 77%) as an amorphous solid: IR (CHCl₃) 3683, 3013, 2400, 1340 1522, 1235 cm⁻¹; ¹H NMR (500 MHz, CD₃OD, major isomer) $\delta_{\rm H}$ 1341 1.27 (3H, t, J = 7.3 Hz), 1.31 (3H, s), 1.44 (3H, s), 2.05 (2H, m, H5), 1342 3.97 (2H, m), 4.49 (1H, ddd, ${}^{3}J_{PH} = 7.9$ Hz, J = 7.9, 7.9 Hz, H4), 4.62 1343 (1H, d, J = 6.0 Hz, H2), 4.89 (1H, d, J = 6.0 Hz, H3), 5.34 (1H, s, 1344 H1); ${}^{13}C{}^{1}H$ NMR (125.7 MHz, CD₃OD, major isomer) δ_{C} 17.1 1345 (CH₃, d, ${}^{3}J_{PC}$ = 6.4 Hz), 25.2 (CH₃), 26.9 (CH₃), 34.9 (CH₂, d, ${}^{1}J_{PC}$ $_{1346} = 135.6$ Hz, C5), 61.0 (CH₂, d, $^{2}J_{PC} = 5.3$ Hz), 84.3 (CH, C4) 86.4 1347 (CH, d, ${}^{3}J_{PC}$ = 8.4 Hz, C3), 87.6 (CH, C2), 104.5 (CH, C1), 113.2 1348 (C); ${}^{31}P{}^{1}H$ NMR (162 MHz, CD₃OD, major isomer) δ_{P} 18.2 (P); 1349 MS (ESI⁺-TOF) m/z (%) 281 [(M – H)⁺, 100]; HRMS (ESI⁺-TOF) 1350 m/z: $[M - H]^+$ calcd for $C_{10}H_{18}O_7P$ 281.0790; found 281.0783. 1351 Anal. calcd for C10H19O7P: C, 42.56 H, 6.79. Found: C, 42.67; H, 1352 6.79

1353 (R_p)-4-Deoxy-5-ethoxy-3-O-formyl-1,2-O-isopropylidene-5-phos-1354 pha-5-oxo-α-D-erythro-pentopyranose (**46**) and (S_p)-4-Deoxy-5-1355 ethoxy-3-O-formyl-1,2-O-isopropylidene-5-phospha-5-oxo-α-D-er-1356 ythro-pentopyranose (**47**). A solution of the crude alcohol **21** (29.3 1357 mg, 0.104 mmol) in CHCl₃ (2.1 mL) containing PhI(OAc)₂ (67 mg, 1358 0.208 mmol) and I₂ (26.4 mg, 0.114 mmol) was stirred under 1359 nitrogen at room temperature for 2.5 h. The reaction mixture was 1360 then poured into 10% aqueous Na₂S₂O₃, extracted with CHCl₃, dried 1361 over Na₂SO₄, and concentrated. The residue was purified by 1362 Chromatotron chromatography (benzene–EtOAc, 50:50) to give

compounds 46 (9.2 mg, 0.033 mmol, 32%) and 47 (4.4 mg, 0.016 1363 mmol, 15%). Compound 46: colorless oil, $[\alpha]_{D}$ +27.5 (c 1.11, 1364 CHCl₃); IR (CHCl₃) 3009, 1730, 1279, 1149, 1022 cm⁻¹; ¹H NMR 1365 (500 MHz, CDCl₃, simulated coupling constants using DAISY) $\delta_{\rm H}$ 1366 1.38 (3H, t, J = 6.9 Hz), 1.45 (3H, s), 1.65 (3H, s), 2.29 (1H, dddd, 1367 ${}^{2}J_{\rm PH}$ = 19.5 Hz, J = 14.0, 4.6, ${}^{4}J_{\rm w}$ = 0.7 Hz, H2 α), 2.43 (1H, ddd, ${}^{2}J_{\rm PH}$ 1368 = 18.6 Hz, J = 14.0, 12.6 Hz, H2 β), 4.20 (2H, m), 4.35 (1H, ddd, J = 1369 2.8, 2.5 Hz, ${}^{4}J_{w} = 0.7$, H4), 5.51 (1H, dddd, ${}^{3}J_{PH} = 2.5$ Hz, J = 12.6, 1370 4.6, 2.8 Hz, ${}^{4}J_{w} = 1.1$ Hz, H3), [Decoupling by selective irradiation at 1371 CHO (8.09 ppm) (1H, dddd, ${}^{3}J_{PH} = 2.5$ Hz, J = 12.2, 4.3, 2.5 Hz, 1372 H3)], 5.64 (1H, dd, ${}^{3}J_{PH}$ = 3.9 Hz, J = 2.5 Hz, H5), 8.09 (1H, dd, ${}^{5}J_{PH}$ 1373 = 2.7 Hz, ${}^{4}J_{w}$ = 1.1 Hz, CHO) [Decoupling by selective irradiation at 1374 H3 (5.51 ppm) (1H, d, ${}^{5}J_{PH}$ = 3.0 Hz, CHO)]; ${}^{13}C{}^{1}H$ NMR (125.7 1375 MHz, CDCl₃) $\delta_{\rm C}$ 16.4 (CH₃, d, ⁴J_{PC} = 5.3 Hz), 23.2 (CH₂, d, ¹J_{PC} = 1376 125.0 Hz, C2), 25.8 (CH₃), 27.4 (CH₃), 62.3 (CH₂, d, ${}^{2}J_{PC}$ = 6.4 Hz), 1377 66.1 (CH, d, ${}^{2}J_{PC}$ = 5.3 Hz, C3), 75.2 (CH, d, ${}^{3}J_{PC}$ = 4.2 Hz, C4), 97.6 1378 (CH, d, ${}^{2}J_{PC} = 4.2$ Hz, C5), 113.7 (C), 159.5(CH, CHO); ${}^{31}P{}^{1}H{}$ 1379 NMR (162 MHz, CDCl₃) $\delta_{\rm P}$ 18.0 (P); MS (ESI⁺-TOF) m/z (%) 303 1380 $[(M + Na)^+, 100];$ HRMS (ESI⁺-TOF) m/z: $[M + Na]^+$ calcd for 1381 C10H17NaO7P 303.0610; found 303.0615. Anal. calcd for C10H17O7P: 1382 C, 42.86; H, 6.12. Found: C, 42.90; H, 6.50. Compound 47: colorless 1383 oil, [α]_D +1.7 (c 0.35, CHCl₃); IR (CHCl₃) 2931, 1731, 1242, 1147, 1384 1021 cm⁻¹; ¹H NMR (500 MHz, CDCl₃, simulated coupling 1385 constants using DAISY) $\delta_{\rm H}$ 1.37 (3H, t, J = 6.9 Hz), 1.43 (3H, s), 1386 1.62 (3H, s), 2.33 (1H, ddd, ${}^{2}J_{PH} = 20.1$ Hz, J = 13.3, 4.5 Hz, H2 α), 1387 2.43 (1H, ddd, ${}^{2}J_{PH}$ = 18.2 Hz, J = 13.3, 12.9 Hz, H2 β), 4.22 (2H, m), 1388 4.44 (1H, dd, J = 3.0, 2.6 Hz, H4), 5.67 (1H, ddddd, ${}^{3}J_{PH} = 3.1$ Hz, J_{1389} = 12.9, 4.5, 2.6 Hz, ${}^{4}J_{w}$ = 0.8 Hz, H3) [Decoupling by selective 1390 irradiation at CHO (8.08 ppm) (1H, dddd, ${}^{3}J_{PH} = 3.0$ Hz, J = 12.8, 1391 5.4, 3.0 Hz, H3)], 5.82 (1H, dd, ${}^{3}J_{PH} = 8.5$ Hz, J = 3.0 Hz, H5), 8.08 1392 (1H, dd, ${}^{5}J_{PH} = 2.8$ Hz, ${}^{4}J_{w} = 0.8$ Hz, CHO); ${}^{13}C{}^{1}H{}$ NMR (125.7 1393 MHz, CDCl₃) $\delta_{\rm C}$ 16.4 (CH₃, d, ⁴J_{PC} = 6.4 Hz), 23.7 (CH₂, d, ¹J_{PC} = 1394 125.0 Hz, C2), 25.7 (CH₃), 27.0 (CH₃), 62.9 (CH₂, d, ${}^{2}J_{PC} = 6.4$ Hz), 1395 65.9 (CH, d, ${}^{2}J_{PC}$ = 7.4 Hz, C3), 75.3 (CH, d, ${}^{3}J_{PC}$ = 4.2 Hz, C4), 97.5 1396 (CH, d, ${}^{2}J_{PC}$ = 3.2 Hz, C5), 113.1 (C), 159.2 (CH, CHO); ${}^{31}P{}^{1}H{}$ 1397 NMR (162 MHz, CDCl₃) $\delta_{\rm P}$ 19.6 (P); MS (ESI⁺-TOF) m/z (%) 303 1398 $[(M + Na)^+, 100];$ HRMS (ESI⁺-TOF) m/z: $[M + Na]^+$ calcd for 1399 C10H17NaO7P 303.0610; found 303.0612. Anal. calcd for C10H17O7P: 1400 C, 42.86; H, 6.12. Found: C, 43.19; H, 5.89. 1401

Benzyl 5-Deoxy-5-ethoxyphenylphosphoryl-2,3-O-isopropyli- 1402 dene- β -D-ribofuranoside (22). A solution of iodine 18 (1.2 g, 1403 3.075 mmol) in PhP(OEt)₂ (5.9 mL) was heated at 160 °C under 1404 nitrogen for 28 h. The mixture was concentrated under high vacuum, 1405 and the residue was purified by column chromatography (hexanes- 1406 EtOAc, 70:30 \rightarrow 60:40) to give starting material 18 (500 mg, 1.28 1407 mmol, 41%) and 22 (396 mg, 0.917 mmol, 30%, 51% brsm, dr, 6:4): 1408 colorless oil, ³¹P{¹H} NMR (162 MHz, CDCl₃) $\delta_{\rm P}$ 39.4 (P, minor), 1409 39.8 (P, major); MS (ESI⁺-TOF) m/z (%) 455 [(M + Na)⁺, 100]; 1410 HRMS (ESI⁺-TOF) m/z: [M + Na]⁺ calcd for C₂₃H₂₉NaO₆P 1411 455.1599; found 455.1603. Anal. calcd for C₂₃H₂₉O₆P: C, 63.88; H, 1412 6.76. Found: C, 63.66; H, 7.02.

5-Deoxy-5-ethoxyphenylphosphoryl-2,3-O-isopropylidene-D-ri- 1414 bofuranose (23). A solution of 22 (396 mg, 0.916 mmol) in EtOAc 1415 (10.5 mL) containing Pd/C 10% (353 mg) was stirred at room 1416 temperature under 1 atm of hydrogen (balloon) for 20 h. The mixture 1417 was then filtered over Celite and concentrated under reduced 1418 pressure. The residue was purified by Chromatotron chromatography 1419 (hexanes–EtOAc, 9:95) to give 23 (306 mg, 0.89 mmol, 97%) as a 1420 colorless oil. ³¹P{¹H} NMR (162 MHz, CDCl₃) $\delta_{\rm P}$ 40.9 (P, major), 1421 42.4 (P, minor); MS (ESI⁺-TOF) m/z (%) 365 [(M + Na)⁺, 100]; 1422 HRMS (ESI⁺-TOF) m/z: [M + Na]⁺ calcd for C₁₆H₂₃NaO₆P 1423 365.1130; found 365.1138.

5-Deoxy-5-phenylphosphoryl-2,3-O-isopropylidene-D-ribofura- 1425 nose (24). A solution of 23 (278 mg, 0.812 mmol) was treated with 2 1426 M NaOH (3.65 mL) in EtOH and stirred at room temperature for 42 1427 h. The mixture was neutralized with acid ion-exchange resin 1428 Amberlite IR120, filtered, and concentrated under reduced pressure. 1429 The residue was used in the next reaction without further purification 1430 24 (250 mg, 0.80 mmol): ³¹P{¹H} NMR (202.5 MHz, CDCl₃) $\delta_{\rm P}$ 1431 41.1 (P, major); MS (ESI⁺-TOF) m/z (%) 455 [(M – H)⁺, 100]; 1432 1433 HRMS (ESI⁺-TOF) m/z: $[M - H]^+$ calcd for $C_{14}H_{18}O_6P$ 313.0841; 1434 found 313.0838. Anal. calcd for $C_{14}H_{18}O_6P$: C, 53.51; H, 6.09. 1435 Found: C, 53.27; H, 6.18.

(S_P)-4-Deoxy-3-O-formyl-1,2-O-isopropylidene-5-phenyl-5-phos-1436 1437 pha-5-oxo- α - \dot{D} -ervthro-pentopyranose (48) and (R_b)-4-Deoxy-3-O-1438 formyl-1,2-O-isopropylidene-5-phenyl-5-phospha-5-oxo- α -D-eryth-1439 ro-pentopyranose (49). A solution of the crude alcohol 24 (42.4 mg, 1440 0.135 mmol) in dry CH_2Cl_2 (7.4 mL) containing PhI(OAc)₂ (96.6 1441 mg, 0.3 mmol) and $\rm I_2$ (41.1 mg, 0.152 mmol) under nitrogen was 1442 stirred and irradiated with two 80 W tungsten-filament lamps at room 1443 temperature for 3.5 h. The reaction mixture was then poured into 10% 1444 aqueous Na2S2O3, extracted with CH2Cl2, dried over Na2SO4, and 1445 concentrated. The residue was purified by Chromatotron chromatog-1446 raphy (hexanes-EtOAc, 20:80) to give compounds 48 (12.2 mg, 1447 0.039 mmol, 29%) and 49 (21.4 mg, 0.069 mmol, 51%). Compound 1448 48: crystalline solid, mp 166.2–167.4 °C (from *n*-hexane–EtOAc); 1449 IR (CHCl₃) 1729, 1229, 1139, 1036 cm⁻¹; $[\alpha]_{\rm D}$ -12.7 (c 0.67, 1450 CHCl₃); ¹H NMR (500 MHz, CDCl₃, simulated coupling constants 1451 using DAISY) $\delta_{\rm H}$ 1.46 (3H, s), 1.85 (3H, s), 2.58 (1H, dddd, ${}^{2}J_{\rm PH}$ = 1452 10.1 Hz, J = 14.6, 5.1, ${}^{4}J_{w} = 0.9$ Hz, H2 α), 2.79 (1H, ddd, ${}^{2}J_{PH} = 21.3$ 1453 Hz, J = 14.6, 12.6 Hz, H2 β), 4.54 (1H, ddd, J = 3.8, 1.8 Hz, ${}^{4}J_{w} = 0.9$ 1454 Hz, H4), 5.39 (1H, ddddd, ${}^{3}J_{PH}$ = 2.0 Hz, J = 12.6, 5.1, 1.8 Hz, ${}^{4}J_{w}$ = 1455 1.1 Hz, H3) [Decoupling by selective irradiation at CHO (8.08 ppm) 1456 (1H, dddd, ${}^{3}J_{PH}$ = 1.8 Hz, J = 12.2, 4.9, 1.8 Hz, H3)], 5.92 (1H, dd, $_{1457}$ $^{3}J_{PH} = 19.0$ Hz, J = 3.8 Hz, H5), 7.48–7.55 (2H, m), 7.56–7.62 (1H, 1458 m), 7.73–7.80 (2H, m), 8.08 (1H, dd, ${}^{5}J_{PH} = 2.2$ Hz, ${}^{4}J_{w} = 1.1$ Hz, 1459 CHO) [Decoupling by selective irradiation at H3 (5.39 ppm) (1H, d, $_{1460}$ $^{5}J_{PH} = 2.2 \text{ Hz}, \text{ H3})]; {}^{13}\text{C}{}^{1}\text{H} \text{NMR} (125.7 \text{ MHz}, \text{CDCl}_{3}) \delta 26.0$ 1461 (CH₃), 26.2 (CH₃), 26.9 (CH₂, d, ${}^{1}J$ = 80.5 Hz, C2), 66.3 (CH, d, ${}^{2}J$ 1462 = 4.2 Hz, C3), 75.1 (CH, d, ${}^{3}J = 5.3$ Hz, C4), 99.4 (CH, d, ${}^{2}J = 10.6$ 1463 Hz, C5), 114.2 (C), 128.9 (2 × CH, d, ${}^{3}I = 12.7$ Hz), 130.3 (2 × CH, 1464 d, ${}^{2}J$ = 11.7 Hz), 131.6 (C, d, ${}^{1}J$ = 142.0 Hz), 132.8 (CH, d, ${}^{4}J$ = 2.1 1465 Hz), 159.7 (C, C1); ${}^{31}P{}^{1}H$ NMR (202.5 MHz, CDCl₃) δ_{P} 30.9 (P); 1466 MS (ESI⁺-TOF) m/z (%) 335 [(M + Na)⁺, 100]; HRMS (ESI⁺-1467 TOF) m/z: [M + Na]⁺ calcd for C₁₄H₁₇NaO₆P 335.0660; found 1468 335.0658. Anal. calcd for C14H17O6P: C, 53.85; H, 5.49. Found: C, 1469 53.69; H, 5.68. Compound 49: colorless oil, $[\alpha]_{\rm D}$ -30.2 (c 0.61, 1470 CHCl₃); IR (CHCl₃) 1731, 1243, 1229, 1146, 1032 cm⁻¹; ¹H NMR 1471 (500 MHz, CDCl₃, simulated coupling constants using DAISY) $\delta_{\rm H}$ 1472 1.49 (3H, s), 1.70 (3H, s), 2.37 (1H, dddd, ${}^{2}J_{PH} = 12.9$ Hz, J = 13.0, ¹⁴⁷³ 4.2, ⁴ $J_w = 0.7$ Hz, H2 α), 2.50 (1H, ddd, ² $J_{PH} = 10.0$ Hz, J = 13.0, 12.8 ¹⁴⁷⁴ Hz, H2 β), 4.53 (1H, dd, J = 2.9, 2.3 Hz, ⁴ $J_w = 0.7$ Hz, H4), 6.02 (1H, ¹⁴⁷⁵ ddddd, ³ $J_{PH} = 3.3$ Hz, J = 12.8, 4.2, 2.9 Hz, ⁴ $J_w = 1.1$ Hz, H3) 1476 [Decoupling by selective irradiation at CHO (8.10 ppm) (1H, dddd, $_{1477}$ $^{3}J_{PH} = 3.2$ Hz, J = 12.9, 4.1, 3.2 Hz, H3)], 6.04 (1H, br d, $^{3}J_{PH} = 0.7$ 1478 Hz, J = 2.3 Hz, H5), 7.50-7.55 (2H, m), 7.60-7.65 (1H, m), 7.80-1479 7.86 (2H, m), 8.10 (1H, dd, ${}^{5}J_{\rm PH}$ = 2.1 Hz, ${}^{4}J_{\rm w}$ = 1.1 Hz, CHO) 1480 [Decoupling by selective irradiation at H3 (6.02 ppm) (1H, d, ${}^{5}J_{PH} =$ 1481 2.2 Hz, CHO)]; ¹³C{¹H} NMR (125.7 MHz, CDCl₃) δ 25.6 (CH₃), 1482 26.4 (CH₂, d, ${}^{1}J_{PC}$ = 83.7 Hz, C2), 27.9 (CH₃), 65.3 (CH, d, ${}^{2}J_{PC}$ = 1483 2.1 Hz, C3), 75.9 (CH, d, ${}^{4}J_{PC}$ = 3.2 Hz, C4), 97.5 (CH, d, ${}^{2}J_{PC}$ = 4.2 1484 Hz, C5), 113.1 (C), 128.77 (2 × CH, d, ${}^{3}J_{PC}$ = 13.8 Hz), 128.84 (C, 1485 d, ${}^{1}J_{PC}$ = 143.1 Hz), 131.1 (2 × CH, d, ${}^{2}J_{PC}$ = 10.6 Hz), 133.3 (CH, d, ⁴ J_{PC} = 3.2 Hz), 159.3 (C, C1); ³¹P{¹H} NMR (202.5 MHz, CDCl₃) 1487 $\delta_{\rm P}$ 34.1 (P); MS (ESI⁺-TOF) m/z (%) 335 [(M + Na)⁺, 100]; HRMS 1488 (ESI⁺-TOF) m/z: $[M + Na]^+$ calcd for $C_{14}H_{17}NaO_6P$ 335.0660; 1489 found 335.0656. Anal. calcd for C14H17O6P: C, 53.85; H, 5.49. 1490 Found: C, 54.09; H, 5.76.

1491 1-O-Benzoyl-6-O-tert-butyldiphenylsilyl-2,3-O-isopropylidene-α-1492 D-mannofuranose (**26**). To a solution of 1-O-benzoyl-2,3-O-1493 isopropylidene-α-D-mannofuranose **25**³⁹ (188 mg, 0.58 mmol) in 1494 dry DMF (2 mL) were added imidazole (79 mg, 1.16 mmol), DMAP 1495 (1 mg, 0.008 mmol), and TBDPSiCl (200 µL, 0.769 mmol) at room 1496 temperature under nitrogen. The mixture was then stirred for 2 h, 1497 poured into water, and extracted with CH₂Cl₂. The organic extracts 1498 were concentrated under reduced pressure, and the residue was 1499 purified by Chromatotron chromatography (hexanes–EtOAc, 85:15) 1500 to give **26** (300 mg, 0.532 mmol, 92%) as a colorless oil: [α]_D +8.1 (*c*, 1501 1.54, CHCl₃); IR (CHCl₃) 3564, 2934, 2858, 1728, 1427, 1259, 1091 1502 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ_H 0.99 (9H, s), 1.39 (3H, s), 1.51 (3H, s), 2.79 (1H, d, J = 6.9 Hz, OH), 3.89 (2H, m, H6), 4.10 1503 (1H, ddd, J = 7.4, 7.4, 3.7, 3.7 Hz, H5), 4.34 (1H, dd, J = 8.5, 3.5 Hz, 1504 H4), 4.88 (1H, d, J = 5.7 Hz, H2), 5.03 (1H, dd, J = 5.7, 3.5 Hz, H3), 1505 6.43 (1H, s, H1), 7.31–7.46 (8H, m), 7.53–7.58 (1H, m), 7.59–7.69 1506 (4H, m), 7.97–8.04 (2H, m); $^{13}C{}^{1H}$ NMR (125.7 MHz, CDCl₃) 1507 δ_{C} 19.2 (C), 24.8 (CH₃), 26.1 (CH₃), 26.7 (3 × CH₃), 64.9 (CH₂, 1508 C6), 69.4 (CH, C5), 79.9 (CH, C3), 81.0 (CH, C4), 85.0 (CH, C2), 1509 101.4 (CH, C1), 113.2 (C), 127.7 (4 × CH), 128.4 (2 × CH), 129.5 1510 (C), 129.7 (2 × CH), 129.8 (2 × CH), 132.7 (C), 133.0 (C), 133.4 1511 (CH), 135.5 (2 × CH), 135.5 (2 × CH), 164.9 (C); MS (ESI⁺-TOF) 1512 m/z (%) 585 [(M + Na)⁺, 100]; HRMS (ESI⁺-TOF) m/z [M + Na]⁺ 1513 calcd for C₃₂H₃₈NaO₇Si 585.2285; found 585.2290. Anal. calcd for 1514 C₃₂H₃₈O₇Si: C, 68.30; H, 6.81. Found: C, 68.21; H, 6.85.

1-O-Benzoyl-6-O-tert-butyldiphenylsilyl-2,3-O-isopropylidene- α - 1516 D-lyxo-hexofuranos-5-ulose (27). To a stirred solution of 26 (3 g, 5.3 1517 mmol) in dry CH₂Cl₂ (160 mL) at room temperature were added MS 1518 3 Å (5 g) and PCC (3 g, 13.9 mmol). After 9 h, isopropanol (2 mL) 1519 was added and the mixture diluted with Et₂O and filtered through 1520 Celite. The filtrated was concentrated under reduced pressure, and 1521 the residue was purified by silica gel column chromatography 1522 (hexanes-EtOAc, $90:10 \rightarrow 85:15$) to give 27 (2.68 g, 4.8 mmol, 1523 91%) as a colorless oil: $[\alpha]_D$ –18.8 (c, 1.22, CHCl₃); IR (CHCl₃) 1524 2860, 1737, 1428, 1260, 1105 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 1525 1.13 (9H, s), 1.31 (6H, s), 4.52 (2H, s, H6), 4.86 (1H, d, J = 5.7 Hz, 1526 H2), 4.99 (1H, d, J = 4.1 Hz, H4), 5.30 (1H, dd, J = 5.7, 4.1 Hz, H3), 1527 6.48 (1H, s, H1), 7.36–7.48 (8H, m), 7.57–7.62 (1H, m), 7.65–7.73 1528 (4H, m), 7.98–8.00 (2H, m); ¹³C{¹H} NMR $(125.7 \text{ MHz}, \text{CDCl}_3) \delta$ 1529 19.3 (C), 24.6 (CH₃), 25.7 (CH₃), 26.8 (3 × CH₃), 69.0 (CH₂, C6), 1530 80.3 (CH, C3), 84.3 (CH, C2), 86.1 (CH, C4), 101.1 (CH, C1), 1531 113.7 (C), 127.77 (2 × CH), 127.8 (2 × CH), 128.5 (2 × CH), 129.2 1532 (C), 129.7 (2 × CH), 129.86 (CH), 129.93 (CH), 132.5 (C), 132.6 1533 (C), 133.6 (CH), 135.48 (2 × CH), 135.51 (2 × CH), 164.6 (C), 1534 202.3 (C, C5); MS (ESI⁺-TOF) m/z (%) 583 [(M + Na)⁺, 100]; 1535 HRMS (ESI⁺-TOF) m/z [M + Na]⁺ calcd for C₃₂H₃₆NaO₇Si 1536 583.2128; found 583.2128. Anal. calcd for C32H36O7Si: C, 68.55; H, 1537 6.47. Found: C, 68.70; H, 6.45. 1538

1-O-Benzoyl-6-O-tert-butyldiphenylsilyl-5-C-dimethoxyphos- 1539 phoryl-2,3-O-isopropylidene- α -D-mannofuranose (28R) and 1-O- 1540 Benzoyl-6-O-tert-butyldiphenylsilyl-5-C-dimethoxyphosphoryl-2,3-1541 O-isopropylidene- β -L-gulofuranose (285). To a solution of 27 (314 1542 mg, 0.56 mmol) in (MeO)₂P(O)H (2.3 mL, 25.1 mmol) was added 1543 DBU (100 μ L, 0.67 mmol) at 0 °C under nitrogen, and the mixture 1544 was stirred for 30 min at this temperature. An aqueous saturated 1545 solution of NH₄Cl (0.3 mL) was then added, and the stirring was 1546 continued for 4 h. The mixture was then extracted with CHCl₃, 1547 washed with water, and the organic extract was concentrated under 1548 reduced pressure. The residue was purified by silica gel column 1549 chromatography (hexanes-EtOAc, 50:50) to give 28R (42 mg, 1550 0.063mmol, 11%) and 28S (260 mg, 0.388 mmol, 69%). Compound 1551 **28R**: Colorless oil, $[\alpha]_D$ +36.5 (c, 1.23, CHCl₃); IR (CHCl₃) 3469, 1552 3001, 2959, 1729, 1428, 1260, 1059 cm⁻¹; ¹H NMR (500 MHz, 1553 $CDCl_3$) δ 1.11 (9H, s), 1.22 (3H, s), 1.45(3 H, s), 3.74 (3H, d, ${}^{3}J_{PH} = 1554$ 10.7 Hz), 3.80 (3H, d, ${}^{3}J_{PH} = 10.7$ Hz), 4.04 (1H, dd, ${}^{3}J_{PH} = 18.6$ Hz, 1555 J = 10.7 Hz, H6a), 4.20 (1H, dd, ${}^{3}J_{PH} = 10.4$ Hz, J = 10.4 Hz, H6b), 1556 4.21 (1H, d, ${}^{3}J_{PH}$ = 20.8 Hz, OH), 4.65 (1H, dd, ${}^{3}J_{PH}$ = 3.6 Hz, J = 3.6 1557 Hz, H4), 4.78 (1H, d, J = 6.0 Hz, H2), 4.86 (1H, dd, J = 5.7, 3.2 Hz, 1558 H3), 6.44 (1H, s, H1), 7.36-7.47 (8H, m), 7.57-7.60 (1H, s), 7.67-1559 7.76 (4H, m), 7.99-8.01 (2H, m); ¹³C{¹H} NMR (125.7 MHz, 1560 CDCl₃) δ 19.3 (C), 24.3 (CH₃), 25.8 (CH₃), 26.8 (3 × CH₃), 53.3 1561 $(CH_3, d, {}^2J_{PC} = 7.4 Hz), 54.0 (CH_3, d, {}^2J_{PC} = 7.4 Hz), 66.1 (CH_2, d, 1562)$ ${}^{2}J_{PC}$ = 2.1 Hz, C6), 76.7 (C, d, ${}^{1}J_{PC}$ = 167.4 Hz, C5), 80.1 (CH), 81.1 1563 (CH, d, J_{PC} = 10.6 Hz, C3), 85.0 (CH, C2), 100.6 (CH, C1), 113.5 1564 (C), 127.7 (4 × CH), 128.5 (2 × CH), 129.4 (C), 129.7 (2 × CH), 1565 129.85 (CH), 129.87 (CH), 132.7 (C), 132.8 (C), 133.5 (CH), 135.7 1566 $(2 \times CH)$, 135.8 $(2 \times CH)$, 164.9 (C); ³¹P{¹H} NMR (202.5 MHz, 1567) CDCl₃) δ 22.7 (P); MS (ESI⁺-TOF) m/z (%) 693 [(M + Na)⁺, 100]; 1568 HRMS (ESI⁺-TOF) m/z [M + Na]⁺ calcd for C₃₄H₄₃O₁₀NaPSi 1569 693.2261; found 693.2264. Anal. calcd for C34H43O10PSi: C, 60.88; 1570 H, 6.46. Found: C, 60.58; H, 6.54. Compound 28S: Crystalline solid, 1571 mp 140.2–141.3 °C (from CH_2Cl_2-n -hexane); $[\alpha]_D$ +16.6 (c, 1.23, 1572

1573 CHCl₃); IR (CHCl₃) 3460, 3001, 2957, 1729, 1452, 1428, 1248, 1574 1090 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 0.88 (9H, s), 1.40 (3H, 1575 s), 1.56 (3H, s), 3.78 (3H, d, ${}^{3}J_{PH} = 10.4$ Hz), 3.84 (3H, d, ${}^{3}J_{PH} = 10.4$ 1576 Hz), 3.88 (1H, dd, ${}^{3}J_{PH}$ = 10.1 Hz, J = 10.1 Hz, H6a), 4.03 (1H, dd, $_{1577}$ $^{3}J_{PH} = 30.3$ Hz, J = 9.8 Hz, H6b), 4.61 (1H, br s, OH), 4.90 (1H, d, J 1578 = 2.8 Hz, H4), 4.97 (1H, d, J = 5.7 Hz, H2), 5.27 (1H, dd, J = 5.7, 2.8 1579 Hz, H3), 6.55 (1H, d, ${}^{5}J_{\rm PH}$ = 2.2 Hz, H1), 7.29–7.42 (8H, m), 7.47– 1580 7.53 (1H, m), 7.59–7.61 (2H, m), 7.70–7.74 (2H, m), 7.92–7.97 1581 (2H, m); $^{13}C^{1}H$ NMR (125.7 MHz, CDCl₃) δ 19.0 (C), 24.7 1582 (CH₃), 26.0 (CH₃), 26.4 (3 × CH₃), 53.3 (CH₃, d, ${}^{2}J_{PC} = 7.4$ Hz), 1583 53.7 (CH₃, d, ${}^{2}J_{PC} = 8.5$ Hz), 64.3 (CH₂, d, ${}^{2}J_{PC} = 2.1$ Hz, C6), 76.8 1584 (C, d, ${}^{1}J_{PC} = 154.7$ Hz, C5), 77.4 (CH, ${}^{2}J_{PC} = 21.8$ Hz, C4), 82.0 1585 (CH, C3), 86.2 (CH, C2), 100.7 (CH, C1), 113.7 (C), 127.55 (2 × 1586 CH), 127.63 (2 × CH), 128.3 (2 × CH), 129.3 (C), 129.57 (CH), 1587 129.60 (CH), 129.8 (2 × CH), 132.4 (C), 132.8 (C), 133.3 (CH), 1588 135.5 (2 × CH), 135.7 (2 × CH), 164.9 (C); ${}^{31}P{}^{1}H$ NMR (202.5 1589 MHz, CDCl₃) δ 24.1 (P); MS (ESI⁺-TOF) m/z (%) 693 [(M + Na)⁺, 1590 100]; HRMS (ESI⁺-TOF) m/z [M + Na]⁺ calcd for C₃₄H₄₃O₁₀NaPSi 1591 693.2261; found 693.2255. Anal. calcd for C34H43O10PSi: C, 60.88; 1592 H, 6.46. Found: C, 60.85; H, 6.41.

1593 5-Deoxy-5-dimethoxyphosphoryl-1-O-benzoyl-6-O-tert-butyldi-1594 phenylsilyl-2,3-O-1-isopropylidene- β -L-gulofuranose (**29**) and 5-1595 Deoxy-5-dimethoxyphosphoryl-1-O-benzoyl-6-O-tert-butyldiphe-1596 nylsilyl-2,3-O-1-isopropylidene-α-*D*-mannofuranose (**30**). Methyl 1597 oxalyl chloride (110 μ L, 1.2 mmol) was added to a solution of 28S 1598 (161 mg, 0.24 mmol) and DMAP (146.6 mg, 1.2 mmol) in dry 1599 MeCN (2 mL) at 0 °C, and the mixture was stirred at this 1600 temperature for 30 min under nitrogen. Additional amounts of MeCN 1601 (1 mL), methyl oxalyl chloride (55 μ L, 0.6 mmol), and DMAP (73.3 1602 mg, 0.6 mmol) were then added, and the stirring was continued for 30 1603 min. Most of the solvent was distilled off in vacuo, and the residue was 1604 dissolved with CHCl₃. The organic layer was washed with water, 1605 saturated NaHCO3 solution and brine, dried with Na2SO4, and 1606 evaporated under reduced pressure to give methoxalyl derivatives as a 1607 pale yellow syrup. The crude was coevaporated with dry toluene 1608 under reduced pressure. A solution of the residue in toluene (2 mL) 1609 was treated with tributyltin hydride (97 μ L, 0.36 mmol) and AIBN 1610 (5.9 mg, 0.036 mmol), and the mixture was stirred at reflux 1611 temperature for 2 h under nitrogen. Additional AIBN (5.9 mg, 0.036 1612 mmol) was added every 40 min. The mixture was then concentrated 1613 under reduced pressure, and the residue was partitioned between 1614 MeCN and hexane. The MeCN layer was extracted three times with 1615 hexane and then concentrated under reduced pressure. The residue 1616 was purified first by silica gel column chromatography (hexanes→ 1617 hexanes-EtOAc, 6:4) and then by Chromatotron chromatography 1618 (hexanes-EtOAc, 70:30) to give 29 (110 mg, 0.168 mmol, 70%) and 1619 30 (28 mg, 0.043 mmol, 18%). Compound 29: colorless oil, $[\alpha]_{\rm D}$ 1620 +40.6 (c, 1.18, CHCl₃); IR (CHCl₃) 2957, 2859, 1728, 1428, 1261, 1621 1105, 1063 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ ppm 1.10 (9H, s), 1622 1.21 (3H, s), 1.41 (3H, s), 2.63 (1H, dddd, ${}^{2}J_{\rm PH}$ = 18.0 Hz, J = 10.1, 1623 3.8, 3.8 Hz, H5), 3.70 (3H, d, ${}^{3}J_{PH} = 11.0$ Hz), 3.73 (3H, d, ${}^{3}J_{PH} =$ 1624 11.0 Hz), 4.01 (1 H, ddd, ${}^{3}J_{PH}$ = 26.8 Hz, J = 10.4, 3.8 Hz, H6a), 4.21 1625 (1H, ddd, ${}^{3}J_{\rm PH}$ = 11.0 Hz, J = 11.0, 3.9 Hz, H6b), 4.48 (1H, dd, J = 1626 5.4, 3.5 Hz, H3), 4.61 (1 H, ddd, ${}^{3}J_{PH} = 6.7$ Hz, J = 10.0, 3.2 Hz, H4), 1627 4.71 (1 H, d, J = 5.7 Hz, H2), 6.37 (1H, s, H1), 7.35–7.48 (9 H, m), 1628 7.67-7.74 (4 H, m), 7.99-8.01 (2H, m); ¹³C{¹H} NMR (125.7 1629 MHz, CDCl₃) δ 19.3 (C), 24.8 (CH₃), 26.0 (CH₃), 26.8 (3 \times CH₃), 1630 39.5 (CH, d, ${}^{1}J_{PC}$ = 143.1 Hz, C5), 52.4 (CH₃, d, ${}^{2}J_{PC}$ = 6.4 Hz), 52.9 1631 (CH₃, d, ${}^{2}J_{PC} = 7.4$ Hz), 61.1 (CH₂, d, ${}^{2}J_{PC} = 7.4$ Hz, C6), 79.4 (CH, 1632 d, ${}^{3}J_{PC} = 11.7$ Hz, C3), 79.8 (CH, d, ${}^{2}J_{PC} = 4.2$ Hz, C4), 84.7 (CH, 1633 C2), 101.2 (CH, C1), 112.9 (C), 127.67 (2 × CH), 127.71 (2 × 1634 CH), 128.4 (2 × CH), 129.7 (2 × CH), 129.76 (CH), 129.77 (CH), 1635 133.0 (2 \times C), 133.4 (CH), 135.7 (4 \times CH), 164.9 (C) (the 1636 benzoate ipso carbon is missing); ³¹P{¹H} NMR (202.5 MHz, 1637 CDCl₃) δ 30.5 (P); MS (ESI⁺-TOF) m/z (%) 677 [(M + Na)⁺, 100]; 1638 HRMS (ESI⁺-TOF) m/z [M + Na]⁺ calcd for C₃₄H₄₃NaO₉PSi 1639 677.2312; found 677.2313. Anal. calcd for C34H43O9PSi: C, 62.37; H, 1640 6.62. Found: C, 62.23; H, 6.63. Compound **30**: colorless oil, $[\alpha]_{\rm D}$ 1641 +20.9 (c, 1.13, CHCl₃); IR (CHCl₃) 2956, 2857, 1727, 1428, 1260, 1642 1092 cm⁻¹; ¹H NMR (500 MHz, CDCl₃, simulated coupling

constants using DAISY) δ 0.87 (9H, s), 1.37 (3H, s), 1.47 (3H, s), 1643 2.60 (1H, dddd, ${}^{2}J_{PH}$ = 20.0 Hz, J = 10.8, 3.3, 2.0 Hz, H5), 3.72 (3H, 1644 d, ${}^{3}J_{PH} = 10.7$ Hz), 3.77 (3H, d, ${}^{3}J_{PH} = 11.0$ Hz), 4.14 (1H, ddd, ${}^{3}J_{PH}$ 1645 = 34.5 Hz, J = 9.9, 3.3 Hz, H6a), 4.14 (1H, ddd, ${}^{3}J_{PH} = 11.3$ Hz, J = 16469.9, 2.0 Hz, H6b), 4.74 (1H, ddd, ${}^{3}J_{PH} = 4.3$ Hz, J = 10.8, 2.9, Hz, 1647 H4), 4.84 (1H, d, J = 5.7 Hz, H2), 4.92 (1H, dd, J = 5.7, 2.9 Hz, H3), 1648 6.36 (1H, br s, J = 0.4 Hz, H1), 7.23-7.35 (8H, m), 7.42-7.47 (1H, 1649 m), 7.54-7.59 (2H, m), 7.67-7.69 (2H, m), 7.89-7.93 (2H, m); ¹H 1650 NMR (500 MHz, $C_6 D_6$, simulated coupling constants using DAISY) δ 1651 1.06 (9H, s), 1.15 (3H, s), 1.31 (3H, s), 2.61 (1H, dddd, ${}^{2}J_{PH} = 20.0$ 1652 Hz, J = 10.9, 3.1, 1.8 Hz, H5), 3.45 (3H, d, ${}^{3}J_{PH} = 10.7$ Hz), 3.51 (3H, 1653 d, ${}^{3}J_{PH} = 11.0$ Hz), 4.31 (1H, ddd, ${}^{3}J_{PH} = 34.7$ Hz, J = 9.9, 3.1 Hz, 1654 H6a), 4.31 (1H, ddd, ${}^{3}J_{PH}$ = 10.8 Hz, J = 9.9, 1.8 Hz, H6b), 4.63 (1H, 1655 d, J = 5.7 Hz, H2), 4.92 (1H, dd, J = 5.7, 2.9 Hz, H3), 5.03 (1H, ddd, 1656 ³J_{PH} = 4.2 Hz, J = 10.9, 2.9 Hz, H4), 6.73 (1H, br s, J = 0.9 Hz, H1), 1657 6.95-7.02 (2H, m), 7.04-7.09 (1H, m), 7.18-7.25 (2H, m), 7.27-1658 7.32 (2H, m), 7.36–7.39 (2H, m), 7.90 (2H, d, J = 6.9 Hz), 8.00 (2H, 1659 d, J = 6.9 Hz), 8.04 (2H, d, J = 7.6 Hz); ¹³C{¹H} NMR (125.7 MHz, 1660 CDCl₃) δ 19.2 (C), 25.2 (CH₃), 26.3 (CH₃), 26.5 (3 × CH₃), 38.4 1661 (CH, d, ${}^{1}J_{PC}$ = 137.8 Hz, C5), 52.2 (CH₃, d, ${}^{2}J_{PC}$ = 6.4 Hz), 52.6 1662 $(CH_3, d, {}^2J_{PC} = 5.3 Hz), 60.0 (CH_2, d, {}^2J_{PC} = 8.5 Hz, C6), 77.9 (CH, 1663)$ d, ${}^{2}J_{PC}$ = 8.5 Hz, C4), 80.3 (CH, C3), 85.8 (CH, C2), 100.9 (CH, 1664 C1), 112.8 (C), 127.6 (2 × CH), 127.6 (2 × CH), 128.3 (2 × CH), 1665 129.49 (CH), 129.54 (CH), 129.8 $(2 \times CH)$, 132.8 $(2 \times C)$, 133.3 1666 (CH), 135.6 (4 × CH), 165.1 (C) (the benzoate ipso carbon is 1667 missing); ${}^{31}P{}^{1}H$ NMR (202.5 MHz, CDCl₂) δ 30.0 (\bar{P}); MS (ESI⁺- 1668 TOF) m/z (%) 677 [(M + Na)⁺, 100]; HRMS (ESI⁺-TOF) m/z [M 1669 + Na]⁺ calcd for C₃₄H₄₃NaO₉PSi 677.2312; found 677.2310. Anal. 1670 calcd for C34H43O9PSi: C, 62.37; H, 6.62. Found: C, 62.09; H, 6.84. 1671

5-Deoxy-5-dimethoxyphosphoryl-6-O-tert-butyldiphenylsilyl- 1672 2,3-O-1-isopropylidene-L-gulofuranose (31). A solution of 29 (67 1673 mg, 0.102 mmol) in dry MeOH (2.7 mL) containing NaOMe (11 mg, 1674 0.204 mmol) was stirred at room temperature for 2 h. The mixture 1675 was neutralized with acid ion-exchange resin Amberlite IR120, 1676 filtered, and concentrated under reduced pressure. The residue was 1677 purified by Chromatotron chromatography (hexanes-EtOAc, 20:80) 1678 to give 31 (54 mg, 0.098 mmol, 96%, mixture of anomers, $\alpha - \beta$, 1679 92:8): colorless oil, major isomer, α -anomer: ¹H NMR (500 MHz, 1680 CDCl₃) δ 1.08 (9H, s), 1.19 (3H, s), 1.36 (3H, s), 2.58 (1H, dddd, 1681 ${}^{2}J_{\rm PH} = 18.3$ Hz, J = 10.5, 3.7, 3.7 Hz, H5), 3.72 (3H, d, ${}^{3}J_{\rm PH} = 11.0_{1682}$ Hz), 3.75 (3H, d, ${}^{3}J_{PH} = 11.0$ Hz), 3.94 (1H, ddd, ${}^{3}J_{PH} = 27.7$ Hz, J = 168310.7, 3.5 Hz, H6a), 4.10 (1H, ddd, ${}^{3}J_{PH} = 10.2$ Hz, J = 10.2, 4.1 Hz, 1684 H6b), 4.41 (1H, dd, J = 5.4, 3.5 Hz, H3), 4.50 (1H, d, J = 5.7 Hz, 1685 H2), 4.56 (1H, ddd, ${}^{3}J_{PH}$ = 6.5 Hz, J = 10.2, 3.2 Hz, H4), 5.40 (1H, s, 1686 H1), 7.36–7.46 (6H, m), 7.68–7.71(4H, m); ¹³C{¹H} NMR (125.7 1687 MHz, CDCl₃) δ 19.2 (C), 24.8 (CH₃), 26.1 (CH₃), 26.8 (3 × CH₃), 1688 39.6 (CH, d, ${}^{1}J_{PC}$ = 140.9 Hz, C5), 52.4 (CH₃, d, J = 7.4 Hz), 52.8 1689 $(CH_3, d, J = 6.4 Hz), 61.1 (CH_2, d, {}^2J_{PC} = 6.4 Hz, C6), 77.0 (CH, d, 1690)$ ${}^{2}J_{PC}$ = 4.5 Hz, C4), 79.9 (CH, d, ${}^{3}J_{PC}$ = 12.7 Hz, C3), 85.4 (CH, C2), 1691 100.9 (CH, C1), 112.0 (C), 127.6 (2 × CH), 127.7 (2 × CH), 129.68 1692 (CH), 129.73 (CH), 133.1 (C), 133.2 (C), 135.7 $(4 \times CH)$; ³¹P{¹H} 1693 NMR (202.5 MHz, CDCl₃) δ 32.2 (P, α -anomer), 31.3 (P, β - 1694 anomer); MS (ESI⁺-TOF) m/z (%) 573 [(M + Na)⁺, 100]; HRMS 1695 (ESI⁺-TOF) m/z [M + Na]⁺ calcd for C₂₇H₃₉NaO₈PSi 573.2050; 1696 found 573.2048. 1697

5-Deoxy-5-dimethoxyphosphoryl-6-O-tert-butyldiphenylsilyl- 1698 2,3-O-1-isopropylidene-*D*-mannofuranose (**32**). A solution of **30** 1699 (13.5 mg, 0.021 mmol) in dry MeOH (0.55 mL) containing NaOMe 1700 (2.3 mg, 0.042 mmol) was stirred at room temperature for 2 h. The 1701 mixture was neutralized with acid ion-exchange resin Amberlite 1702 IR120, filtered, and concentrated under reduced pressure. The residue 1703 was purified by Chromatotron chromatography (hexanes–EtOAc, 1704 30:70) to give **32** (9.4 mg, 0.017 mmol, 81%, mixture of anomers, 1705 α-β, 92:8): colorless oil, major isomer, α-anomer: ¹H NMR (500 1706 MHz, CDCl₃) δ 1.08 (9H, s), 1.31 (3H, s), 1.37 (3H, s), 1.63 (1H, br 1707 s), 2.57 (1H, dddd, ²J_{PH} = 19.9 Hz, *J* = 10.4, 4.1, 2.5 Hz, H5), 3.74 1708 (3H, d, *J* = 11.0 Hz), 3.76 (3H, d, *J* = 10.7 Hz), 4.15 (1H, ddd, ³J_{PH} = 1709 31.2 Hz, *J* = 9.8, 4.1 Hz, H6a), 4.26 (1H, ddd, ³J_{PH} = 13.6 Hz, *J* = 1710 10.2, 2.4 Hz, H6b), 4.57 (1H, d, *J* = 5.7 Hz, H2), 4.59 (1 H, ddd, ³J_{PH} 1711 = 5.4 Hz, *J* = 10.4, 2.7, H4), 4.81 (1H, dd, *J* = 5.7, 2.8 Hz, H3), 5.16 1712 1713 (1H, br s, H1), 7.35–7.44 (6H, m), 7.71–7.75 (4H, m); ${}^{13}C{}^{1}H$ 1714 NMR (125.7 MHz, CDCl₃) δ 19.4 (C), 25.1 (CH₃), 26.2 (CH₃), 26.7 1715 (3 × CH₃), 38.3 (CH, d, ${}^{1}J_{PC}$ = 137.8 Hz, CS), 52.1 (CH₃, d, ${}^{2}J_{PC}$ = 1716 7.4 Hz), 52.6 (CH₃, d, ${}^{2}J_{PC}$ = 6.4 Hz), 60.6 (CH₂, d, ${}^{2}J_{PC}$ = 9.5 Hz, 1717 C6), 75.6 (CH, d, *J* = 6.4 Hz, C4), 80.6 (CH, C3), 85.8 (CH, C2), 1718 100.6 (CH, C1), 112.1 (C), 127.51 (2 × CH), 127.54 (2 × CH), 1719 129.6 (2 × CH), 133.6 (C), 133.8 (C), 135.7 (2 × CH), 135.8 (2 × 1720 CH); ${}^{31}P{}^{1}H$ NMR (202.5 MHz, CDCl₃) δ 30.7 (P, α-anomer), 1721 30.4 (P, β-anomer); MS (ESI⁺-TOF) *m/z* (%) 573 [(M + Na)⁺, 1722 100]; HRMS (ESI⁺-TOF) *m/z* [M + Na]⁺ calcd for C₂₇H₃₉NaO₈PSi 1723 573.2050; found 573.2050.

(S_P)-4-(tert-Butyldiphenylsilyloxy)methyl-4-deoxy-3-O-formyl-1724 1725 1,2-O-isopropylidene-5-methoxy-5-oxa-5-phospha- β -D-arabino-1726 pyranose (50) and (R_P) -4-(tert-Butyldiphenylsilyloxy)methyl-4-1727 deoxy-3-O-formyl-1,2-O-isopropylidene-5-methoxy-5-oxa-5-phos-1728 pha- β -D-arabinopyranose (51). A solution of 31 (18.6 mg, 0.034 1729 mmol) in dry MeOH (0.18 mL) containing NaOH (15 mg, 0.375 1730 mmol) was stirred at 40-43 °C for 30 h. The mixture was neutralized 1731 with acid ion-exchange resin Amberlite IR120, filtered, and 1732 concentrated under reduced pressure. The crude residue was used 1733 in the next reaction without further purification. To a solution of the 1734 residue (17.7 mg) in dry CH₂Cl₂ (1.6 mL) were added PhI(OAc)₂ 1735 (22.5 mg, 0.07 mmol) and I_2 (8.4 mg, 0.033 mmol). The mixture 1736 under nitrogen was stirred and irradiated with two 80 W tungsten-1737 filament lamps at room temperature for 2 h. The solution was directly poured onto a Chromatotron chromatography plate and subsequently 1738 1739 eluted (hexanes-EtOAc, 50:50) to give 50 (4.8 mg, 0.009 mmol, 1740 26%) and 51 (7.6 mg, 0.014 mmol, 42%). Compound 50: colorless 1741 oil, [α]_D +7.0 (*c*, 0.89, CHCl₃); IR (CHCl₃) 2958, 1732, 1472, 1428, 1742 1387, 1273, 1114 cm⁻¹; ¹H NMR (500 MHz, CDCl₃, simulated 1743 coupling constants using DAISY) δ 1.05 (9H, s), 1.42 (3H, s), 1.64 1744 (3H, s), 2.84 (1H, dddd, ${}^{2}J_{PH} = 23.0 \text{ Hz}, J = 10.6, 4.3, 4.1, \text{Hz}, \text{H2}),$ 1745 3.68 (3H, d, ${}^{3}J_{PH}$ = 11.0 Hz), 3.77 (1H, ddd, ${}^{3}J_{PH}$ = 4.5 Hz, J = 10.6, 1746 10.3 Hz, H6a), 4.15 (1H, ddd, ${}^{3}J_{PH}$ = 4.8 Hz, J = 10.3, 4.3 Hz, H6b), 1747 4.21 (1H, dd, J = 3.3, 2.6 Hz, H4), 5.69 (1H, dd, ${}^{3}J_{PH} = 5.9$ Hz, J = 2.61748 Hz, H5), 6.01 (1H, ddd, ${}^{3}J_{PH}$ = 32.5 Hz, J = 4.1, 3.3 Hz, H3), 7.36– 1749 7.47 (6H, m), 7.60-7.62 (4H, m), 7.95 (1H, s); ¹³C{¹H} NMR 1750 (125.7 MHz, CDCl₃) δ 19.1 (C), 25.8 (CH₃), 26.8 (3 × CH₃), 27.5 1751 (CH₃), 35.9 (CH, d, ${}^{1}J_{PC}$ = 127.2 Hz, C2), 52.3 (CH₃, d, ${}^{2}J_{PC}$ = 7.4 1752 Hz), 56.8 (CH₂, d, ${}^{2}J_{PC}$ = 5.3 Hz, C6), 66.4 (CH, d, ${}^{2}J_{PC}$ = 7.4 Hz, 1753 C3), 74.5 (CH, d, ${}^{3}J_{PC}$ = 7.4 Hz, C4), 99.2 (CH, d, ${}^{2}J_{PC}$ = 7.4 Hz, 1754 C5), 113.5 (C), 127.8 (2 × CH), 127.9 (2 × CH), 130.0 (2 × CH), 1755 132.62 (C), 132.64 (C), 135.6 (2 × CH), 135.7 (2 × CH), 159.4 1756 (CH); ${}^{31}P{}^{1}H$ NMR (202.5 MHz, CDCl₃) δ 17.3 (P); MS (ESI⁺-1757 TOF) m/z (%) 557 [(M + Na)⁺, 100]; HRMS (ESI⁺-TOF) m/z [M 1758 + Na]⁺ calcd for C₂₆H₃₅NaO₈PSi 557.1737; found 557.1724. Anal. 1759 calcd for C₂₆H₃₅O₈PSi: C, 58.41; H, 6.60. Found: C, 58.01; H, 6.99. 1760 Compound 51: colorless oil, $[\alpha]_D$ +35.5 (c, 1.1, CHCl₃); IR (CHCl₃) 1761 2958, 1731, 1472, 1428, 1387, 1250, 1113 cm⁻¹; ¹H NMR (500 MHz, 1762 CDCl₃, simulated coupling constants using DAISY) δ 1.06 (9H, s), 1763 1.41 (3H, s), 1.58 (3H, s), 2.66 (1H, dddd, ${}^{2}J_{PH} = 20.5$ Hz, J = 9.9, 1764 5.6, 3.6 Hz, H2), 3.66 (3H, d, ${}^{2}J_{\rm PH}$ = 11.3 Hz), 3.93 (1H, ddd, ${}^{3}J_{\rm PH}$ = 1765 7.9 Hz, J = 10.7, 9.9 Hz, H6a), 4.04 (1H, ddd, ${}^{3}J_{PH} = 5.4$ Hz, J = 10.7, 1766 5.6 Hz, H6b), 4.30 (1H, dd, J = 3.8, 3.1 Hz, H4), 5.85 (1H, dd, ${}^{3}J_{PH} =$ 1767 9.2 Hz, J = 3.1 Hz, H5), 5.98 (1H, ddd, ${}^{3}J_{PH} = 31.7$ Hz, J = 3.8, 3.6 1768 Hz, H3), 7.35-7.46 (6H, m), 7.62-7.65 (4H, m), 8.04 (1H, s); $^{13}C{^{1}H}$ NMR (125.7 MHz, CDCl₃) δ 19.1 (C), 25.7 (CH₃), 26.8 (3 $1770 \times CH_3$, 27.1 (CH₃), 35.2 (CH, d, ${}^1J_{PC} = 126.1$ Hz, C2), 52.5 (CH₃, 1771 d, ${}^{2}J_{PC}$ = 6.4 Hz), 57.7 (CH₂, d, ${}^{2}J_{PC}$ = 5.3 Hz, C6), 66.8 (CH, d, ${}^{2}J_{PC}$ 1772 = 7.4 Hz, C3), 74.1 (CH, d, ${}^{3}J_{PC}$ = 7.4 Hz, C4), 99.0 (CH, d, ${}^{2}J_{PC}$ = 1773 6.4 Hz, C5), 113.0 (C), 127.81 (2 × CH), 127.83 (2 × CH), 129.9 1774 (CH), 130.0 (CH), 132.5 (C), 132.9 (C), 135.59 (2 × CH), 135.63 1775 (2 × CH), 159.5 (CH); ${}^{31}P{}^{1}H$ NMR (202.5 MHz, CDCl₃) δ 18.0 1776 (P); MS (ESI⁺-TOF) m/z (%) 557 [(M + Na)⁺, 100]; HRMS (ESI⁺-1777 TOF) m/z [M + Na]⁺ calcd for C₂₆H₃₅NaO₈PSi 557.1737; found 1778 557.1737. Anal. calcd for C₂₆H₃₅O₈PSi: C, 58.41; H, 6.60. Found: C, 1779 58.49; H, 6.99

4-Deoxy-3-O-formyl-1,2-O-isopropylidene-4-methylene-5-me-1781 thoxy-5-oxa-5-phospha- β -D-threo-pentopyranose (53). A solution 1782 of 32 (45.6 mg, 0.083 mmol) in dry MeOH (0.44 mL) containing NaOH (35 mg, 0.88 mmol) was stirred at 40-43 °C for 30 h. The 1783 mixture was neutralized with acid ion-exchange resin Amberlite 1784 IR120, filtered, and concentrated under reduced pressure. The crude 1785 residue was used in the next reaction without further purification. To 1786 a solution of the residue (41 mg) in dry CH₂Cl₂ (4 mL) were added 1787 $PhI(OAc)_2$ (60.2 mg, 0.187 mmol) and I_2 (22 mg, 0.087 mmol). The $_{\rm 1788}$ mixture was stirred under nitrogen and irradiated with two 80 W 1789 tungsten-filament lamps at room temperature for 5.5 h. The rather 1790 complex mixtures obtained were directly poured onto a Chromato- 1791 tron chromatography plate and subsequently eluted (hexanes- 1792 EtOAc, $40:60 \rightarrow 30:70$) to give 53 (3 mg, 0.011 mmol, 13%) as 1793 the sole identifiable product. Compound 53: colorless oil, IR 1794 (CHCl₃) 2929, 2858, 1732, 1600, 1462, 1373, 1117, 1044 cm⁻¹; 1795 ¹H NMR (500 MHz, CDCl₃) $\delta_{\rm H}$ 1.42 (3H, s), 1.59 (3H, s), 3.74 (3H, 1796 d, ${}^{3}J_{PH} = 11.3$ Hz), 4.19 (1H, dd, J = 2.5, 2.5 Hz, H4), 5.88 (1H, dd, J_{1797} = 5.4, 2.5 Hz, H3), 5.95 (1H, dd, ${}^{3}J_{PH}$ = 23.6, J = 2.8 Hz, H5), 6.34 1798 (1H, d, ${}^{3}J_{PH}$ = 43.8 Hz, P-H6trans), 6.51 (1H, d, ${}^{3}J_{PH}$ = 20.5 Hz, P- 1799 H6*cis*), 8.08 (1H, s); ${}^{13}C{}^{1}H$ NMR (125.7 MHz, CDCl₃) δ_{C} 25.9 1800 (CH_3) , 27.4 (CH_3) , 52.4 $(CH_3, d, {}^2J_{PC} = 5.3 \text{ Hz})$, 71.6 $(CH, d, {}^2J_{PC} = 1801$ 10.6 Hz, C5), 77.2 (CH, C4), 99.5 (CH, d, ${}^{2}J_{PC}$ = 6.4 Hz, C3), 113.6 1802 (C), 138.3 (CH₂, d, ${}^{2}J_{PC}$ = 7.4 Hz, C6), 158.8 (C), (the C2 is not 1803 observed); ${}^{31}P{}^{1}H$ NMR (162 MHz, CDCl₃) δ_{P} 7.7 (P);MS (ESI⁺- 1804 TOF) m/z (%) 301 [(M + Na)⁺, 100]; HRMS (ESI⁺-TOF) m/z: [M 1805 + Na]⁺ calcd for $C_{10}H_{15}NaO_7P$ 301.0453; found 301.0444. 1806

ASSOCIATED CONTENT Supporting Information

1807 1808

1819

1820

1827

1843

The Supporting Information is available free of charge at 1809 https://pubs.acs.org/doi/10.1021/acs.joc.0c00059. 1810

X-ray crystallographic structure of compound **48** 1811 (CCDC 1973012); these data are provided free of 1812 charge by The Cambridge Crystallographic Data Centre 1813 via http://www.ccdc.cam.ac.uk/data_request/cif X-ray 1814 compound 48 (CIF) 1815 Ring conformations of 2-oxo-1,2-oxaphosphocyclanes 1816

36–51; copies of the ¹H, ¹³C $\{^{1}H\}$, and ³¹P $\{^{1}H\}$ NMR ¹⁸¹⁷ spectra of all new compounds (PDF) ¹⁸¹⁸

AUTHOR INFORMATION

Corresponding Authors

María S. Rodríguez – Sintesis de Productos Naturales, Instituto1821de Productos Naturales y Agrobiología del CSIC, 38206 La1822Laguna, Tenerife, Spain; Email: mrodriguez@ipna.csic.es1823Ernesto Suárez – Sintesis de Productos Naturales, Instituto de1824Productos Naturales y Agrobiología del CSIC, 38206 La1825Laguna, Tenerife, Spain; Email: esuarez@ipna.csic.es1826

Authors

- Daniel Hernández-Guerra Sintesis de Productos Naturales,
Instituto de Productos Naturales y Agrobiología del CSIC,
38206 La Laguna, Tenerife, Spain1829Alan R. Kennedy WestCHEM Department of Pure and
Applied Chemistry, University of Strathclyde, Glasgow G1 1XL,
1832
Scotland, U.K.; Implicit org/0000-0003-3652-60151833
- Elisa I. Leo'n Sintesis de Productos Naturales, Instituto de Productos Naturales y Agrobiología del CSIC, 38206 La Laguna, Tenerife, Spain
- Angeles Martín Sintesis de Productos Naturales, Instituto de 1837

 Productos Naturales y Agrobiología del CSIC, 38206 La 1838

 Laguna, Tenerife, Spain; ☉ orcid.org/0000-0001-5524-4828

 1839

Ine's Pe'rez-Martín – Śintesis de Productos Naturales, Instituto 1840 de Productos Naturales y Agrobiología del CSIC, 38206 La 1841 Laguna, Tenerife, Spain 1842

Complete contact information is available at:

The Journal of Organic Chemistry

1844 https://pubs.acs.org/10.1021/acs.joc.0c00059

1845 Notes

1846 The authors declare no competing financial interest.

1847 **ACKNOWLEDGMENTS**

1848 Financial support by the Investigation Programs of the 1849 Ministerio de Economia y Competitividad (No. CTQ2010-1850 18244), Fundación CajaCanarias (No. 2015-BIO08), and the 1851 Gobierno de Canarias (No. ProID2017010017) is acknowl-1852 edged. D.H.-G. thanks the Ministerio de Economía y 1853 Competitividad for a fellowship. The authors thank Dr. Shinya 1854 Fushinobu (University of Tokyo, http://enzyme13.bt.a.u-1855 tokyo.ac.jp/CP/) for access to the Cremer-Pople parameter 1856 calculator.

1857 **REFERENCES**

1858 (1) (a) Brewster, R.; Vandergeten, M. C.; Montel, F. Syntheses of 1859 Heteraphosphacyclanes: Follow the Guide! Eur. J. Org. Chem. 2014, 1860 2014, 905-917. (b) Spilling, C. D.; Malla, R. K. Synthesis of Non-1861 Racemic α-Hydroxyphosphonates via Asymmetric Phospho-Aldol 1862 Reaction. In Topics in Current Chemistry; Montchamp, J.-L., Ed.; 1863 Springer: Berlin Heidelberg, 2015; pp 83-136. (c) Odinets, I. L.; 1864 Aladzheva, I. M. Synthetic Approaches to 1,2-Heteraphosphacyclanes. 1865 In Phosphorous Heterocycles I; Gupta, R. R., Ed.; Springer: Berlin 1866 Heidelberg, 2009; pp 185-228. For reviews on biological activity, 1867 see:. (d) Volle, J.-N.; Guillon, R.; Bancel, F.; Bekro, Y.-A.; Pirat, J.-L.; 1868 Virieux, D. Phosphono- and Phosphinolactones in the Life Sciences. 1869 Adv. Heterocycl. Chem. 2016, 129-193. (e) Virieux, D.; Volle, J.-N.; 1870 Bakalara, N.; Pirat, J.-L. Synthesis and Biological Applications of 1871 Phosphinates and Derivatives. In Topics in Current Chemistry; 1872 Montchamp, J.-L., Ed.; Springer: Berlin Heidelberg, 2015; pp 39-1873 114.

1874 (2) (a) Abramov, V. S. Reaction of Dialkylphosphites with 1875 Aldehydes and Ketones (a New Method of Synthesis of Esters of 1876 Hydroxyalkanesphosphonic Acids). *Dokl. Akad. Nauk SSSR* **1950**, *73*, 1877 487–489. (b) Pudovik, A. N. Addition of Dialkyl Phosphites to 1878 Imines. New Methods of Synthesis of Esters of Amino Phosphonic 1879 Acids. *Dokl. Akad. Nauk SSSR* **1952**, *83*, 865–869.

1880 (3) (a) Thiem, J.; Günther, M.; Paulsen, H.; Kopf, J. Phospho-1881 rhaltige Kohlenhydrate, XVI. Ringerweiterung von Furanose-Ringen 1882 zu 1,2 λ^5 -Oxaphosphorinanen. *Chem. Ber.* **1977**, *110*, 3190–3200. 1883 (b) Thiem, J.; Günther, M. Abramow-Reaktion von Kohlen-1884 Hydratderivaten mit Freien Anomeren Zentren. *Phosphorus Sulfur* 1885 *Relat. Elem.* **1984**, *20*, 67–79.

1886 (4) (a) Molin, H.; Norèn, J. O.; Claesson, A. Studies of the Synthesis 1887 of Sugar Phosphonates Related to 3-Deoxy-D-manno-2-octulosonic 1888 Acid (Kdo). Carbohydr. Res. 1989, 194, 209-221. (b) Darrow, J. W.; 1889 Drueckhammer, D. G. Cyclic Phosphonate Analogs of Hexopyra-1890 noses. J. Org. Chem. 1994, 59, 2976-2985. (c) Harvey, T. C.; 1891 Simiand, C.; Weiler, L.; Withers, S. G. Synthesis of Cyclic 1892 Phosphonate Analogs of Ribose and Arabinose. J. Org. Chem. 1997, 1893 62, 6722-6723. (d) Polozov, A. M.; Cremer, S. E.; Fanwick, P. E. Stereospecific Thionation of 2-Ethoxy-1,2-oxaphosphorinane 2-Oxide 1894 1895 and its Derivatives with Lawesson's Reagent. Can. J. Chem. 1999, 77, 1896 1274-1280. (e) Hanessian, S.; Rogel, O. Synthesis of Glycopho-1897 stones: Cyclic Phosphonate Analogues of Biologically Relevant 1898 Sugars. J. Org. Chem. 2000, 65, 2667-2674. and references cited 1899 therein. (f) Ferry, A.; Guinchard, X.; Retailleau, P.; Crich, D. 1900 Synthesis, Characterization, and Coupling Reactions of Six-Membered 1901 Cyclic P-Chiral Ammonium Phosphonite-Boranes; Reactive H-1902 Phosphinate Equivalents for the Stereoselective Synthesis of 1903 Glycomimetics. J. Am. Chem. Soc. 2012, 134, 12289-12301. 1904 (g) Ferry, A.; Malik, G.; Retailleau, P.; Guinchard, X.; Crich, D. 1905 Alternative Synthesis of P-Chiral Phosphonite-Borane Complexes: 1906 Application to the Synthesis of Phostone-Phostone Dimers. J. Org. 1907 Chem. 2013, 78, 6858-6867. (h) Clarion, L.; Jacquard, C.; SainteCatherine, O.; Decoux, M.; Loiseau, S.; Rolland, M.; Lecouvey, M.; 1908 Hugnot, J.-P.; Volle, J.-N.; Virieux, D.; Pirat, J.-L.; Bakalara, N. *C*- 1909 Glycoside Mimetics Inhibit Glioma Stem Cell Proliferation, 1910 Migration, and Invasion. *J. Med. Chem.* **2014**, *57*, 8293–8306. and 1911 references cited therein. 1912

(5) (a) Stoianova, D. S.; Hanson, P. R. A Ring-Closing Metathesis 1913 Strategy to Phosphonosugars. Org. Lett. 2001, 3, 3285–3288. 1914 (b) Stoianova, D. S.; Whitehead, A.; Hanson, P. R. P-Heterocyclic 1915 Building Blocks: Application to the Stereoselective Synthesis of P-1916 Sugars. J. Org. Chem. 2005, 70, 5880–5889. 1917

(6) (a) Wróblewski, A. E. Synthesis of Carbohydrates Having 1918 Phosphorus in the Anomeric Position. *Carbohydr. Res.* **1984**, *125*, 1919 C1–C4. (b) Wróblewski, A. E. Analogues of Methyl D-Ribo- and D- 1920 Arabino-Furanosides Having Phosphorus in the Anomeric Position. *Z.* 1921 *Naturforsch.* **1986**, *41*, 791–792. (c) Bisseret, P.; Boiteau, J. G.; 1922 Eustache, J. Cyclic Phosphonomethylphosphinates: A New Type of 1923 Phosphorus-Containing Sugars. *Tetrahedron Lett.* **2003**, *44*, 2351–1924 2354. 1925

(7) Dayde, B.; Pierra, C.; Gosselin, G.; Surleraux, D.; Ilagouma, A. 1926
T.; Laborde, C.; Volle, J. N.; Virieux, D.; Pirat, J.-L. Synthesis of 1927
Unnatural Phosphonosugar Analogues. *Eur. J. Org. Chem.* 2014, 2014, 1928
1333–1337. 1929

(8) (a) Hassani, Z.; Saleh, A.; Turpault, S.; Khiati, S.; Morelle, W.; 1930 Vignon, J.; Hugnot, J. P.; Uro-Coste, E.; Legrand, P.; Delaforge, M.; 1931 Loiseau, S.; Clarion, L.; Lecouvey, M.; Volle, J.-N.; Virieux, D.; Pirat, 1932 J.-L.; Duffau, H.; Bakalara, N. Phostine PST3.1a Targets MGAT5 and 1933 Inhibits Glioblastoma-Initiating Cell Invasiveness and Proliferation. 1934 Mol. Cancer Res. 2017, 15, 1376-1387. (b) Babouri, R.; Rolland, M.; 1935 Sainte-Catherine, O.; Kabouche, Z.; Lecouvey, M.; Bakalara, N.; 1936 Volle, J. N.; Virieux, D.; Pirat, J.-L. α -Halogenated Oxaphosphinanes: 1937 Synthesis, Unexpected Reactions and Evaluation as Inhibitors of 1938 Cancer Cell Proliferation. Eur. J. Med. Chem. 2015, 104, 33-41. 1939 (c) Clarion, L.; Jacquard, C.; Sainte-Catherine, O.; Loiseau, S.; 1940 Filippini, D.; Hirlemann, M.-H.; Volle, J.-N.; Virieux, D.; Lecouvey, 1941 M.; Pirat, J.-L.; Bakalara, N. Oxaphosphinanes: New Therapeutic 1942 Perspectives for Glioblastoma. J. Med. Chem. 2012, 55, 2196-2211. 1943 (d) Pirat, J.-L.; Virieux, D.; Clarion, L.; Volle, J.-N.; Bakalara, N.; 1944 Mersel, M.; Montbrun, J.; Cristau, H.-J. New Phosphorus Containing 1945 Heterocyclic Compounds, Sugar Analogues, and Compositions 1946 Having Anti-Cancer Activity Containing the Same. WO2009/ 1947 004096 A1, 2009. 1948

(9) (a) Hanessian, S.; Rogel, O. Synthesis of a Phostone 1949
Glycomimetic of the Endothelin Converting Enzyme Inhibitor 1950
Phosphoramidon. *Bioorg. Med. Chem. Lett.* 1999, 9, 2441–2446. 1951
(b) Darrow, J. W.; Drueckhammer, D. G. A Cyclic Phosphonamidate 1952
Analogue of Glucose as a Selective Inhibitor of Inverting 1953
Glycosidases. *Bioorg. Med. Chem.* 1996, 4, 1341–1348. 1954

(10) (a) Suárez, E.; Rodriguez, M. S. β -Fragmentation of Alkoxyl 1955 Radicals: Synthetic Applications. In Radicals in Organic Synthesis; 1956 Renaud, P.; Sibi, M. P., Eds.; Wiley-VCH Verlag GmbH: Weinheim, 1957 Germany, 2001; Vol. 2, pp 440–454. (b) Pérez-Martín, I.; Suárez, E. 1958 Radicals and Carbohydrates. In Encyclopedia of Radicals in Chemistry, 1959 Biology and Materials; Chatgilialoglu, C.; Studer, A., Eds.; John Wiley 1960 & Sons, Ltd: Chichester, UK, 2012; pp 1131-1174. For articles, see:. 1961 (c) Hernández-Guerra, D.; Rodríguez, M. S.; Suárez, E. Synthesis of 1962 Chiral β -Iodo- and Vinylorganophosphorus(V) Compounds by 1963 Fragmentation of Carbohydrate Anomeric Alkoxyl Radicals. Org. 1964 Lett. 2013, 15, 250-253. (d) Hernández-Guerra, D.; Rodríguez, M. 1965 S.; Suárez, E. Fragmentation of Carbohydrate Anomeric Alkoxyl 1966 Radicals: Synthesis of Chiral Polyhydroxylated β -Iodo- and 1967 Alkenylorganophosphorus(V) Compounds. Eur. J. Org. Chem. 2014, 1968 2014, 5033-5055. (e) Francisco, C. G.; González, A. G.; Kennedy, A. 1969 R.; Paz, N. R.; Suárez, E. Fragmentation of Carbohydrate Anomeric 1970 Alkoxyl Radicals: New Synthesis of Chiral 1-Fluoro-1-halo-1-iodo 1971 Alditols. Chem. - Eur. J. 2008, 14, 6704-6712. (f) González, C. C.; 1972 Kennedy, A. R.; León, E. I.; Riesco-Fagundo, C.; Suárez, E. 1973 Fragmentation of Carbohydrate Anomeric Alkoxy Radicals: A New 1974 Synthesis of Chiral 1-Halo-1-iodo Alditols. Chem. - Eur. J. 2003, 9, 1975 5800-5809. (g) de Armas, P.; Francisco, C. G.; Suárez, E. 1976 1977 Hypervalent Iodine Reagents: Formation of Convenient Chiral 1978 Synthetic Intermediates by Fragmentation of Carbohydrate Anomeric 1979 Alkoxy Radicals. *Angew. Chem., Int. Ed.* **1992**, *31*, 772–774.

1980 (11) Francisco, C. G.; León, E. I.; Martín, A.; Moreno, P.; 1981 Rodríguez, M. S.; Suárez, E. Reductive Fragmentation of Carbohy-1982 drate Anomeric Alkoxy Radicals. Synthesis of Alditols with Potential 1983 Utility as Chiral Synthesis. *J. Org. Chem.* **2001**, *66*, 6967–6976.

1984 (12) Francisco, C. G.; Gonzalez Martin, C.; Suarez, E. Synthesis of
1985 α-Iodoalkyl Esters and α-Iodoalkyl Carbonates from Carbohydrates.
1986 Formation of Convenient Chiral Synthetic Intermediates. J. Org.
1987 Chem. 1998, 63, 8092–8093.

1988 (13) Murphy, J. A. The Radical-Polar Crossover Reaction. In 1989 Radicals in Organic Synthesis; Renaud, P.; Sibi, M. P., Eds.; Wiley-1990 VCH Verlag GmbH: Weinheim, Germany, 2001; Vol. 1, pp 298–315. 1991 (14) (a) Santana, A. G.; Paz, N. R.; Francisco, C. G.; Suárez, E.; 1992 González, C. C. Synthesis of Branched Iminosugars through a 1993 Hypervalent Iodine(III)-Mediated Radical-Polar Crossover Reaction. 1994 J. Org. Chem. 2013, 78, 7527–7543. (b) de Armas, P.; Francisco, C. 1995 G.; Suárez, E. Fragmentation of Carbohydrate Anomeric Alkoxy 1996 Radicals. Tandem β -Fragmentation-Cyclization of Alcohols. J. Am. 1997 Chem. Soc. 1993, 115, 8865–8866.

1998 (15) (a) Arbusow, B. A. Michaelis-Arbusow- Und Perkow-1999 Reaktionen. *Pure Appl. Chem.* **1964**, *9*, 307–336. (b) Michaelis, A.; 2000 Kaehne, R. Ueber das Verhalten der Jodalkyle Gegen die Sogen. 2001 Phosphorigsäureester oder O-Phosphine. *Ber. Dtsch. Chem. Ges.* **1898**, 2002 31, 1048–1055. (c) Bhattacharya, A. K.; Thyagarajan, G. Michaelis– 2003 Arbuzov Rearrangement. *Chem. Rev.* **1981**, *81*, 415–430.

2004 (16) For another synthesis of a 2-deoxy phostine by Barton-2005 McCombie deoxygenation of the 2-hydroxyl group, see ref 8c.

2006 (17) (a) Bolitt, V.; Mioskowski, C.; Lee, S. G.; Falck, J. R. Direct 2007 Preparation of 2-Deoxy-D-glucopyranosides from Glucals without 2008 Ferrier Rearrangement. *J. Org. Chem.* **1990**, 55, 5812–5813. 2009 (b) Koviach, J. L.; Chappell, M. D.; Halcomb, R. L. Design and 2010 Synthesis of Conformationally Constrained Glycosylated Amino 2011 Acids. *J. Org. Chem.* **2001**, 66, 2318–2326.

2012 (18) (a) Pal, P.; Shaw, A. K. Stereoselective Total Syntheses of 2013 (+)-Exo- and (-)-Exo-Brevicomins, (+)-Endo- and (-)-Endo-2014 Brevicomins, (+)- and (-)-Cardiobutanolides, (+)-Goniofufurone. 2015 *Tetrahedron* 2011, 67, 4036–4047. (b) Oishi, T.; Ando, K.; Chida, N. 2016 Stereoselective Total Synthesis of (+)-Myriocin from D-Mannose. 2017 *Chem. Commun.* 2001, 1, 1932–1933.

(19) For recent selected examples of Michaelis-Arbuzov on 2018 2019 carbohydrate systems, see: (a) Kapil, S.; Petit, C.; Drago, V. N.; 2020 Ronning, D. R.; Sucheck, S. J. Synthesis and in Vitro Characterization 2021 of Trehalose-Based Inhibitors of Mycobacterial Trehalose 6-2022 Phosphate Phosphatases. ChemBioChem 2019, 20, 260-269. 2023 (b) Veleti, S. K.; Lindenberger, J. J.; Ronning, D. R.; Sucheck, S. J. 2024 Synthesis of a C-Phosphonate Mimic of Maltose-1-Phosphate and 2025 Inhibition Studies on Mycobacterium Tuberculosis GlgE. Bioorg. Med. 2026 Chem. 2014, 22, 1404-1411. (c) Vannam, R.; Peczuh, M. W. 2027 Synthesis of C-Septanosides from Pyranoses via Vinyl Addition and 2028 Electrophilic Cyclization. Org. Lett. 2013, 15, 4122-4125. (d) Choi, 2029 S.; Mansoorabadi, S. O.; Liu, Y.; Chien, T.-C.; Liu, H. Analysis of 2030 UDP-D-Apiose/UDP-D-Xylose Synthase-Catalyzed Conversion of 2031 UDP-D-Apiose Phosphonate to UDP-D-Xylose Phosphonate: 2032 Implications for a Retroaldol-Aldol Mechanism. J. Am. Chem. Soc. 2033 2012, 134, 13946-13949.

2034 (20) (a) Hanaya, T.; Sugiyama, K. I.; Kawamoto, H.; Yamamoto, H. 2035 Stereoselectivity in Deoxygenation of 5-Hydroxy-5-Phosphinyl-2036 Hexofuranoses (α -Hydroxyphosphonates). *Carbohydr. Res.* **2003**, 2037 338, 1641–1650. For analogous Pudovik-Abramov additions on 2038 carbohydrates, see: (b) Wang, G. N.; Lau, P. S.; Li, Y.; Ye, X. S. 2039 Synthesis and Evaluation of Glucosamine-6-Phosphate Analogues as 2040 Activators of glmS Riboswitch. *Tetrahedron* **2012**, *68*, 9405–9412. 2041 (c) Králíková, Š.; Buděšínký, M.; Masojídková, M.; Rosenberg, I. 2042 Nucleoside S'-C-Phosphonates: Reactivity of the α -Hydroxyphosph-2043 onate Moiety. *Tetrahedron* **2006**, *62*, 4917–4932. (21) Dolan, S. C.; MacMillan, J. A New Method for the 2044 Deoxygenation of Tertiary and Secondary Alcohols. J. Chem. Soc., 2045 Chem. Commun. **1985**, 1588–1589. 2046

(22) For the synthesis of **36-39** analogs, with a 3,4-O- $_{2047}$ isopropylidene-1-phospha-1-oxo-D-*lyxo*-hexopyranose structure pos- $_{2048}$ sessing a B_{2,5} conformation, see refs 3a, 3b, 4a, 4g, j. $_{2049}$

(23) Coxon, B. Developments in the Karplus Equation as they 2050 Relate to the NMR Coupling Constants of Carbohydrates. Adv. 2051 Carbohydr. Chem. Biochem. 2009, 62, 17–82. 2052

(24) (a) Quin, L. D. A Guide to Organophosphorus Chemistry; Wiley- 2053 Interscience, 2000, pp 140, and references cited therein. (b) Buchwald, 2054 S. L.; Friedman, J. M.; Knowles, J. R. Stereochemistry of Nucleophilic 2055 Displacement on Two Phosphoric Monoesters and a Phosphoguani- 2056 dine: The Role of Metaphosphate. J. Am. Chem. Soc. **1984**, 106, 2057 4911-4916. For an early demonstration of stereochemical inversion, 2058 see: (c) Green, M.; Hudson, R. F. In The Stereochemistry of the 2059 Transition State of a Displacement at a Phosphoryl Centre, Proceedings 2060 of the Chemical Society of London, 1962; pp 307. 2061

(25) (a) Yamamoto, H.; Yamamoto, K.; Inokawa, S.; Yamashita, M.; 2062 Armour, M. A.; Nakashima, T. T. Synthesis of 1,2,3,4,6-Penta-O- 2063 acetyl-5-deoxy-5-C-[(*RS*)-ethylphosphinyl]- α - and - β -D-glucopyrano- 2064 ses and Their Structural Analysis by 400-MHz Proton Nuclear 2065 Magnetic Resonance. J. Org. Chem. **1983**, 48, 435–440. (b) Racha, S.; 2066 Vargeese, C.; Vemishetti, P.; El-Subbagh, H. I.; Abushanab, E.; 2067 Panzica, R. P. Synthesis and Biological Evaluation of 1',2'-Seconucleo- 2068 S'-phosphonates. J. Med. Chem. **1996**, 39, 1130–1135. (c) Casero, F.; 2069 Cipolla, L.; Lay, L.; Nicotra, F.; Panza, L.; Russo, G. Stereoselective 2070 Synthesis of the Isosteric Phosphono Analogues of N-Acetyl- α -D- 2071 glucosamine 1-Phosphate and N-Acetyl- α -D-mannosamine 1-Phos-2072 phate. J. Org. Chem. **1996**, 61, 3428–3432. See also ref 1b. 2073

(26) Program Matlab GUI as described in the following: 2074 (a) Hendrickx, P. M.; Martins, J. C. A User-Friendly Matlab Program 2075 and GUI for the Pseudorotation Analysis of Saturated Five-Membered 2076 Ring Systems Based on Scalar Coupling Constants. Chem. Cent. J. 2077 **2008**, 2, No. 20. The ${}^{3}J_{H2\alpha,H3}$, ${}^{3}J_{H2\beta,H3}$, and ${}^{3}J_{H3,H4}$ constants were 2078 obtained by iterative simulation of the spectra using DAISY as 2079 implemented in TopSpin, version 4.0.6, for Bruker. For a description 2080 of the pseudorotation concept, see: (b) Altona, C.; Sundaralingam, M. 2081 Conformational Analysis of the Sugar Ring in Nucleosides and 2082 Nucleotides. A New Description Using the Concept of Pseudor- 2083 otation. J. Am. Chem. Soc. 1972, 94, 8205-8212. (c) Houseknecht, J. 2084 B.; Altona, C.; Hadad, C. M.; Lowary, T. L. Conformational Analysis 2085 of Furanose Rings with PSEUROT: Parametrization for Rings 2086 Possessing the Arabino, Lyxo, Ribo, and Xylo Stereochemistry and 2087 Application to Arabinofuranosides. J. Org. Chem. 2002, 67, 4647- 2088 4651. 2089

(27) For others 44 and 45 analogs with a 1-phospha-1-oxo-D-gluco- 2090 hexopyranose skeleton possessing a ${}^{4}C_{1}$ conformation, see refs 4b, 4c. 2091 (28) Babouri, R.; Clarion, L.; Rolland, M.; Van der Lee, A.; 2092 Kabouche, Z.; Volle, J. N.; Virieux, D.; Pirat, J. L. Synthesis of 2093 Oxaphosphinane-Based Pseudodisaccharides. *Eur. J. Org. Chem.* 2017, 2094 2017, 5357–5369. See also refs 4c,i.

(29) Abraham, R. J.; Gottschalck, H.; Paulsen, H.; Thomas, W. A. 2096 The Proton Magnetic Resonance Spectra and Conformations of 2097 Cyclic Compounds. Part II. The p.m.r. Spectra of the Conduritols. *J.* 2098 *Chem. Soc.* **1965**, 6268–6277. 2099

(30) Mooren, M. M. W.; Wijmenga, S. S.; van der Marel, G. A.; van 2100 Boom, J. H.; Hilbers, C. W. The Solution Structure of the Circular 2101 Trinucleotide Cr(GpGpGp) Determined by NMR and Molecular 2102 Mechanics Calculation. *Nucleic Acids Res.* **1994**, *22*, 2658–2666. See 2103 also ref 23. 2104

(31) For the synthesis of related 2-alkyl-3-methylene-1,2-oxaphos- 2105 phinane derivatives, see: Xu, Y.; Li, Z. Palladium—catalyzed Synthesis 2106 of 3-Methylene-1-Oxa-2-Phosphacycloalkane-2-Oxide Derivatives the 2107 Phosphorus Analogs of α -Methylenelactones. *Tetrahedron Lett.* **1986**, 2108 27, 3017–3020. 2109

(32) Pirrung, M. C. The Synthetic Organic Chemist's Companion; 2110 John Wiley & Sons, Inc: Hoboken, NJ, USA, 2007; pp 171. 2111 (33) For convenience, the atom-numbering system used along this 2113 section and in the assignments of the Experimental Section, 2114 corresponds to the one depicted in structures of Schemes and 2115 Tables, although a IUPAC systematic nomenclature has been used 2116 throughout this paper.

(34) (a) Foster, A. B.; Overend, W. G.; Stacey, M.; Wiggins, L. F.
S35. Methanesulphonyl Derivatives of D-Galactose. *J. Chem. Soc.* **1949**, 2542–2546. (b) Fernandez-Mayoralas, A.; Marra, A.; Trumtel,
M.; Veyrières, A.; Sinaÿ, P. Preparation of Pyranoid Glycal Derivatives
from Phenyl Thioglycosides and Glycosyl Phenyl Sulphones. *Carbohydr. Res.* **1989**, *188*, 81–95. (c) Marcaurelle, L. A.; Shin, Y.;
Goon, S.; Bertozzi, C. R. Synthesis of Oxime-Linked Mucin Mimics
Containing the Tumor-Related TN and Sialyl TN Antigens. *Org. Lett.* **2001**, *3*, 3691–3694.

2126 (35) (a) Lee, J. B.; Nolan, T. J. Sugars with Potential Antiviral 2127 Activity-I. A New Method for the Preparation of Glycorufanoyl 2128 Chlorides and the Synthesis of a Mannosyl Nucleoside. *Tetrahedron* 2129 **1967**, 23, 2789–2794. (b) Eitelman, S. J.; Hall, R. H.; Jordaan, A. An 2130 Alternative Route to Furanoid and Pyranoid Glycals. *J. Chem. Soc.*, 2131 *Perkin Trans.* 1 **1978**, 595–600. (c) Brady, T. P.; Kim, S. H.; Wen, K.; 2132 Kim, C.; Theodorakis, E. A. Norrisolide: Total Synthesis and Related

2133 Studies. Chem. – Eur. J. 2005, 11, 7175–7190.

2134 (36) Bettelli, E.; Cherubini, P.; D'Andrea, P.; Passacantilli, P.; 2135 Piancatelli, G. Mercuration-Reductive Demercuration of Glycals: A 2136 Mild and Convenient Entry to 2-Deoxy-Sugars. *Tetrahedron* **1998**, *54*, 2137 6011–6018.

2138 (37) Kinzy, W.; Schmidt, R. R. Application of the Trichloroaceti-2139 midate Method to the Synthesis of Glycopeptides of the Mucin Type 2140 Containing a β -D-Galp-(1 \rightarrow 3)-D-GalpNAc Unit. *Carbohydr. Res.* 2141 **1987**, *164*, 265–276.

2142 (38) Duvold, T.; Francis, G. W.; Papaioannou, D. Benzyl 2,3-O-2143 Isopropylidene- β -D-Ribo-1,4-Pentodialdofuranoside as a D-Ribose 2144 Chiron for the Synthesis of Terpenyl Tetraols and Aminotriols. 2145 *Tetrahedron Lett.* **1995**, *36*, 3153–3156.

2146 (39) Suhara, Y.; Kittaka, A.; Ono, K.; Kurihara, M.; Fujishima, T.; 2147 Yoshida, A.; Takayama, H. Design and Efficient Synthesis of New 2148 Stable 1 α ,25-Dihydroxy-19-Norvitamin D3 Analogues Containing 2149 Amide Bond. *Bioorg. Med. Chem. Lett.* **2002**, *12*, 3533–3536.